drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.71k
| drug2_id
int64 1
1.71k
| drug1_name
stringlengths 4
31
| drug2_name
stringlengths 4
31
| drug1_desc
stringlengths 27
1.09k
⌀ | drug2_desc
stringlengths 27
1.06k
⌀ | label
stringlengths 58
191
| label_idx
int64 0
85
| all_paths
listlengths 1
10
| all_paths_str
listlengths 1
10
| path_str
stringlengths 0
2.58k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB09282
|
DB00722
| 1,558 | 676 |
Molsidomine
|
Lisinopril
|
Molsidomine is an orally active, long-acting vasodilator, which belongs to the class of medications known as syndnones. Interestingly, it is being studied as being a preventive measure in cerebral infarction.
|
Lisinopril is an angiotensin converting enzyme inhibitor (ACEI) used to treat hypertension, heart failure, and myocardial infarction.[L8384,L8387,L8390] Lisinopril and [captopril] are the only ACEIs that are not prodrugs. It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Lisinopril was granted FDA approval on 29 December 1987.
|
Molsidomine may increase the hypotensive activities of Lisinopril.
| 59 |
[
[
[
1558,
82,
676
]
],
[
[
1558,
82,
315
],
[
315,
71,
676
]
],
[
[
1558,
82,
607
],
[
607,
155,
676
]
],
[
[
1558,
82,
506
],
[
506,
32,
676
]
],
[
[
1558,
82,
461
],
[
461,
69,
676
]
],
[
[
1558,
82,
516
],
[
516,
225,
676
]
],
[
[
1558,
82,
1072
],
[
1072,
236,
676
]
],
[
[
1558,
82,
1061
],
[
1061,
82,
676
]
],
[
[
1558,
82,
306
],
[
306,
244,
676
]
],
[
[
1558,
82,
615
],
[
615,
95,
676
]
]
] |
[
[
[
"Molsidomine",
"{u} may increase the hypotensive activities of {v}",
"Lisinopril"
]
],
[
[
"Molsidomine",
"{u} may increase the hypotensive activities of {v}",
"Enalapril"
],
[
"Enalapril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lisinopril"
]
],
[
[
"Molsidomine",
"{u} may increase the hypotensive activities of {v}",
"Ramipril"
],
[
"Ramipril",
"{u} (Compound) resembles {v} (Compound)",
"Lisinopril"
]
],
[
[
"Molsidomine",
"{u} may increase the hypotensive activities of {v}",
"Avanafil"
],
[
"Avanafil",
"{u} may increase the antihypertensive activities of {v}",
"Lisinopril"
]
],
[
[
"Molsidomine",
"{u} may increase the hypotensive activities of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may decrease the metabolism of {v}",
"Lisinopril"
]
],
[
[
"Molsidomine",
"{u} may increase the hypotensive activities of {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lisinopril"
]
],
[
[
"Molsidomine",
"{u} may increase the hypotensive activities of {v}",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may increase the hypotensive activities of {v}",
"Lisinopril"
]
],
[
[
"Molsidomine",
"{u} may increase the hypotensive activities of {v}",
"Bethanidine"
],
[
"Bethanidine",
"{u} may increase the hypotensive activities of {v}",
"Lisinopril"
]
],
[
[
"Molsidomine",
"{u} may increase the hypotensive activities of {v}",
"Aliskiren"
],
[
"Aliskiren",
"{u} may increase the hyperkalemic activities of {v}",
"Lisinopril"
]
],
[
[
"Molsidomine",
"{u} may increase the hypotensive activities of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the serum concentration of {v}",
"Lisinopril"
]
]
] |
Molsidomine may increase the hypotensive activities of Enalapril and Enalapril may increase the severity of adverse effects when combined with Lisinopril
Molsidomine may increase the hypotensive activities of Ramipril and Ramipril (Compound) resembles Lisinopril (Compound)
Molsidomine may increase the hypotensive activities of Avanafil and Avanafil may increase the antihypertensive activities of Lisinopril
Molsidomine may increase the hypotensive activities of Diltiazem and Diltiazem may decrease the metabolism of Lisinopril
Molsidomine may increase the hypotensive activities of Felodipine and Felodipine may increase the severity of adverse effects when combined with Lisinopril
Molsidomine may increase the hypotensive activities of Hydroflumethiazide and Hydroflumethiazide may increase the hypotensive activities of Lisinopril
Molsidomine may increase the hypotensive activities of Bethanidine and Bethanidine may increase the hypotensive activities of Lisinopril
Molsidomine may increase the hypotensive activities of Aliskiren and Aliskiren may increase the hyperkalemic activities of Lisinopril
Molsidomine may increase the hypotensive activities of Sildenafil and Sildenafil may increase the serum concentration of Lisinopril
|
DB01159
|
DB00502
| 522 | 245 |
Halothane
|
Haloperidol
|
A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178)
|
Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and mesocortical systems of the brain. Haloperidol is indicated for the treatment of the manifestations of several psychotic disorders including schizophrenia, acute psychosis, Tourette syndrome, and other severe behavioural states. It is also used off-label for the management of chorea associated with Huntington's disease and for the treatment of intractable hiccups as it is a potent antiemetic. Dopamine-antagonizing medications such as haloperidol are though to improve psychotic symptoms and states that are caused by an over-production of dopamine, such as schizophrenia, which is
|
The metabolism of Haloperidol can be decreased when combined with Halothane.
| 46 |
[
[
[
522,
69,
245
]
],
[
[
522,
71,
954
],
[
954,
225,
245
]
],
[
[
522,
6,
7128
],
[
7128,
160,
245
]
],
[
[
522,
180,
161
],
[
161,
26,
245
]
],
[
[
522,
184,
674
],
[
674,
30,
245
]
],
[
[
522,
192,
679
],
[
679,
38,
245
]
],
[
[
522,
38,
1261
],
[
1261,
192,
245
]
],
[
[
522,
225,
280
],
[
280,
196,
245
]
],
[
[
522,
71,
1097
],
[
1097,
196,
245
]
],
[
[
522,
69,
499
],
[
499,
196,
245
]
]
] |
[
[
[
"Halothane",
"{u} may decrease the metabolism of {v}",
"Haloperidol"
]
],
[
[
"Halothane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluspirilene"
],
[
"Fluspirilene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Haloperidol"
]
],
[
[
"Halothane",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Haloperidol"
]
],
[
[
"Halothane",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Haloperidol"
]
],
[
[
"Halothane",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Haloperidol"
]
],
[
[
"Halothane",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Haloperidol"
]
],
[
[
"Halothane",
"{u} may increase the central nervous system depressant activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Haloperidol"
]
],
[
[
"Halothane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propofol"
],
[
"Propofol",
"{u} may increase the QTc prolonging activities of {v}",
"Haloperidol"
]
],
[
[
"Halothane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ezogabine"
],
[
"Ezogabine",
"{u} may increase the QTc prolonging activities of {v}",
"Haloperidol"
]
],
[
[
"Halothane",
"{u} may decrease the metabolism of {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may increase the QTc prolonging activities of {v}",
"Haloperidol"
]
]
] |
Halothane may increase the severity of adverse effects when combined with Fluspirilene and Fluspirilene may increase the severity of adverse effects when combined with Haloperidol
Halothane (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Haloperidol (Compound)
Halothane can increase the metabolism of Primidone and Primidone can increase the metabolism of Haloperidol
Halothane can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Haloperidol
Halothane may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Haloperidol
Halothane may increase the central nervous system depressant activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Haloperidol
Halothane may increase the severity of adverse effects when combined with Propofol and Propofol may increase the QTc prolonging activities of Haloperidol
Halothane may increase the severity of adverse effects when combined with Ezogabine and Ezogabine may increase the QTc prolonging activities of Haloperidol
Halothane may decrease the metabolism of Clomipramine and Clomipramine may increase the QTc prolonging activities of Haloperidol
|
DB00238
|
DB01039
| 173 | 432 |
Nevirapine
|
Fenofibrate
|
A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class.
|
Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.
|
The metabolism of Fenofibrate can be increased when combined with Nevirapine.
| 3 |
[
[
[
173,
26,
432
]
],
[
[
173,
26,
346
],
[
346,
1,
432
]
],
[
[
173,
6,
7128
],
[
7128,
160,
432
]
],
[
[
173,
21,
28622
],
[
28622,
175,
432
]
],
[
[
173,
180,
164
],
[
164,
26,
432
]
],
[
[
173,
26,
142
],
[
142,
26,
432
]
],
[
[
173,
26,
384
],
[
384,
28,
432
]
],
[
[
173,
26,
326
],
[
326,
31,
432
]
],
[
[
173,
97,
1099
],
[
1099,
223,
432
]
],
[
[
173,
249,
1085
],
[
1085,
223,
432
]
]
] |
[
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Fenofibrate"
]
],
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Clofibrate"
],
[
"Clofibrate",
"{u} (Compound) resembles {v} (Compound)",
"Fenofibrate"
]
],
[
[
"Nevirapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Fenofibrate"
]
],
[
[
"Nevirapine",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fenofibrate"
]
],
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Fenofibrate"
]
],
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Fenofibrate"
]
],
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Fenofibrate"
]
],
[
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may increase the hypoglycemic activities of {v}",
"Fenofibrate"
]
],
[
[
"Nevirapine",
"{u} may decrease the serum concentration of {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may decrease the metabolism of {v}",
"Fenofibrate"
]
],
[
[
"Nevirapine",
"{u} may increase the serum concentration of {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may decrease the metabolism of {v}",
"Fenofibrate"
]
]
] |
Nevirapine can increase the metabolism of Clofibrate and Clofibrate (Compound) resembles Fenofibrate (Compound)
Nevirapine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Fenofibrate (Compound)
Nevirapine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Fenofibrate (Compound)
Nevirapine can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Fenofibrate
Nevirapine can increase the metabolism of Phenytoin and Phenytoin can increase the metabolism of Fenofibrate
Nevirapine can increase the metabolism of Phenprocoumon and Phenprocoumon may increase the anticoagulant activities of Fenofibrate
Nevirapine can increase the metabolism of Glipizide and Glipizide may increase the hypoglycemic activities of Fenofibrate
Nevirapine may decrease the serum concentration of Idelalisib and Idelalisib may decrease the metabolism of Fenofibrate
Nevirapine may increase the serum concentration of Olaparib and Olaparib may decrease the metabolism of Fenofibrate
|
DB00732
|
DB01116
| 25 | 17 |
Atracurium besylate
|
Trimethaphan
|
A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.
|
A nicotinic antagonist that has been used as a ganglionic blocker in hypertension, as an adjunct to anesthesia, and to induce hypotension during surgery.
|
The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Trimethaphan.
| 48 |
[
[
[
25,
71,
17
]
],
[
[
25,
43,
190
],
[
190,
236,
17
]
],
[
[
25,
178,
20
],
[
20,
24,
17
]
],
[
[
25,
61,
1400
],
[
1400,
215,
17
]
],
[
[
25,
71,
942
],
[
942,
225,
17
]
],
[
[
25,
225,
69
],
[
69,
71,
17
]
],
[
[
25,
71,
44
],
[
44,
71,
17
]
],
[
[
25,
81,
1531
],
[
1531,
235,
17
]
],
[
[
25,
246,
1294
],
[
1294,
92,
17
]
],
[
[
25,
249,
1326
],
[
1326,
95,
17
]
]
] |
[
[
[
"Atracurium besylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trimethaphan"
]
],
[
[
"Atracurium besylate",
"{u} may increase the neuromuscular blocking activities of {v}",
"Bepridil"
],
[
"Bepridil",
"{u} may increase the hypotensive activities of {v}",
"Trimethaphan"
]
],
[
[
"Atracurium besylate",
"{u} may increase the anticholinergic activities of {v}",
"Umeclidinium"
],
[
"Umeclidinium",
"{u} may increase the anticholinergic activities of {v}",
"Trimethaphan"
]
],
[
[
"Atracurium besylate",
"{u} may increase the constipating activities of {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may increase the constipating activities of {v}",
"Trimethaphan"
]
],
[
[
"Atracurium besylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diphenoxylate"
],
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trimethaphan"
]
],
[
[
"Atracurium besylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Profenamine"
],
[
"Profenamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trimethaphan"
]
],
[
[
"Atracurium besylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trimethaphan"
]
],
[
[
"Atracurium besylate",
"{u} may increase the ulcerogenic activities of {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may increase the ulcerogenic activities of {v}",
"Trimethaphan"
]
],
[
[
"Atracurium besylate",
"{u} may decrease the therapeutic efficacy of {v}",
"Demecarium"
],
[
"Demecarium",
"{u} may decrease the therapeutic efficacy of {v}",
"Trimethaphan"
]
],
[
[
"Atracurium besylate",
"{u} may increase the serum concentration of {v}",
"Methyclothiazide"
],
[
"Methyclothiazide",
"{u} may increase the serum concentration of {v}",
"Trimethaphan"
]
]
] |
Atracurium besylate may increase the neuromuscular blocking activities of Bepridil and Bepridil may increase the hypotensive activities of Trimethaphan
Atracurium besylate may increase the anticholinergic activities of Umeclidinium and Umeclidinium may increase the anticholinergic activities of Trimethaphan
Atracurium besylate may increase the constipating activities of Eluxadoline and Eluxadoline may increase the constipating activities of Trimethaphan
Atracurium besylate may increase the severity of adverse effects when combined with Diphenoxylate and Diphenoxylate may increase the severity of adverse effects when combined with Trimethaphan
Atracurium besylate may increase the severity of adverse effects when combined with Profenamine and Profenamine may increase the severity of adverse effects when combined with Trimethaphan
Atracurium besylate may increase the severity of adverse effects when combined with Tolterodine and Tolterodine may increase the severity of adverse effects when combined with Trimethaphan
Atracurium besylate may increase the ulcerogenic activities of Potassium chloride and Potassium chloride may increase the ulcerogenic activities of Trimethaphan
Atracurium besylate may decrease the therapeutic efficacy of Demecarium and Demecarium may decrease the therapeutic efficacy of Trimethaphan
Atracurium besylate may increase the serum concentration of Methyclothiazide and Methyclothiazide may increase the serum concentration of Trimethaphan
|
DB11268
|
DB00569
| 794 | 758 |
Protocatechualdehyde
|
Fondaparinux
|
Also known as protocatechuic aldehyde, protocatechualdehyde is a naturally-occuring phenolic aldehyde that is found in barley, green cavendish bananas, grapevine leaves and root of the herb S. miltiorrhiza. Protocatechualdehyde possesses antiproliferative and pro-apoptotic properties against human breast cancer cells and colorectal cancer cells by reducing the expression of pro-oncogenes β-catenin and cyclin D1.
|
Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII). Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture
|
Protocatechualdehyde may increase the anticoagulant activities of Fondaparinux.
| 5 |
[
[
[
794,
28,
758
]
],
[
[
794,
28,
775
],
[
775,
182,
758
]
],
[
[
794,
28,
342
],
[
342,
28,
758
]
],
[
[
794,
182,
560
],
[
560,
28,
758
]
],
[
[
794,
34,
574
],
[
574,
188,
758
]
],
[
[
794,
71,
1231
],
[
1231,
225,
758
]
],
[
[
794,
225,
1444
],
[
1444,
71,
758
]
],
[
[
794,
88,
1351
],
[
1351,
242,
758
]
],
[
[
794,
246,
1229
],
[
1229,
92,
758
]
],
[
[
794,
28,
775
],
[
775,
182,
784
],
[
784,
182,
758
]
]
] |
[
[
[
"Protocatechualdehyde",
"{u} may increase the anticoagulant activities of {v}",
"Fondaparinux"
]
],
[
[
"Protocatechualdehyde",
"{u} may increase the anticoagulant activities of {v}",
"Ifenprodil"
],
[
"Ifenprodil",
"{u} may increase the anticoagulant activities of {v}",
"Fondaparinux"
]
],
[
[
"Protocatechualdehyde",
"{u} may increase the anticoagulant activities of {v}",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Fondaparinux"
]
],
[
[
"Protocatechualdehyde",
"{u} may increase the anticoagulant activities of {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may increase the anticoagulant activities of {v}",
"Fondaparinux"
]
],
[
[
"Protocatechualdehyde",
"{u} may decrease the anticoagulant activities of {v}",
"Diethylstilbestrol"
],
[
"Diethylstilbestrol",
"{u} may decrease the anticoagulant activities of {v}",
"Fondaparinux"
]
],
[
[
"Protocatechualdehyde",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nintedanib"
],
[
"Nintedanib",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fondaparinux"
]
],
[
[
"Protocatechualdehyde",
"{u} may increase the severity of adverse effects when combined with {v}",
"Limaprost"
],
[
"Limaprost",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fondaparinux"
]
],
[
[
"Protocatechualdehyde",
"{u} may increase bleeding risks when combined with {v}",
"Acemetacin"
],
[
"Acemetacin",
"{u} may increase bleeding risks when combined with {v}",
"Fondaparinux"
]
],
[
[
"Protocatechualdehyde",
"{u} may decrease the therapeutic efficacy of {v}",
"Megestrol acetate"
],
[
"Megestrol acetate",
"{u} may decrease the therapeutic efficacy of {v}",
"Fondaparinux"
]
],
[
[
"Protocatechualdehyde",
"{u} may increase the anticoagulant activities of {v}",
"Ifenprodil"
],
[
"Ifenprodil",
"{u} may increase the anticoagulant activities of {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may increase the anticoagulant activities of {v}",
"Fondaparinux"
]
]
] |
Protocatechualdehyde may increase the anticoagulant activities of Ifenprodil and Ifenprodil may increase the anticoagulant activities of Fondaparinux
Protocatechualdehyde may increase the anticoagulant activities of Acenocoumarol and Acenocoumarol may increase the anticoagulant activities of Fondaparinux
Protocatechualdehyde may increase the anticoagulant activities of Rivaroxaban and Rivaroxaban may increase the anticoagulant activities of Fondaparinux
Protocatechualdehyde may decrease the anticoagulant activities of Diethylstilbestrol and Diethylstilbestrol may decrease the anticoagulant activities of Fondaparinux
Protocatechualdehyde may increase the severity of adverse effects when combined with Nintedanib and Nintedanib may increase the severity of adverse effects when combined with Fondaparinux
Protocatechualdehyde may increase the severity of adverse effects when combined with Limaprost and Limaprost may increase the severity of adverse effects when combined with Fondaparinux
Protocatechualdehyde may increase bleeding risks when combined with Acemetacin and Acemetacin may increase bleeding risks when combined with Fondaparinux
Protocatechualdehyde may decrease the therapeutic efficacy of Megestrol acetate and Megestrol acetate may decrease the therapeutic efficacy of Fondaparinux
Protocatechualdehyde may increase the anticoagulant activities of Ifenprodil and Ifenprodil may increase the anticoagulant activities of Anagrelide and Anagrelide may increase the anticoagulant activities of Fondaparinux
|
DB00191
|
DB09128
| 1,335 | 957 |
Phentermine
|
Brexpiprazole
|
Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug.[A174361, A174364] It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential). Phentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960. This initial product, formed by the combination of phentermine with [fenfluramine] and [dexfenfluramine] was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers.[A174376, T403] Later on, phentermine was approved alone and in combination with topiramate in 2012 as a new alternative that required lower doses of phentermine to
|
Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors. Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor. It also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. Currently approved for the treatment of depression, schizophrenia, and agitation
|
Phentermine may decrease the stimulatory activities of Brexpiprazole.
| 60 |
[
[
[
1335,
83,
957
]
],
[
[
1335,
245,
491
],
[
491,
38,
957
]
],
[
[
1335,
98,
1262
],
[
1262,
192,
957
]
],
[
[
1335,
225,
587
],
[
587,
38,
957
]
],
[
[
1335,
98,
543
],
[
543,
38,
957
]
],
[
[
1335,
83,
997
],
[
997,
57,
957
]
],
[
[
1335,
83,
980
],
[
980,
58,
957
]
],
[
[
1335,
83,
915
],
[
915,
71,
957
]
],
[
[
1335,
98,
478
],
[
478,
71,
957
]
],
[
[
1335,
245,
961
],
[
961,
71,
957
]
]
] |
[
[
[
"Phentermine",
"{u} may decrease the stimulatory activities of {v}",
"Brexpiprazole"
]
],
[
[
"Phentermine",
"{u} may increase the analgesic activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brexpiprazole"
]
],
[
[
"Phentermine",
"{u} may decrease the sedative activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brexpiprazole"
]
],
[
[
"Phentermine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Brexpiprazole"
]
],
[
[
"Phentermine",
"{u} may decrease the sedative activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brexpiprazole"
]
],
[
[
"Phentermine",
"{u} may decrease the stimulatory activities of {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Brexpiprazole"
]
],
[
[
"Phentermine",
"{u} may decrease the stimulatory activities of {v}",
"Amisulpride"
],
[
"Amisulpride",
"{u} may increase the antipsychotic activities of {v}",
"Brexpiprazole"
]
],
[
[
"Phentermine",
"{u} may decrease the stimulatory activities of {v}",
"Fencamfamin"
],
[
"Fencamfamin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brexpiprazole"
]
],
[
[
"Phentermine",
"{u} may decrease the sedative activities of {v}",
"Olopatadine"
],
[
"Olopatadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brexpiprazole"
]
],
[
[
"Phentermine",
"{u} may increase the analgesic activities of {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brexpiprazole"
]
]
] |
Phentermine may increase the analgesic activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Brexpiprazole
Phentermine may decrease the sedative activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Brexpiprazole
Phentermine may increase the severity of adverse effects when combined with Ethanol and Ethanol may increase the central nervous system depressant activities of Brexpiprazole
Phentermine may decrease the sedative activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Brexpiprazole
Phentermine may decrease the stimulatory activities of Lithium cation and Lithium cation may increase the neurotoxic activities of Brexpiprazole
Phentermine may decrease the stimulatory activities of Amisulpride and Amisulpride may increase the antipsychotic activities of Brexpiprazole
Phentermine may decrease the stimulatory activities of Fencamfamin and Fencamfamin may increase the severity of adverse effects when combined with Brexpiprazole
Phentermine may decrease the sedative activities of Olopatadine and Olopatadine may increase the severity of adverse effects when combined with Brexpiprazole
Phentermine may increase the analgesic activities of Fentanyl and Fentanyl may increase the severity of adverse effects when combined with Brexpiprazole
|
DB09449
|
DB00678
| 1,492 | 567 |
Sodium phosphate, monobasic
|
Losartan
|
Sodium phosphate is a saline laxative that is thought to work by increasing fluid in the small intestine. It usually results in a bowel movement after 30 minutes to 6 hours.
|
Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or [hydrochlorothiazide]. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide.[L7423,L7426] Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.
|
Sodium phosphate, monobasic may increase the nephrotoxic activities of Losartan.
| 56 |
[
[
[
1492,
79,
567
]
],
[
[
1492,
79,
239
],
[
239,
1,
567
]
],
[
[
1492,
79,
174
],
[
174,
155,
567
]
],
[
[
1492,
233,
236
],
[
236,
223,
567
]
],
[
[
1492,
233,
166
],
[
166,
69,
567
]
],
[
[
1492,
225,
221
],
[
221,
69,
567
]
],
[
[
1492,
79,
642
],
[
642,
225,
567
]
],
[
[
1492,
233,
745
],
[
745,
225,
567
]
],
[
[
1492,
79,
557
],
[
557,
71,
567
]
],
[
[
1492,
225,
438
],
[
438,
71,
567
]
]
] |
[
[
[
"Sodium phosphate, monobasic",
"{u} may increase the nephrotoxic activities of {v}",
"Losartan"
]
],
[
[
"Sodium phosphate, monobasic",
"{u} may increase the nephrotoxic activities of {v}",
"Valsartan"
],
[
"Valsartan",
"{u} (Compound) resembles {v} (Compound)",
"Losartan"
]
],
[
[
"Sodium phosphate, monobasic",
"{u} may increase the nephrotoxic activities of {v}",
"Tasosartan"
],
[
"Tasosartan",
"{u} (Compound) resembles {v} (Compound)",
"Losartan"
]
],
[
[
"Sodium phosphate, monobasic",
"{u} may increase the nephrotoxic activities of {v}",
"Salicylic acid"
],
[
"Salicylic acid",
"{u} may decrease the metabolism of {v}",
"Losartan"
]
],
[
[
"Sodium phosphate, monobasic",
"{u} may increase the nephrotoxic activities of {v}",
"Zaltoprofen"
],
[
"Zaltoprofen",
"{u} may decrease the metabolism of {v}",
"Losartan"
]
],
[
[
"Sodium phosphate, monobasic",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nortriptyline"
],
[
"Nortriptyline",
"{u} may decrease the metabolism of {v}",
"Losartan"
]
],
[
[
"Sodium phosphate, monobasic",
"{u} may increase the nephrotoxic activities of {v}",
"Benazepril"
],
[
"Benazepril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Losartan"
]
],
[
[
"Sodium phosphate, monobasic",
"{u} may increase the nephrotoxic activities of {v}",
"Fenoprofen"
],
[
"Fenoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Losartan"
]
],
[
[
"Sodium phosphate, monobasic",
"{u} may increase the nephrotoxic activities of {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Losartan"
]
],
[
[
"Sodium phosphate, monobasic",
"{u} may increase the severity of adverse effects when combined with {v}",
"Imipramine"
],
[
"Imipramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Losartan"
]
]
] |
Sodium phosphate, monobasic may increase the nephrotoxic activities of Valsartan and Valsartan (Compound) resembles Losartan (Compound)
Sodium phosphate, monobasic may increase the nephrotoxic activities of Tasosartan and Tasosartan (Compound) resembles Losartan (Compound)
Sodium phosphate, monobasic may increase the nephrotoxic activities of Salicylic acid and Salicylic acid may decrease the metabolism of Losartan
Sodium phosphate, monobasic may increase the nephrotoxic activities of Zaltoprofen and Zaltoprofen may decrease the metabolism of Losartan
Sodium phosphate, monobasic may increase the severity of adverse effects when combined with Nortriptyline and Nortriptyline may decrease the metabolism of Losartan
Sodium phosphate, monobasic may increase the nephrotoxic activities of Benazepril and Benazepril may increase the severity of adverse effects when combined with Losartan
Sodium phosphate, monobasic may increase the nephrotoxic activities of Fenoprofen and Fenoprofen may increase the severity of adverse effects when combined with Losartan
Sodium phosphate, monobasic may increase the nephrotoxic activities of Torasemide and Torasemide may increase the severity of adverse effects when combined with Losartan
Sodium phosphate, monobasic may increase the severity of adverse effects when combined with Imipramine and Imipramine may increase the severity of adverse effects when combined with Losartan
|
DB00622
|
DB00289
| 158 | 610 |
Nicardipine
|
Atomoxetine
|
A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]
|
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associated with ADHD including distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. Although the underlying pathophysiology that causes ADHD remains unclear, evidence suggests that dysregulation in noradrenergic and dopaminergic pathways plays a critical role in suboptimal executive functioning within prefrontal regions of the brain, which are involved in attention and memory. Atomoxetine has been shown to specifically increase NA and DA within the prefrontal cortex, but not in the nucleus accumbens (NA) or striatum. This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and stri
|
The metabolism of Atomoxetine can be decreased when combined with Nicardipine.
| 46 |
[
[
[
158,
69,
610
]
],
[
[
158,
225,
504
],
[
504,
1,
610
]
],
[
[
158,
223,
221
],
[
221,
69,
610
]
],
[
[
158,
223,
211
],
[
211,
155,
610
]
],
[
[
158,
223,
219
],
[
219,
1,
610
]
],
[
[
158,
82,
355
],
[
355,
69,
610
]
],
[
[
158,
6,
18777
],
[
18777,
160,
610
]
],
[
[
158,
21,
28747
],
[
28747,
175,
610
]
],
[
[
158,
180,
156
],
[
156,
26,
610
]
],
[
[
158,
249,
150
],
[
150,
26,
610
]
]
] |
[
[
[
"Nicardipine",
"{u} may decrease the metabolism of {v}",
"Atomoxetine"
]
],
[
[
"Nicardipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propranolol"
],
[
"Propranolol",
"{u} (Compound) resembles {v} (Compound)",
"Atomoxetine"
]
],
[
[
"Nicardipine",
"{u} may decrease the metabolism of {v}",
"Nortriptyline"
],
[
"Nortriptyline",
"{u} may decrease the metabolism of {v}",
"Atomoxetine"
]
],
[
[
"Nicardipine",
"{u} may decrease the metabolism of {v}",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} (Compound) resembles {v} (Compound)",
"Atomoxetine"
]
],
[
[
"Nicardipine",
"{u} may decrease the metabolism of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} (Compound) resembles {v} (Compound)",
"Atomoxetine"
]
],
[
[
"Nicardipine",
"{u} may increase the hypotensive activities of {v}",
"Phenoxybenzamine"
],
[
"Phenoxybenzamine",
"{u} may decrease the metabolism of {v}",
"Atomoxetine"
]
],
[
[
"Nicardipine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Atomoxetine"
]
],
[
[
"Nicardipine",
"{u} (Compound) causes {v} (Side Effect)",
"Palpitations"
],
[
"Palpitations",
"{u} (Side Effect) is caused by {v} (Compound)",
"Atomoxetine"
]
],
[
[
"Nicardipine",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Atomoxetine"
]
],
[
[
"Nicardipine",
"{u} may increase the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Atomoxetine"
]
]
] |
Nicardipine may increase the severity of adverse effects when combined with Propranolol and Propranolol (Compound) resembles Atomoxetine (Compound)
Nicardipine may decrease the metabolism of Nortriptyline and Nortriptyline may decrease the metabolism of Atomoxetine
Nicardipine may decrease the metabolism of Ketoprofen and Ketoprofen (Compound) resembles Atomoxetine (Compound)
Nicardipine may decrease the metabolism of Warfarin and Warfarin (Compound) resembles Atomoxetine (Compound)
Nicardipine may increase the hypotensive activities of Phenoxybenzamine and Phenoxybenzamine may decrease the metabolism of Atomoxetine
Nicardipine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Atomoxetine (Compound)
Nicardipine (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Atomoxetine (Compound)
Nicardipine can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Atomoxetine
Nicardipine may increase the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Atomoxetine
|
DB06724
|
DB02187
| 86 | 115 |
Calcium carbonate
|
Equilin
|
Calcium carbonate is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. Calcium carbonate may also be used as a nutritional supplement or to treat hypocalcemia.
|
An estrogenic steroid produced by horses. It has a total of four double bonds in the A- and B-ring. High concentration of equilin is found in the urine of pregnant mares.
|
The bioavailability of Equilin can be decreased when combined with Calcium carbonate.
| 2 |
[
[
[
86,
25,
115
]
],
[
[
86,
25,
124
],
[
124,
249,
115
]
],
[
[
86,
25,
79
],
[
79,
155,
115
]
],
[
[
86,
92,
78
],
[
78,
25,
115
]
],
[
[
86,
243,
776
],
[
776,
225,
115
]
],
[
[
86,
97,
588
],
[
588,
71,
115
]
],
[
[
86,
243,
564
],
[
564,
249,
115
]
],
[
[
86,
97,
496
],
[
496,
249,
115
]
],
[
[
86,
243,
1093
],
[
1093,
251,
115
]
],
[
[
86,
25,
124
],
[
124,
155,
299
],
[
299,
1,
115
]
]
] |
[
[
[
"Calcium carbonate",
"{u} can decrease the bioavailability of {v}",
"Equilin"
]
],
[
[
"Calcium carbonate",
"{u} can decrease the bioavailability of {v}",
"Estrone"
],
[
"Estrone",
"{u} may increase the serum concentration of {v}",
"Equilin"
]
],
[
[
"Calcium carbonate",
"{u} can decrease the bioavailability of {v}",
"Estrone sulfate"
],
[
"Estrone sulfate",
"{u} (Compound) resembles {v} (Compound)",
"Equilin"
]
],
[
[
"Calcium carbonate",
"{u} may decrease the therapeutic efficacy of {v}",
"Bismuth subcitrate potassium"
],
[
"Bismuth subcitrate potassium",
"{u} can decrease the bioavailability of {v}",
"Equilin"
]
],
[
[
"Calcium carbonate",
"{u} may decrease the absorption and serum concentration of {v}",
"Rosoxacin"
],
[
"Rosoxacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Equilin"
]
],
[
[
"Calcium carbonate",
"{u} may decrease the serum concentration of {v}",
"Chloroquine"
],
[
"Chloroquine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Equilin"
]
],
[
[
"Calcium carbonate",
"{u} may decrease the absorption and serum concentration of {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may increase the serum concentration of {v}",
"Equilin"
]
],
[
[
"Calcium carbonate",
"{u} may decrease the serum concentration of {v}",
"Ketoconazole"
],
[
"Ketoconazole",
"{u} may increase the serum concentration of {v}",
"Equilin"
]
],
[
[
"Calcium carbonate",
"{u} may decrease the absorption and serum concentration of {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may decrease the serum concentration of {v}",
"Equilin"
]
],
[
[
"Calcium carbonate",
"{u} can decrease the bioavailability of {v}",
"Estrone"
],
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Ethinylestradiol"
],
[
"Ethinylestradiol",
"{u} (Compound) resembles {v} (Compound)",
"Equilin"
]
]
] |
Calcium carbonate can decrease the bioavailability of Estrone and Estrone may increase the serum concentration of Equilin
Calcium carbonate can decrease the bioavailability of Estrone sulfate and Estrone sulfate (Compound) resembles Equilin (Compound)
Calcium carbonate may decrease the therapeutic efficacy of Bismuth subcitrate potassium and Bismuth subcitrate potassium can decrease the bioavailability of Equilin
Calcium carbonate may decrease the absorption and serum concentration of Rosoxacin and Rosoxacin may increase the severity of adverse effects when combined with Equilin
Calcium carbonate may decrease the serum concentration of Chloroquine and Chloroquine may increase the severity of adverse effects when combined with Equilin
Calcium carbonate may decrease the absorption and serum concentration of Atazanavir and Atazanavir may increase the serum concentration of Equilin
Calcium carbonate may decrease the serum concentration of Ketoconazole and Ketoconazole may increase the serum concentration of Equilin
Calcium carbonate may decrease the absorption and serum concentration of Isoniazid and Isoniazid may decrease the serum concentration of Equilin
Calcium carbonate can decrease the bioavailability of Estrone and Estrone (Compound) resembles Ethinylestradiol (Compound) and Ethinylestradiol (Compound) resembles Equilin (Compound)
|
DB01175
|
DB01081
| 324 | 942 |
Escitalopram
|
Diphenoxylate
|
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from
|
A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II.
|
Escitalopram may increase the serotonergic activities of Diphenoxylate.
| 63 |
[
[
[
324,
86,
942
]
],
[
[
324,
225,
918
],
[
918,
225,
942
]
],
[
[
324,
225,
465
],
[
465,
71,
942
]
],
[
[
324,
86,
984
],
[
984,
1,
942
]
],
[
[
324,
225,
674
],
[
674,
30,
942
]
],
[
[
324,
42,
1262
],
[
1262,
192,
942
]
],
[
[
324,
86,
1083
],
[
1083,
38,
942
]
],
[
[
324,
225,
405
],
[
405,
192,
942
]
],
[
[
324,
225,
287
],
[
287,
38,
942
]
],
[
[
324,
225,
1046
],
[
1046,
208,
942
]
]
] |
[
[
[
"Escitalopram",
"{u} may increase the serotonergic activities of {v}",
"Diphenoxylate"
]
],
[
[
"Escitalopram",
"{u} may increase the severity of adverse effects when combined with {v}",
"Difenoxin"
],
[
"Difenoxin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diphenoxylate"
]
],
[
[
"Escitalopram",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meperidine"
],
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diphenoxylate"
]
],
[
[
"Escitalopram",
"{u} may increase the serotonergic activities of {v}",
"Methadyl acetate"
],
[
"Methadyl acetate",
"{u} (Compound) resembles {v} (Compound)",
"Diphenoxylate"
]
],
[
[
"Escitalopram",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Diphenoxylate"
]
],
[
[
"Escitalopram",
"{u} may increase the QTc prolonging activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Diphenoxylate"
]
],
[
[
"Escitalopram",
"{u} may increase the serotonergic activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Diphenoxylate"
]
],
[
[
"Escitalopram",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Diphenoxylate"
]
],
[
[
"Escitalopram",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Diphenoxylate"
]
],
[
[
"Escitalopram",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Diphenoxylate"
]
]
] |
Escitalopram may increase the severity of adverse effects when combined with Difenoxin and Difenoxin may increase the severity of adverse effects when combined with Diphenoxylate
Escitalopram may increase the severity of adverse effects when combined with Meperidine and Meperidine may increase the severity of adverse effects when combined with Diphenoxylate
Escitalopram may increase the serotonergic activities of Methadyl acetate and Methadyl acetate (Compound) resembles Diphenoxylate (Compound)
Escitalopram may increase the severity of adverse effects when combined with Pregabalin and Pregabalin can increase the therapeutic efficacy of Diphenoxylate
Escitalopram may increase the QTc prolonging activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Diphenoxylate
Escitalopram may increase the serotonergic activities of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Diphenoxylate
Escitalopram may increase the severity of adverse effects when combined with Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Diphenoxylate
Escitalopram may increase the severity of adverse effects when combined with Zolpidem and Zolpidem may increase the central nervous system depressant activities of Diphenoxylate
Escitalopram may increase the severity of adverse effects when combined with Metyrosine and Metyrosine may increase the sedative activities of Diphenoxylate
|
DB00614
|
DB09082
| 58 | 395 |
Furazolidone
|
Vilanterol
|
A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
|
Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol
|
The risk or severity of adverse effects can be increased when Furazolidone is combined with Vilanterol.
| 48 |
[
[
[
58,
71,
395
]
],
[
[
58,
82,
911
],
[
911,
36,
395
]
],
[
[
58,
185,
1019
],
[
1019,
196,
395
]
],
[
[
58,
185,
589
],
[
589,
42,
395
]
],
[
[
58,
71,
956
],
[
956,
42,
395
]
],
[
[
58,
240,
556
],
[
556,
42,
395
]
],
[
[
58,
178,
41
],
[
41,
223,
395
]
],
[
[
58,
240,
861
],
[
861,
223,
395
]
],
[
[
58,
82,
472
],
[
472,
223,
395
]
],
[
[
58,
223,
530
],
[
530,
223,
395
]
]
] |
[
[
[
"Furazolidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Vilanterol"
]
],
[
[
"Furazolidone",
"{u} may increase the hypotensive activities of {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may decrease the bronchodilatory activities of {v}",
"Vilanterol"
]
],
[
[
"Furazolidone",
"{u} may increase the hypoglycemic activities of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the QTc prolonging activities of {v}",
"Vilanterol"
]
],
[
[
"Furazolidone",
"{u} may increase the hypoglycemic activities of {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may increase the QTc prolonging activities of {v}",
"Vilanterol"
]
],
[
[
"Furazolidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may increase the QTc prolonging activities of {v}",
"Vilanterol"
]
],
[
[
"Furazolidone",
"{u} may increase the serotonergic activities of {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may increase the QTc prolonging activities of {v}",
"Vilanterol"
]
],
[
[
"Furazolidone",
"{u} may increase the anticholinergic activities of {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may decrease the metabolism of {v}",
"Vilanterol"
]
],
[
[
"Furazolidone",
"{u} may increase the serotonergic activities of {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may decrease the metabolism of {v}",
"Vilanterol"
]
],
[
[
"Furazolidone",
"{u} may increase the hypotensive activities of {v}",
"Isradipine"
],
[
"Isradipine",
"{u} may decrease the metabolism of {v}",
"Vilanterol"
]
],
[
[
"Furazolidone",
"{u} may decrease the metabolism of {v}",
"Dihydroergotamine"
],
[
"Dihydroergotamine",
"{u} may decrease the metabolism of {v}",
"Vilanterol"
]
]
] |
Furazolidone may increase the hypotensive activities of Oxprenolol and Oxprenolol may decrease the bronchodilatory activities of Vilanterol
Furazolidone may increase the hypoglycemic activities of Mifepristone and Mifepristone may increase the QTc prolonging activities of Vilanterol
Furazolidone may increase the hypoglycemic activities of Disopyramide and Disopyramide may increase the QTc prolonging activities of Vilanterol
Furazolidone may increase the severity of adverse effects when combined with Tetrabenazine and Tetrabenazine may increase the QTc prolonging activities of Vilanterol
Furazolidone may increase the serotonergic activities of Citalopram and Citalopram may increase the QTc prolonging activities of Vilanterol
Furazolidone may increase the anticholinergic activities of Clemastine and Clemastine may decrease the metabolism of Vilanterol
Furazolidone may increase the serotonergic activities of Fluvoxamine and Fluvoxamine may decrease the metabolism of Vilanterol
Furazolidone may increase the hypotensive activities of Isradipine and Isradipine may decrease the metabolism of Vilanterol
Furazolidone may decrease the metabolism of Dihydroergotamine and Dihydroergotamine may decrease the metabolism of Vilanterol
|
DB06603
|
DB01097
| 1,098 | 582 |
Panobinostat
|
Leflunomide
|
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
|
Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999.
|
The risk or severity of adverse effects can be increased when Panobinostat is combined with Leflunomide.
| 48 |
[
[
[
1098,
71,
582
]
],
[
[
1098,
251,
156
],
[
156,
26,
582
]
],
[
[
1098,
95,
191
],
[
191,
26,
582
]
],
[
[
1098,
42,
863
],
[
863,
203,
582
]
],
[
[
1098,
210,
1388
],
[
1388,
56,
582
]
],
[
[
1098,
249,
1037
],
[
1037,
59,
582
]
],
[
[
1098,
196,
1027
],
[
1027,
59,
582
]
],
[
[
1098,
249,
508
],
[
508,
223,
582
]
],
[
[
1098,
249,
561
],
[
561,
69,
582
]
],
[
[
1098,
196,
633
],
[
633,
69,
582
]
]
] |
[
[
[
"Panobinostat",
"{u} may increase the severity of adverse effects when combined with {v}",
"Leflunomide"
]
],
[
[
"Panobinostat",
"{u} may decrease the serum concentration of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Leflunomide"
]
],
[
[
"Panobinostat",
"{u} may increase the serum concentration of {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} can increase the metabolism of {v}",
"Leflunomide"
]
],
[
[
"Panobinostat",
"{u} may increase the QTc prolonging activities of {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may increase the neuroexcitatory activities of {v}",
"Leflunomide"
]
],
[
[
"Panobinostat",
"{u} may increase the immunosuppressive activities of {v}",
"Roflumilast"
],
[
"Roflumilast",
"{u} may increase the immunosuppressive activities of {v}",
"Leflunomide"
]
],
[
[
"Panobinostat",
"{u} may increase the serum concentration of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may decrease the antihypertensive activities of {v}",
"Leflunomide"
]
],
[
[
"Panobinostat",
"{u} may increase the QTc prolonging activities of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may decrease the antihypertensive activities of {v}",
"Leflunomide"
]
],
[
[
"Panobinostat",
"{u} may increase the serum concentration of {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may decrease the metabolism of {v}",
"Leflunomide"
]
],
[
[
"Panobinostat",
"{u} may increase the serum concentration of {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may decrease the metabolism of {v}",
"Leflunomide"
]
],
[
[
"Panobinostat",
"{u} may increase the QTc prolonging activities of {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may decrease the metabolism of {v}",
"Leflunomide"
]
]
] |
Panobinostat may decrease the serum concentration of Carbamazepine and Carbamazepine can increase the metabolism of Leflunomide
Panobinostat may increase the serum concentration of Aprepitant and Aprepitant can increase the metabolism of Leflunomide
Panobinostat may increase the QTc prolonging activities of Gemifloxacin and Gemifloxacin may increase the neuroexcitatory activities of Leflunomide
Panobinostat may increase the immunosuppressive activities of Roflumilast and Roflumilast may increase the immunosuppressive activities of Leflunomide
Panobinostat may increase the serum concentration of Betaxolol and Betaxolol may decrease the antihypertensive activities of Leflunomide
Panobinostat may increase the QTc prolonging activities of Sotalol and Sotalol may decrease the antihypertensive activities of Leflunomide
Panobinostat may increase the serum concentration of Delavirdine and Delavirdine may decrease the metabolism of Leflunomide
Panobinostat may increase the serum concentration of Ixazomib and Ixazomib may decrease the metabolism of Leflunomide
Panobinostat may increase the QTc prolonging activities of Cisapride and Cisapride may decrease the metabolism of Leflunomide
|
DB00433
|
DB00976
| 270 | 528 |
Prochlorperazine
|
Telithromycin
|
Prochlorperazine, also known as compazine, is a piperazine phenothiazine and first-generation antipsychotic drug that is used for the treatment of severe nausea and vomiting, as well as short-term management of psychotic disorders such as generalized non-psychotic anxiety and schizophrenia.[label] It mainly works by depressing the chemoreceptor trigger zone and blocking D2 dopamine receptors in the brain. It was shown to also block histaminergic, cholinergic and noradrenergic receptors. Prochlorperazine was first developed in the 1950s and was first approved by the FDA in 1956. Although newer antiemetic agents such as 5-HT3 antagonists are more heavily promoted, prochlorperazine is still widely used in nausea and vomiting.
|
Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections.
|
The metabolism of Telithromycin can be decreased when combined with Prochlorperazine.
| 46 |
[
[
[
270,
69,
528
]
],
[
[
270,
69,
1088
],
[
1088,
42,
528
]
],
[
[
270,
6,
4590
],
[
4590,
160,
528
]
],
[
[
270,
21,
28714
],
[
28714,
175,
528
]
],
[
[
270,
180,
173
],
[
173,
26,
528
]
],
[
[
270,
71,
970
],
[
970,
196,
528
]
],
[
[
270,
69,
575
],
[
575,
196,
528
]
],
[
[
270,
82,
1027
],
[
1027,
42,
528
]
],
[
[
270,
95,
588
],
[
588,
196,
528
]
],
[
[
270,
246,
67
],
[
67,
196,
528
]
]
] |
[
[
[
"Prochlorperazine",
"{u} may decrease the metabolism of {v}",
"Telithromycin"
]
],
[
[
"Prochlorperazine",
"{u} may decrease the metabolism of {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Prochlorperazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Telithromycin"
]
],
[
[
"Prochlorperazine",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Telithromycin"
]
],
[
[
"Prochlorperazine",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Telithromycin"
]
],
[
[
"Prochlorperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thiothixene"
],
[
"Thiothixene",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Prochlorperazine",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Prochlorperazine",
"{u} may increase the hypotensive activities of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Prochlorperazine",
"{u} may increase the serum concentration of {v}",
"Chloroquine"
],
[
"Chloroquine",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
],
[
[
"Prochlorperazine",
"{u} may decrease the therapeutic efficacy of {v}",
"Amantadine"
],
[
"Amantadine",
"{u} may increase the QTc prolonging activities of {v}",
"Telithromycin"
]
]
] |
Prochlorperazine may decrease the metabolism of Clarithromycin and Clarithromycin may increase the QTc prolonging activities of Telithromycin
Prochlorperazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Telithromycin (Compound)
Prochlorperazine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Telithromycin (Compound)
Prochlorperazine can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Telithromycin
Prochlorperazine may increase the severity of adverse effects when combined with Thiothixene and Thiothixene may increase the QTc prolonging activities of Telithromycin
Prochlorperazine may decrease the metabolism of Sulfisoxazole and Sulfisoxazole may increase the QTc prolonging activities of Telithromycin
Prochlorperazine may increase the hypotensive activities of Sotalol and Sotalol may increase the QTc prolonging activities of Telithromycin
Prochlorperazine may increase the serum concentration of Chloroquine and Chloroquine may increase the QTc prolonging activities of Telithromycin
Prochlorperazine may decrease the therapeutic efficacy of Amantadine and Amantadine may increase the QTc prolonging activities of Telithromycin
|
DB00701
|
DB09054
| 431 | 1,099 |
Amprenavir
|
Idelalisib
|
Amprenavir is a protease inhibitor used to treat HIV infection.
|
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth
|
The metabolism of Idelalisib can be decreased when combined with Amprenavir.
| 46 |
[
[
[
431,
69,
1099
]
],
[
[
431,
71,
243
],
[
243,
37,
1099
]
],
[
[
431,
223,
482
],
[
482,
69,
1099
]
],
[
[
431,
69,
396
],
[
396,
69,
1099
]
],
[
[
431,
249,
198
],
[
198,
69,
1099
]
],
[
[
431,
97,
629
],
[
629,
69,
1099
]
],
[
[
431,
225,
369
],
[
369,
69,
1099
]
],
[
[
431,
71,
513
],
[
513,
69,
1099
]
],
[
[
431,
225,
1456
],
[
1456,
71,
1099
]
],
[
[
431,
69,
582
],
[
582,
225,
1099
]
]
] |
[
[
[
"Amprenavir",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Amprenavir",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Idelalisib"
]
],
[
[
"Amprenavir",
"{u} may decrease the metabolism of {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Amprenavir",
"{u} may decrease the metabolism of {v}",
"Terbinafine"
],
[
"Terbinafine",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Amprenavir",
"{u} may increase the serum concentration of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Amprenavir",
"{u} may decrease the serum concentration of {v}",
"Estramustine"
],
[
"Estramustine",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Amprenavir",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pergolide"
],
[
"Pergolide",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Amprenavir",
"{u} may increase the severity of adverse effects when combined with {v}",
"Temsirolimus"
],
[
"Temsirolimus",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
]
],
[
[
"Amprenavir",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methysergide"
],
[
"Methysergide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Idelalisib"
]
],
[
[
"Amprenavir",
"{u} may decrease the metabolism of {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Idelalisib"
]
]
] |
Amprenavir may increase the severity of adverse effects when combined with Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Idelalisib
Amprenavir may decrease the metabolism of Verapamil and Verapamil may decrease the metabolism of Idelalisib
Amprenavir may decrease the metabolism of Terbinafine and Terbinafine may decrease the metabolism of Idelalisib
Amprenavir may increase the serum concentration of Cyclosporine and Cyclosporine may decrease the metabolism of Idelalisib
Amprenavir may decrease the serum concentration of Estramustine and Estramustine may decrease the metabolism of Idelalisib
Amprenavir may increase the severity of adverse effects when combined with Pergolide and Pergolide may decrease the metabolism of Idelalisib
Amprenavir may increase the severity of adverse effects when combined with Temsirolimus and Temsirolimus may decrease the metabolism of Idelalisib
Amprenavir may increase the severity of adverse effects when combined with Methysergide and Methysergide may increase the severity of adverse effects when combined with Idelalisib
Amprenavir may decrease the metabolism of Leflunomide and Leflunomide may increase the severity of adverse effects when combined with Idelalisib
|
DB09224
|
DB00356
| 988 | 276 |
Melperone
|
Chlorzoxazone
|
Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. Melperone has been used for a span of greater than 30 years in the European Union. It has been well established in the treatment of confusion, anxiety, restlessness (particularly in the elderly) and schizophrenia as It is known to be well-tolerated with an excellent safety profile. Recently, it has been studied as a treatment of psychosis related to Parkinson's disease.
|
A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
|
The risk or severity of adverse effects can be increased when Melperone is combined with Chlorzoxazone.
| 48 |
[
[
[
988,
71,
276
]
],
[
[
988,
71,
161
],
[
161,
26,
276
]
],
[
[
988,
225,
171
],
[
171,
26,
276
]
],
[
[
988,
184,
674
],
[
674,
30,
276
]
],
[
[
988,
38,
1261
],
[
1261,
192,
276
]
],
[
[
988,
192,
587
],
[
587,
38,
276
]
],
[
[
988,
54,
471
],
[
471,
208,
276
]
],
[
[
988,
71,
499
],
[
499,
223,
276
]
],
[
[
988,
225,
648
],
[
648,
223,
276
]
],
[
[
988,
225,
916
],
[
916,
71,
276
]
]
] |
[
[
[
"Melperone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorzoxazone"
]
],
[
[
"Melperone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Chlorzoxazone"
]
],
[
[
"Melperone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Chlorzoxazone"
]
],
[
[
"Melperone",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Chlorzoxazone"
]
],
[
[
"Melperone",
"{u} may increase the central nervous system depressant activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Chlorzoxazone"
]
],
[
[
"Melperone",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Chlorzoxazone"
]
],
[
[
"Melperone",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Chlorzoxazone"
]
],
[
[
"Melperone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may decrease the metabolism of {v}",
"Chlorzoxazone"
]
],
[
[
"Melperone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may decrease the metabolism of {v}",
"Chlorzoxazone"
]
],
[
[
"Melperone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etomidate"
],
[
"Etomidate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorzoxazone"
]
]
] |
Melperone may increase the severity of adverse effects when combined with Primidone and Primidone can increase the metabolism of Chlorzoxazone
Melperone may increase the severity of adverse effects when combined with Pentobarbital and Pentobarbital can increase the metabolism of Chlorzoxazone
Melperone can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Chlorzoxazone
Melperone may increase the central nervous system depressant activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Chlorzoxazone
Melperone may increase the central nervous system depressant activities of Ethanol and Ethanol may increase the central nervous system depressant activities of Chlorzoxazone
Melperone may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Chlorzoxazone
Melperone may increase the severity of adverse effects when combined with Clomipramine and Clomipramine may decrease the metabolism of Chlorzoxazone
Melperone may increase the severity of adverse effects when combined with Nefazodone and Nefazodone may decrease the metabolism of Chlorzoxazone
Melperone may increase the severity of adverse effects when combined with Etomidate and Etomidate may increase the severity of adverse effects when combined with Chlorzoxazone
|
DB00768
|
DB01072
| 478 | 564 |
Olopatadine
|
Atazanavir
|
Olopatadine is a selective histamine H1 antagonist and mast cell stabilizer that works by attenuating inflammatory and allergic reactions. It is a structural analog of [doxepin], which has a minimal anti-allergic activity. Olopatadine works by blocking the effects of histamine, which is a primary inflammatory mediator that causes inflammatory and allergic reactions. An ophthalmic solution of olopatadine was approved by the FDA and European Union for the treatment of seasonal and perennial allergic conjunctivitis in 1996 and 2002, respectively. In comparison to other anti-allergenic ophthalmic medications, olopatadine displays a good comfort and tolerability profile since it does not cause perturbation of cell membranes. Olopatadine is used for the symptomatic treatment of ocular itching associated with allergic conjunctivitis in ophthalmic formulations and seasonal allergic rhinitis in intranasal formulations. It is currently marketed
|
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003.
|
The metabolism of Atazanavir can be decreased when combined with Olopatadine.
| 46 |
[
[
[
478,
69,
564
]
],
[
[
478,
69,
429
],
[
429,
1,
564
]
],
[
[
478,
6,
4590
],
[
4590,
160,
564
]
],
[
[
478,
21,
28631
],
[
28631,
175,
564
]
],
[
[
478,
180,
150
],
[
150,
26,
564
]
],
[
[
478,
71,
956
],
[
956,
42,
564
]
],
[
[
478,
49,
863
],
[
863,
42,
564
]
],
[
[
478,
225,
1007
],
[
1007,
42,
564
]
],
[
[
478,
213,
1027
],
[
1027,
42,
564
]
],
[
[
478,
225,
259
],
[
259,
69,
564
]
]
] |
[
[
[
"Olopatadine",
"{u} may decrease the metabolism of {v}",
"Atazanavir"
]
],
[
[
"Olopatadine",
"{u} may decrease the metabolism of {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} (Compound) resembles {v} (Compound)",
"Atazanavir"
]
],
[
[
"Olopatadine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Atazanavir"
]
],
[
[
"Olopatadine",
"{u} (Compound) causes {v} (Side Effect)",
"Cough increased"
],
[
"Cough increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Atazanavir"
]
],
[
[
"Olopatadine",
"{u} can increase the metabolism of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Atazanavir"
]
],
[
[
"Olopatadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may increase the QTc prolonging activities of {v}",
"Atazanavir"
]
],
[
[
"Olopatadine",
"{u} may increase the neuroexcitatory activities of {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Atazanavir"
]
],
[
[
"Olopatadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Atazanavir"
]
],
[
[
"Olopatadine",
"{u} may decrease the antihypertensive activities of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the QTc prolonging activities of {v}",
"Atazanavir"
]
],
[
[
"Olopatadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flunitrazepam"
],
[
"Flunitrazepam",
"{u} may decrease the metabolism of {v}",
"Atazanavir"
]
]
] |
Olopatadine may decrease the metabolism of Lopinavir and Lopinavir (Compound) resembles Atazanavir (Compound)
Olopatadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Atazanavir (Compound)
Olopatadine (Compound) causes Cough increased (Side Effect) and Cough increased (Side Effect) is caused by Atazanavir (Compound)
Olopatadine can increase the metabolism of Fosphenytoin and Fosphenytoin can increase the metabolism of Atazanavir
Olopatadine may increase the severity of adverse effects when combined with Tetrabenazine and Tetrabenazine may increase the QTc prolonging activities of Atazanavir
Olopatadine may increase the neuroexcitatory activities of Gemifloxacin and Gemifloxacin may increase the QTc prolonging activities of Atazanavir
Olopatadine may increase the severity of adverse effects when combined with Paliperidone and Paliperidone may increase the QTc prolonging activities of Atazanavir
Olopatadine may decrease the antihypertensive activities of Sotalol and Sotalol may increase the QTc prolonging activities of Atazanavir
Olopatadine may increase the severity of adverse effects when combined with Flunitrazepam and Flunitrazepam may decrease the metabolism of Atazanavir
|
DB00897
|
DB08883
| 586 | 1,257 |
Triazolam
|
Perampanel
|
Withdrawn in the United Kingdom due to risk of psychiatric adverse drug reactions. This drug continues to be available in the U.S. Internationally, triazolam is a Schedule IV drug under the Convention on Psychotropic Substances.
|
Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.
|
Triazolam may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
| 15 |
[
[
[
586,
38,
1257
]
],
[
[
586,
71,
985
],
[
985,
38,
1257
]
],
[
[
586,
225,
653
],
[
653,
38,
1257
]
],
[
[
586,
192,
679
],
[
679,
38,
1257
]
],
[
[
586,
69,
861
],
[
861,
38,
1257
]
],
[
[
586,
270,
312
],
[
312,
38,
1257
]
],
[
[
586,
180,
171
],
[
171,
38,
1257
]
],
[
[
586,
116,
930
],
[
930,
38,
1257
]
],
[
[
586,
38,
1264
],
[
1264,
38,
1257
]
],
[
[
586,
54,
1365
],
[
1365,
208,
1257
]
]
] |
[
[
[
"Triazolam",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Triazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Procaine"
],
[
"Procaine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Triazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Triazolam",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Triazolam",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Triazolam",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Temazepam"
],
[
"Temazepam",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Triazolam",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Triazolam",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Brotizolam"
],
[
"Brotizolam",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Triazolam",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Triazolam",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Perampanel"
]
]
] |
Triazolam may increase the severity of adverse effects when combined with Procaine and Procaine may increase the central nervous system depressant activities of Perampanel
Triazolam may increase the severity of adverse effects when combined with Thioridazine and Thioridazine may increase the central nervous system depressant activities of Perampanel
Triazolam may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Perampanel
Triazolam may decrease the metabolism of Fluvoxamine and Fluvoxamine may increase the central nervous system depressant activities of Perampanel
Triazolam (Compound) resembles Temazepam (Compound) and Triazolam may increase the severity of adverse effects when combined with Temazepam and Temazepam may increase the central nervous system depressant activities of Perampanel
Triazolam can increase the metabolism of Pentobarbital and Pentobarbital may increase the central nervous system depressant activities of Perampanel
Triazolam (Compound) resembles Brotizolam (Compound) and Triazolam may increase the severity of adverse effects when combined with Brotizolam and Brotizolam may increase the central nervous system depressant activities of Perampanel
Triazolam may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Perampanel
Triazolam may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Perampanel
|
DB00794
|
DB00780
| 161 | 53 |
Primidone
|
Phenelzine
|
Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954.
|
Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
|
Primidone may increase the hypotensive activities of Phenelzine.
| 59 |
[
[
[
161,
82,
53
]
],
[
[
161,
225,
63
],
[
63,
71,
53
]
],
[
[
161,
26,
39
],
[
39,
155,
53
]
],
[
[
161,
6,
4590
],
[
4590,
160,
53
]
],
[
[
161,
21,
28384
],
[
28384,
175,
53
]
],
[
[
161,
71,
33
],
[
33,
24,
53
]
],
[
[
161,
225,
41
],
[
41,
24,
53
]
],
[
[
161,
26,
540
],
[
540,
184,
53
]
],
[
[
161,
26,
514
],
[
514,
31,
53
]
],
[
[
161,
97,
1018
],
[
1018,
31,
53
]
]
] |
[
[
[
"Primidone",
"{u} may increase the hypotensive activities of {v}",
"Phenelzine"
]
],
[
[
"Primidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tranylcypromine"
],
[
"Tranylcypromine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenelzine"
]
],
[
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Selegiline"
],
[
"Selegiline",
"{u} (Compound) resembles {v} (Compound)",
"Phenelzine"
]
],
[
[
"Primidone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Phenelzine"
]
],
[
[
"Primidone",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Phenelzine"
]
],
[
[
"Primidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pizotifen"
],
[
"Pizotifen",
"{u} may increase the anticholinergic activities of {v}",
"Phenelzine"
]
],
[
[
"Primidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may increase the anticholinergic activities of {v}",
"Phenelzine"
]
],
[
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Morphine"
],
[
"Morphine",
"{u} can increase the therapeutic efficacy of {v}",
"Phenelzine"
]
],
[
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Rosiglitazone"
],
[
"Rosiglitazone",
"{u} may increase the hypoglycemic activities of {v}",
"Phenelzine"
]
],
[
[
"Primidone",
"{u} may decrease the serum concentration of {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may increase the hypoglycemic activities of {v}",
"Phenelzine"
]
]
] |
Primidone may increase the severity of adverse effects when combined with Tranylcypromine and Tranylcypromine may increase the severity of adverse effects when combined with Phenelzine
Primidone can increase the metabolism of Selegiline and Selegiline (Compound) resembles Phenelzine (Compound)
Primidone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Phenelzine (Compound)
Primidone (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Phenelzine (Compound)
Primidone may increase the severity of adverse effects when combined with Pizotifen and Pizotifen may increase the anticholinergic activities of Phenelzine
Primidone may increase the severity of adverse effects when combined with Clemastine and Clemastine may increase the anticholinergic activities of Phenelzine
Primidone can increase the metabolism of Morphine and Morphine can increase the therapeutic efficacy of Phenelzine
Primidone can increase the metabolism of Rosiglitazone and Rosiglitazone may increase the hypoglycemic activities of Phenelzine
Primidone may decrease the serum concentration of Sunitinib and Sunitinib may increase the hypoglycemic activities of Phenelzine
|
DB00933
|
DB00557
| 990 | 1,262 |
Mesoridazine
|
Hydroxyzine
|
A phenothiazine antipsychotic with effects similar to chlorpromazine.
|
Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety.
|
Mesoridazine may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.
| 15 |
[
[
[
990,
38,
1262
]
],
[
[
990,
71,
989
],
[
989,
1,
1262
]
],
[
[
990,
225,
955
],
[
955,
38,
1262
]
],
[
[
990,
225,
971
],
[
971,
1,
1262
]
],
[
[
990,
225,
648
],
[
648,
225,
1262
]
],
[
[
990,
155,
1378
],
[
1378,
1,
1262
]
],
[
[
990,
6,
18777
],
[
18777,
160,
1262
]
],
[
[
990,
71,
380
],
[
380,
38,
1262
]
],
[
[
990,
38,
405
],
[
405,
38,
1262
]
],
[
[
990,
69,
288
],
[
288,
38,
1262
]
]
] |
[
[
[
"Mesoridazine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
]
],
[
[
"Mesoridazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Hydroxyzine"
]
],
[
[
"Mesoridazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
]
],
[
[
"Mesoridazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zuclopenthixol"
],
[
"Zuclopenthixol",
"{u} (Compound) resembles {v} (Compound)",
"Hydroxyzine"
]
],
[
[
"Mesoridazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydroxyzine"
]
],
[
[
"Mesoridazine",
"{u} (Compound) resembles {v} (Compound)",
"Acetophenazine"
],
[
"Acetophenazine",
"{u} (Compound) resembles {v} (Compound)",
"Hydroxyzine"
]
],
[
[
"Mesoridazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Hydroxyzine"
]
],
[
[
"Mesoridazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Glutethimide"
],
[
"Glutethimide",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
]
],
[
[
"Mesoridazine",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
]
],
[
[
"Mesoridazine",
"{u} may decrease the metabolism of {v}",
"Promazine"
],
[
"Promazine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
]
]
] |
Mesoridazine may increase the severity of adverse effects when combined with Cyclizine and Cyclizine (Compound) resembles Hydroxyzine (Compound)
Mesoridazine may increase the severity of adverse effects when combined with Quetiapine and Quetiapine may increase the central nervous system depressant activities of Hydroxyzine
Mesoridazine may increase the severity of adverse effects when combined with Zuclopenthixol and Zuclopenthixol (Compound) resembles Hydroxyzine (Compound)
Mesoridazine may increase the severity of adverse effects when combined with Nefazodone and Nefazodone may increase the severity of adverse effects when combined with Hydroxyzine
Mesoridazine (Compound) resembles Acetophenazine (Compound) and Acetophenazine (Compound) resembles Hydroxyzine (Compound)
Mesoridazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Hydroxyzine (Compound)
Mesoridazine may increase the severity of adverse effects when combined with Glutethimide and Glutethimide may increase the central nervous system depressant activities of Hydroxyzine
Mesoridazine may increase the central nervous system depressant activities of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Hydroxyzine
Mesoridazine may decrease the metabolism of Promazine and Promazine may increase the central nervous system depressant activities of Hydroxyzine
|
DB00477
|
DB00584
| 392 | 315 |
Chlorpromazine
|
Enalapril
|
The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
|
Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling. Being a prodrug, enalapril is rapidly biotransformed into its active metabolite, [enalaprilat], which is responsible for the pharmacological actions of enalapril. The active metabolite of enalapril competitively inhibits the ACE to hinder the production of angiotensin II, a key component of the renin-angiotensin-aldosterone system that promotes v
|
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Enalapril.
| 48 |
[
[
[
392,
71,
315
]
],
[
[
392,
71,
676
],
[
676,
225,
315
]
],
[
[
392,
71,
642
],
[
642,
71,
315
]
],
[
[
392,
6,
8339
],
[
8339,
160,
315
]
],
[
[
392,
7,
13633
],
[
13633,
161,
315
]
],
[
[
392,
21,
28725
],
[
28725,
175,
315
]
],
[
[
392,
180,
171
],
[
171,
26,
315
]
],
[
[
392,
52,
828
],
[
828,
206,
315
]
],
[
[
392,
223,
230
],
[
230,
213,
315
]
],
[
[
392,
42,
610
],
[
610,
223,
315
]
]
] |
[
[
[
"Chlorpromazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Enalapril"
]
],
[
[
"Chlorpromazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lisinopril"
],
[
"Lisinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Enalapril"
]
],
[
[
"Chlorpromazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benazepril"
],
[
"Benazepril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Enalapril"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Enalapril"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) upregulates {v} (Gene)",
"MCOLN1"
],
[
"MCOLN1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Enalapril"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Enalapril"
]
],
[
[
"Chlorpromazine",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Enalapril"
]
],
[
[
"Chlorpromazine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Enalapril"
]
],
[
[
"Chlorpromazine",
"{u} may decrease the metabolism of {v}",
"Yohimbine"
],
[
"Yohimbine",
"{u} may decrease the antihypertensive activities of {v}",
"Enalapril"
]
],
[
[
"Chlorpromazine",
"{u} may increase the QTc prolonging activities of {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may decrease the metabolism of {v}",
"Enalapril"
]
]
] |
Chlorpromazine may increase the severity of adverse effects when combined with Lisinopril and Lisinopril may increase the severity of adverse effects when combined with Enalapril
Chlorpromazine may increase the severity of adverse effects when combined with Benazepril and Benazepril may increase the severity of adverse effects when combined with Enalapril
Chlorpromazine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Enalapril (Compound)
Chlorpromazine (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Enalapril (Compound)
Chlorpromazine (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Enalapril (Compound)
Chlorpromazine can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Enalapril
Chlorpromazine may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Enalapril
Chlorpromazine may decrease the metabolism of Yohimbine and Yohimbine may decrease the antihypertensive activities of Enalapril
Chlorpromazine may increase the QTc prolonging activities of Atomoxetine and Atomoxetine may decrease the metabolism of Enalapril
|
DB06441
|
DB11079
| 751 | 790 |
Cangrelor
|
Trolamine salicylate
|
Cangrelor is an intravenous, direct-acting, reversible P2Y12 inhibitor for patients undergoing percutaneous coronary intervention (PCI) who have not been yet treated by oral P2Y12 inhibitors. An advantage Cangrelor provides over oral P2Y12 inhibitors (such as prasugrel, ticagrelor, and clopidogrel) is that it is an active drug not requiring metabolic conversion therefore providing a rapid onset and offset of action. Cangrelor was approved by the FDA in June 2015 for intravenous application.
|
Trolamine salicylate is an organic compound or a salt formed between triethanolamine and salicylic acid. Triethanolamine neutralizes the acidity of the salicylic acid. It is a topical analgesic used for temporary relief of minor pain associated with arthritis, simple backache, muscle strains, sprains, and bruises. Unlike other topical analgesics, trolamine salicylate has no distinct odor which improves patient acceptability. It also displays low systemic absorption upon dermal or topical administration and has low skin irritant properties. As with other salicylates, trolamine salicylate is an inhibitor of cyclo-oxygenase (COX) enzymes with no reported selectivity towards a specific enzyme isoform. Trolamine salicylate serves as an active ingredient in topical over-the-counter products for temporary management of mild to moderate muscular and joint pains.
|
The risk or severity of adverse effects can be increased when Cangrelor is combined with Trolamine salicylate.
| 48 |
[
[
[
751,
71,
790
]
],
[
[
751,
182,
384
],
[
384,
28,
790
]
],
[
[
751,
71,
236
],
[
236,
182,
790
]
],
[
[
751,
28,
775
],
[
775,
71,
790
]
],
[
[
751,
182,
795
],
[
795,
71,
790
]
],
[
[
751,
182,
759
],
[
759,
225,
790
]
],
[
[
751,
182,
384
],
[
384,
28,
744
],
[
744,
28,
790
]
],
[
[
751,
182,
744
],
[
744,
182,
384
],
[
384,
28,
790
]
],
[
[
751,
71,
236
],
[
236,
182,
384
],
[
384,
28,
790
]
],
[
[
751,
182,
498
],
[
498,
285,
384
],
[
384,
28,
790
]
]
] |
[
[
[
"Cangrelor",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trolamine salicylate"
]
],
[
[
"Cangrelor",
"{u} may increase the anticoagulant activities of {v}",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Trolamine salicylate"
]
],
[
[
"Cangrelor",
"{u} may increase the severity of adverse effects when combined with {v}",
"Salicylic acid"
],
[
"Salicylic acid",
"{u} may increase the anticoagulant activities of {v}",
"Trolamine salicylate"
]
],
[
[
"Cangrelor",
"{u} may increase the anticoagulant activities of {v}",
"Ifenprodil"
],
[
"Ifenprodil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trolamine salicylate"
]
],
[
[
"Cangrelor",
"{u} may increase the anticoagulant activities of {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trolamine salicylate"
]
],
[
[
"Cangrelor",
"{u} may increase the anticoagulant activities of {v}",
"Ditazole"
],
[
"Ditazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trolamine salicylate"
]
],
[
[
"Cangrelor",
"{u} may increase the anticoagulant activities of {v}",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may increase the anticoagulant activities of {v}",
"Trolamine salicylate"
]
],
[
[
"Cangrelor",
"{u} may increase the anticoagulant activities of {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may increase the anticoagulant activities of {v}",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Trolamine salicylate"
]
],
[
[
"Cangrelor",
"{u} may increase the severity of adverse effects when combined with {v}",
"Salicylic acid"
],
[
"Salicylic acid",
"{u} may increase the anticoagulant activities of {v}",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Trolamine salicylate"
]
],
[
[
"Cangrelor",
"{u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the anticoagulant activities of {v}",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Trolamine salicylate"
]
]
] |
Cangrelor may increase the anticoagulant activities of Phenprocoumon and Phenprocoumon may increase the anticoagulant activities of Trolamine salicylate
Cangrelor may increase the severity of adverse effects when combined with Salicylic acid and Salicylic acid may increase the anticoagulant activities of Trolamine salicylate
Cangrelor may increase the anticoagulant activities of Ifenprodil and Ifenprodil may increase the severity of adverse effects when combined with Trolamine salicylate
Cangrelor may increase the anticoagulant activities of Ticagrelor and Ticagrelor may increase the severity of adverse effects when combined with Trolamine salicylate
Cangrelor may increase the anticoagulant activities of Ditazole and Ditazole may increase the severity of adverse effects when combined with Trolamine salicylate
Cangrelor may increase the anticoagulant activities of Phenprocoumon and Phenprocoumon may increase the anticoagulant activities of Edoxaban and Edoxaban may increase the anticoagulant activities of Trolamine salicylate
Cangrelor may increase the anticoagulant activities of Edoxaban and Edoxaban may increase the anticoagulant activities of Phenprocoumon and Phenprocoumon may increase the anticoagulant activities of Trolamine salicylate
Cangrelor may increase the severity of adverse effects when combined with Salicylic acid and Salicylic acid may increase the anticoagulant activities of Phenprocoumon and Phenprocoumon may increase the anticoagulant activities of Trolamine salicylate
Cangrelor may increase the anticoagulant activities of Dicoumarol and Dicoumarol (Compound) resembles Phenprocoumon (Compound) and Dicoumarol may increase the anticoagulant activities of Phenprocoumon and Phenprocoumon may increase the anticoagulant activities of Trolamine salicylate
|
DB00734
|
DB06153
| 453 | 33 |
Risperidone
|
Pizotifen
|
Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone). Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's
|
Pizotifen belongs to the class of antamines and is related to [cyproheptadine]. It is a potent serotonin and tryptamine antagonist that has been used for migraine prevention for many years. It exhibits weak anticholinergic, antihistamine, and antikinin actions in addition to sedative and appetite-stimulating properties. Some patients receiving pizotifen treatment developed tolerance with the prolonged use of the drug. Numerous studies have revealed the potential antidepressant effects of pizotifen, which are independent of its antimigraine action. While it is suggested that pizotifen may act similarly to the classic tricyclic antidepressants, its full mechanism of antidepressant action is not fully elucidated. Pizotifen hydrochloride is an active ingredient in Sandomigran, which is used for the prophylactic management of migraines. Sandomigran is available in a number of countries but is not approved by the
|
The risk or severity of adverse effects can be increased when Risperidone is combined with Pizotifen.
| 48 |
[
[
[
453,
71,
33
]
],
[
[
453,
236,
53
],
[
53,
178,
33
]
],
[
[
453,
225,
23
],
[
23,
178,
33
]
],
[
[
453,
184,
674
],
[
674,
30,
33
]
],
[
[
453,
59,
543
],
[
543,
38,
33
]
],
[
[
453,
192,
587
],
[
587,
38,
33
]
],
[
[
453,
236,
702
],
[
702,
192,
33
]
],
[
[
453,
38,
405
],
[
405,
192,
33
]
],
[
[
453,
54,
1046
],
[
1046,
208,
33
]
],
[
[
453,
95,
495
],
[
495,
55,
33
]
]
] |
[
[
[
"Risperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pizotifen"
]
],
[
[
"Risperidone",
"{u} may increase the hypotensive activities of {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} may increase the anticholinergic activities of {v}",
"Pizotifen"
]
],
[
[
"Risperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may increase the anticholinergic activities of {v}",
"Pizotifen"
]
],
[
[
"Risperidone",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Pizotifen"
]
],
[
[
"Risperidone",
"{u} may decrease the antihypertensive activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Pizotifen"
]
],
[
[
"Risperidone",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Pizotifen"
]
],
[
[
"Risperidone",
"{u} may increase the hypotensive activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Pizotifen"
]
],
[
[
"Risperidone",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Pizotifen"
]
],
[
[
"Risperidone",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Pizotifen"
]
],
[
[
"Risperidone",
"{u} may increase the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Pizotifen"
]
]
] |
Risperidone may increase the hypotensive activities of Phenelzine and Phenelzine may increase the anticholinergic activities of Pizotifen
Risperidone may increase the severity of adverse effects when combined with Procarbazine and Procarbazine may increase the anticholinergic activities of Pizotifen
Risperidone can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Pizotifen
Risperidone may decrease the antihypertensive activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Pizotifen
Risperidone may increase the central nervous system depressant activities of Ethanol and Ethanol may increase the central nervous system depressant activities of Pizotifen
Risperidone may increase the hypotensive activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Pizotifen
Risperidone may increase the central nervous system depressant activities of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Pizotifen
Risperidone may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Pizotifen
Risperidone may increase the serum concentration of Vemurafenib and Vemurafenib may increase the severity of QTc prolonging effects when combined with Pizotifen
|
DB00925
|
DB01224
| 355 | 955 |
Phenoxybenzamine
|
Quetiapine
|
An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.
|
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].
|
The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Quetiapine.
| 48 |
[
[
[
355,
71,
955
]
],
[
[
355,
69,
648
],
[
648,
249,
955
]
],
[
[
355,
6,
7601
],
[
7601,
160,
955
]
],
[
[
355,
21,
28743
],
[
28743,
175,
955
]
],
[
[
355,
71,
679
],
[
679,
38,
955
]
],
[
[
355,
186,
702
],
[
702,
192,
955
]
],
[
[
355,
1,
72
],
[
72,
38,
955
]
],
[
[
355,
225,
1265
],
[
1265,
192,
955
]
],
[
[
355,
155,
568
],
[
568,
196,
955
]
],
[
[
355,
225,
914
],
[
914,
196,
955
]
]
] |
[
[
[
"Phenoxybenzamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quetiapine"
]
],
[
[
"Phenoxybenzamine",
"{u} may decrease the metabolism of {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may increase the serum concentration of {v}",
"Quetiapine"
]
],
[
[
"Phenoxybenzamine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1B"
],
[
"ADRA1B",
"{u} (Gene) is bound by {v} (Compound)",
"Quetiapine"
]
],
[
[
"Phenoxybenzamine",
"{u} (Compound) causes {v} (Side Effect)",
"Tachycardia"
],
[
"Tachycardia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quetiapine"
]
],
[
[
"Phenoxybenzamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Quetiapine"
]
],
[
[
"Phenoxybenzamine",
"{u} may increase the antihypertensive activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Quetiapine"
]
],
[
[
"Phenoxybenzamine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Quetiapine"
]
],
[
[
"Phenoxybenzamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Quetiapine"
]
],
[
[
"Phenoxybenzamine",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may increase the QTc prolonging activities of {v}",
"Quetiapine"
]
],
[
[
"Phenoxybenzamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desflurane"
],
[
"Desflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Quetiapine"
]
]
] |
Phenoxybenzamine may decrease the metabolism of Nefazodone and Nefazodone may increase the serum concentration of Quetiapine
Phenoxybenzamine (Compound) binds ADRA1B (Gene) and ADRA1B (Gene) is bound by Quetiapine (Compound)
Phenoxybenzamine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Quetiapine (Compound)
Phenoxybenzamine may increase the severity of adverse effects when combined with Thalidomide and Thalidomide may increase the central nervous system depressant activities of Quetiapine
Phenoxybenzamine may increase the antihypertensive activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Quetiapine
Phenoxybenzamine (Compound) resembles Orphenadrine (Compound) and Orphenadrine may increase the central nervous system depressant activities of Quetiapine
Phenoxybenzamine may increase the severity of adverse effects when combined with Nabilone and Nabilone may increase the central nervous system depressant activities of Quetiapine
Phenoxybenzamine (Compound) resembles Tamoxifen (Compound) and Tamoxifen may increase the QTc prolonging activities of Quetiapine
Phenoxybenzamine may increase the severity of adverse effects when combined with Desflurane and Desflurane may increase the QTc prolonging activities of Quetiapine
|
DB00454
|
DB00312
| 465 | 171 |
Meperidine
|
Pentobarbital
|
A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.
|
A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
|
Meperidine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.
| 15 |
[
[
[
465,
38,
171
]
],
[
[
465,
225,
994
],
[
994,
71,
171
]
],
[
[
465,
71,
977
],
[
977,
155,
171
]
],
[
[
465,
6,
4590
],
[
4590,
160,
171
]
],
[
[
465,
21,
28401
],
[
28401,
175,
171
]
],
[
[
465,
71,
257
],
[
257,
180,
171
]
],
[
[
465,
225,
431
],
[
431,
180,
171
]
],
[
[
465,
69,
588
],
[
588,
180,
171
]
],
[
[
465,
180,
147
],
[
147,
180,
171
]
],
[
[
465,
86,
383
],
[
383,
180,
171
]
]
] |
[
[
[
"Meperidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Pentobarbital"
]
],
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butabarbital"
],
[
"Butabarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pentobarbital"
]
],
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
]
],
[
[
"Meperidine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Pentobarbital"
]
],
[
[
"Meperidine",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pentobarbital"
]
],
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sertindole"
],
[
"Sertindole",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
]
],
[
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
]
],
[
[
"Meperidine",
"{u} may decrease the metabolism of {v}",
"Chloroquine"
],
[
"Chloroquine",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
]
],
[
[
"Meperidine",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
]
],
[
[
"Meperidine",
"{u} may increase the serotonergic activities of {v}",
"Granisetron"
],
[
"Granisetron",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
]
]
] |
Meperidine may increase the severity of adverse effects when combined with Butabarbital and Butabarbital may increase the severity of adverse effects when combined with Pentobarbital
Meperidine may increase the severity of adverse effects when combined with Butalbital and Butalbital (Compound) resembles Pentobarbital (Compound)
Meperidine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pentobarbital (Compound)
Meperidine (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Pentobarbital (Compound)
Meperidine may increase the severity of adverse effects when combined with Sertindole and Sertindole can increase the metabolism of Pentobarbital
Meperidine may increase the severity of adverse effects when combined with Amprenavir and Amprenavir can increase the metabolism of Pentobarbital
Meperidine may decrease the metabolism of Chloroquine and Chloroquine can increase the metabolism of Pentobarbital
Meperidine can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Pentobarbital
Meperidine may increase the serotonergic activities of Granisetron and Granisetron can increase the metabolism of Pentobarbital
|
DB00202
|
DB06810
| 939 | 899 |
Succinylcholine
|
Plicamycin
|
Succinylcholine is a depolarizing skeletal muscle relaxant consisting of two molecules of the endogenous neurotransmitter [acetylcholine] (ACh) linked by their acetyl groups. It has been widely used for over 50 years, most commonly in its chloride salt form, as a means of neuromuscular blockade during intubation and surgical procedures. Its rapid onset and offset, with effects beginning within 60 seconds of intravenous administration and lasting between four to six minutes, make succinylcholine particularly useful in the setting of short medical procedures requiring brief periods of muscle relaxation.
|
Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.
|
Succinylcholine may increase the respiratory depressant activities of Plicamycin.
| 39 |
[
[
[
939,
62,
899
]
],
[
[
939,
95,
243
],
[
243,
37,
899
]
],
[
[
939,
43,
1331
],
[
1331,
197,
899
]
],
[
[
939,
95,
1279
],
[
1279,
62,
899
]
],
[
[
939,
193,
557
],
[
557,
71,
899
]
],
[
[
939,
258,
1348
],
[
1348,
234,
899
]
],
[
[
939,
43,
808
],
[
808,
248,
899
]
],
[
[
939,
95,
243
],
[
243,
37,
889
],
[
889,
29,
899
]
],
[
[
939,
43,
1331
],
[
1331,
197,
45
],
[
45,
43,
899
]
],
[
[
939,
95,
1279
],
[
1279,
92,
45
],
[
45,
43,
899
]
]
] |
[
[
[
"Succinylcholine",
"{u} may increase the respiratory depressant activities of {v}",
"Plicamycin"
]
],
[
[
"Succinylcholine",
"{u} may increase the serum concentration of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Plicamycin"
]
],
[
[
"Succinylcholine",
"{u} may increase the neuromuscular blocking activities of {v}",
"Capreomycin"
],
[
"Capreomycin",
"{u} may increase the neuromuscular blocking activities of {v}",
"Plicamycin"
]
],
[
[
"Succinylcholine",
"{u} may increase the serum concentration of {v}",
"Decamethonium"
],
[
"Decamethonium",
"{u} may increase the respiratory depressant activities of {v}",
"Plicamycin"
]
],
[
[
"Succinylcholine",
"{u} may decrease the neuromuscular blocking activities of {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Plicamycin"
]
],
[
[
"Succinylcholine",
"{u} may increase the arrhythmogenic activities of {v}",
"Ouabain"
],
[
"Ouabain",
"{u} may decrease the cardiotoxic activities of {v}",
"Plicamycin"
]
],
[
[
"Succinylcholine",
"{u} may increase the neuromuscular blocking activities of {v}",
"Magnesium salicylate"
],
[
"Magnesium salicylate",
"{u} may decrease the excretion rate {v}",
"Plicamycin"
]
],
[
[
"Succinylcholine",
"{u} may increase the serum concentration of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Carboplatin"
],
[
"Carboplatin",
"{u} may increase the ototoxic activities of {v}",
"Plicamycin"
]
],
[
[
"Succinylcholine",
"{u} may increase the neuromuscular blocking activities of {v}",
"Capreomycin"
],
[
"Capreomycin",
"{u} may increase the neuromuscular blocking activities of {v}",
"Mecamylamine"
],
[
"Mecamylamine",
"{u} may increase the neuromuscular blocking activities of {v}",
"Plicamycin"
]
],
[
[
"Succinylcholine",
"{u} may increase the serum concentration of {v}",
"Decamethonium"
],
[
"Decamethonium",
"{u} may decrease the therapeutic efficacy of {v}",
"Mecamylamine"
],
[
"Mecamylamine",
"{u} may increase the neuromuscular blocking activities of {v}",
"Plicamycin"
]
]
] |
Succinylcholine may increase the serum concentration of Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Plicamycin
Succinylcholine may increase the neuromuscular blocking activities of Capreomycin and Capreomycin may increase the neuromuscular blocking activities of Plicamycin
Succinylcholine may increase the serum concentration of Decamethonium and Decamethonium may increase the respiratory depressant activities of Plicamycin
Succinylcholine may decrease the neuromuscular blocking activities of Torasemide and Torasemide may increase the severity of adverse effects when combined with Plicamycin
Succinylcholine may increase the arrhythmogenic activities of Ouabain and Ouabain may decrease the cardiotoxic activities of Plicamycin
Succinylcholine may increase the neuromuscular blocking activities of Magnesium salicylate and Magnesium salicylate may decrease the excretion rate Plicamycin
Succinylcholine may increase the serum concentration of Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Carboplatin and Carboplatin may increase the ototoxic activities of Plicamycin
Succinylcholine may increase the neuromuscular blocking activities of Capreomycin and Capreomycin may increase the neuromuscular blocking activities of Mecamylamine and Mecamylamine may increase the neuromuscular blocking activities of Plicamycin
Succinylcholine may increase the serum concentration of Decamethonium and Decamethonium may decrease the therapeutic efficacy of Mecamylamine and Mecamylamine may increase the neuromuscular blocking activities of Plicamycin
|
DB00280
|
DB01626
| 589 | 75 |
Disopyramide
|
Pargyline
|
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
|
Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.
|
Disopyramide may increase the hypoglycemic activities of Pargyline.
| 8 |
[
[
[
589,
31,
75
]
],
[
[
589,
31,
39
],
[
39,
82,
75
]
],
[
[
589,
1,
1639
],
[
1639,
155,
75
]
],
[
[
589,
31,
53
],
[
53,
155,
75
]
],
[
[
589,
69,
41
],
[
41,
24,
75
]
],
[
[
589,
185,
423
],
[
423,
31,
75
]
],
[
[
589,
31,
481
],
[
481,
31,
75
]
],
[
[
589,
95,
1019
],
[
1019,
31,
75
]
],
[
[
589,
42,
1018
],
[
1018,
31,
75
]
],
[
[
589,
69,
615
],
[
615,
32,
75
]
]
] |
[
[
[
"Disopyramide",
"{u} may increase the hypoglycemic activities of {v}",
"Pargyline"
]
],
[
[
"Disopyramide",
"{u} may increase the hypoglycemic activities of {v}",
"Selegiline"
],
[
"Selegiline",
"{u} may increase the hypotensive activities of {v}",
"Pargyline"
]
],
[
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Tripelennamine"
],
[
"Tripelennamine",
"{u} (Compound) resembles {v} (Compound)",
"Pargyline"
]
],
[
[
"Disopyramide",
"{u} may increase the hypoglycemic activities of {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} (Compound) resembles {v} (Compound)",
"Pargyline"
]
],
[
[
"Disopyramide",
"{u} may decrease the metabolism of {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may increase the anticholinergic activities of {v}",
"Pargyline"
]
],
[
[
"Disopyramide",
"{u} may increase the hypoglycemic activities of {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may increase the hypoglycemic activities of {v}",
"Pargyline"
]
],
[
[
"Disopyramide",
"{u} may increase the hypoglycemic activities of {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may increase the hypoglycemic activities of {v}",
"Pargyline"
]
],
[
[
"Disopyramide",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the hypoglycemic activities of {v}",
"Pargyline"
]
],
[
[
"Disopyramide",
"{u} may increase the QTc prolonging activities of {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may increase the hypoglycemic activities of {v}",
"Pargyline"
]
],
[
[
"Disopyramide",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Pargyline"
]
]
] |
Disopyramide may increase the hypoglycemic activities of Selegiline and Selegiline may increase the hypotensive activities of Pargyline
Disopyramide (Compound) resembles Tripelennamine (Compound) and Tripelennamine (Compound) resembles Pargyline (Compound)
Disopyramide may increase the hypoglycemic activities of Phenelzine and Phenelzine (Compound) resembles Pargyline (Compound)
Disopyramide may decrease the metabolism of Clemastine and Clemastine may increase the anticholinergic activities of Pargyline
Disopyramide may increase the hypoglycemic activities of Repaglinide and Repaglinide may increase the hypoglycemic activities of Pargyline
Disopyramide may increase the hypoglycemic activities of Sitagliptin and Sitagliptin may increase the hypoglycemic activities of Pargyline
Disopyramide may increase the serum concentration of Mifepristone and Mifepristone may increase the hypoglycemic activities of Pargyline
Disopyramide may increase the QTc prolonging activities of Sunitinib and Sunitinib may increase the hypoglycemic activities of Pargyline
Disopyramide may decrease the metabolism of Sildenafil and Sildenafil may increase the antihypertensive activities of Pargyline
|
DB09342
|
DB00241
| 996 | 977 |
Propoxycaine
|
Butalbital
|
Propoxycaine is a local anesthetic of the ester type that has a rapid onset of action and a longer duration of action than procaine hydrochloride. This drug was removed from the US market in 1996. Although no longer available in the United States, this medication was used in combination with procaine to aid in anesthesia during dental procedures. Used in combination with procaine, it was the only dental local anesthetic available in cartridge form.
|
Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia. Butalbital has a low degree of selectivity and a narrow therapeutic index. Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines thus it is not indicated for such condition. As with other barbiturates
|
The risk or severity of adverse effects can be increased when Propoxycaine is combined with Butalbital.
| 48 |
[
[
[
996,
71,
977
]
],
[
[
996,
225,
145
],
[
145,
1,
977
]
],
[
[
996,
38,
405
],
[
405,
192,
977
]
],
[
[
996,
192,
491
],
[
491,
38,
977
]
],
[
[
996,
54,
1365
],
[
1365,
208,
977
]
],
[
[
996,
225,
380
],
[
380,
71,
977
]
],
[
[
996,
71,
979
],
[
979,
225,
977
]
],
[
[
996,
225,
917
],
[
917,
225,
977
]
],
[
[
996,
71,
1009
],
[
1009,
71,
977
]
],
[
[
996,
225,
197
],
[
197,
116,
977
]
]
] |
[
[
[
"Propoxycaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butalbital"
]
],
[
[
"Propoxycaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thiamylal"
],
[
"Thiamylal",
"{u} (Compound) resembles {v} (Compound)",
"Butalbital"
]
],
[
[
"Propoxycaine",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Butalbital"
]
],
[
[
"Propoxycaine",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Butalbital"
]
],
[
[
"Propoxycaine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Butalbital"
]
],
[
[
"Propoxycaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Glutethimide"
],
[
"Glutethimide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butalbital"
]
],
[
[
"Propoxycaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butalbital"
]
],
[
[
"Propoxycaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prilocaine"
],
[
"Prilocaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butalbital"
]
],
[
[
"Propoxycaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Normethadone"
],
[
"Normethadone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Butalbital"
]
],
[
[
"Propoxycaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amobarbital"
],
[
"Amobarbital",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Butalbital"
]
]
] |
Propoxycaine may increase the severity of adverse effects when combined with Thiamylal and Thiamylal (Compound) resembles Butalbital (Compound)
Propoxycaine may increase the central nervous system depressant activities of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Butalbital
Propoxycaine may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Butalbital
Propoxycaine may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Butalbital
Propoxycaine may increase the severity of adverse effects when combined with Glutethimide and Glutethimide may increase the severity of adverse effects when combined with Butalbital
Propoxycaine may increase the severity of adverse effects when combined with Dexbrompheniramine and Dexbrompheniramine may increase the severity of adverse effects when combined with Butalbital
Propoxycaine may increase the severity of adverse effects when combined with Prilocaine and Prilocaine may increase the severity of adverse effects when combined with Butalbital
Propoxycaine may increase the severity of adverse effects when combined with Normethadone and Normethadone may increase the severity of adverse effects when combined with Butalbital
Propoxycaine may increase the severity of adverse effects when combined with Amobarbital and Amobarbital (Compound) resembles Butalbital (Compound) and Amobarbital may increase the severity of adverse effects when combined with Butalbital
|
DB00633
|
DB01433
| 724 | 984 |
Dexmedetomidine
|
Methadyl acetate
|
An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.
|
A narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.
|
The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methadyl acetate.
| 48 |
[
[
[
724,
71,
984
]
],
[
[
724,
225,
355
],
[
355,
155,
984
]
],
[
[
724,
71,
973
],
[
973,
225,
984
]
],
[
[
724,
192,
72
],
[
72,
38,
984
]
],
[
[
724,
71,
289
],
[
289,
71,
984
]
],
[
[
724,
184,
674
],
[
674,
30,
984
]
],
[
[
724,
38,
702
],
[
702,
192,
984
]
],
[
[
724,
54,
471
],
[
471,
208,
984
]
],
[
[
724,
225,
515
],
[
515,
71,
984
]
],
[
[
724,
82,
453
],
[
453,
71,
984
]
]
] |
[
[
[
"Dexmedetomidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methadyl acetate"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenoxybenzamine"
],
[
"Phenoxybenzamine",
"{u} (Compound) resembles {v} (Compound)",
"Methadyl acetate"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aceprometazine"
],
[
"Aceprometazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methadyl acetate"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Methadyl acetate"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methadyl acetate"
]
],
[
[
"Dexmedetomidine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Methadyl acetate"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Methadyl acetate"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Methadyl acetate"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Alprazolam"
],
[
"Alprazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methadyl acetate"
]
],
[
[
"Dexmedetomidine",
"{u} may increase the hypotensive activities of {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methadyl acetate"
]
]
] |
Dexmedetomidine may increase the severity of adverse effects when combined with Phenoxybenzamine and Phenoxybenzamine (Compound) resembles Methadyl acetate (Compound)
Dexmedetomidine may increase the severity of adverse effects when combined with Aceprometazine and Aceprometazine may increase the severity of adverse effects when combined with Methadyl acetate
Dexmedetomidine may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Methadyl acetate
Dexmedetomidine may increase the severity of adverse effects when combined with Levacetylmethadol and Levacetylmethadol may increase the severity of adverse effects when combined with Methadyl acetate
Dexmedetomidine can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Methadyl acetate
Dexmedetomidine may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Methadyl acetate
Dexmedetomidine may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Methadyl acetate
Dexmedetomidine may increase the severity of adverse effects when combined with Alprazolam and Alprazolam may increase the severity of adverse effects when combined with Methadyl acetate
Dexmedetomidine may increase the hypotensive activities of Risperidone and Risperidone may increase the severity of adverse effects when combined with Methadyl acetate
|
DB06684
|
DB00501
| 1,306 | 886 |
Vilazodone
|
Cimetidine
|
Vilazodone is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT(1A) receptors[Label,A177622]. Vilazodone may also be associated with less sexual dysfunction and weight gain. Vilazodone was given FDA approval on January 21, 2011[L6046,A177622].
|
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
|
The metabolism of Cimetidine can be decreased when combined with Vilazodone.
| 46 |
[
[
[
1306,
69,
886
]
],
[
[
1306,
6,
4590
],
[
4590,
160,
886
]
],
[
[
1306,
21,
28780
],
[
28780,
175,
886
]
],
[
[
1306,
71,
486
],
[
486,
69,
886
]
],
[
[
1306,
95,
476
],
[
476,
69,
886
]
],
[
[
1306,
69,
654
],
[
654,
69,
886
]
],
[
[
1306,
251,
164
],
[
164,
69,
886
]
],
[
[
1306,
225,
1014
],
[
1014,
69,
886
]
],
[
[
1306,
86,
383
],
[
383,
69,
886
]
],
[
[
1306,
270,
175
],
[
175,
69,
886
]
]
] |
[
[
[
"Vilazodone",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
],
[
[
"Vilazodone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cimetidine"
]
],
[
[
"Vilazodone",
"{u} (Compound) causes {v} (Side Effect)",
"Musculoskeletal discomfort"
],
[
"Musculoskeletal discomfort",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cimetidine"
]
],
[
[
"Vilazodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
],
[
[
"Vilazodone",
"{u} may increase the serum concentration of {v}",
"Netupitant"
],
[
"Netupitant",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
],
[
[
"Vilazodone",
"{u} may decrease the metabolism of {v}",
"Tipranavir"
],
[
"Tipranavir",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
],
[
[
"Vilazodone",
"{u} may decrease the serum concentration of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
],
[
[
"Vilazodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluphenazine"
],
[
"Fluphenazine",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
],
[
[
"Vilazodone",
"{u} may increase the serotonergic activities of {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
],
[
[
"Vilazodone",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Trazodone"
],
[
"Trazodone",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
]
] |
Vilazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cimetidine (Compound)
Vilazodone (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Cimetidine (Compound)
Vilazodone may increase the severity of adverse effects when combined with Doxepin and Doxepin may decrease the metabolism of Cimetidine
Vilazodone may increase the serum concentration of Netupitant and Netupitant may decrease the metabolism of Cimetidine
Vilazodone may decrease the metabolism of Tipranavir and Tipranavir may decrease the metabolism of Cimetidine
Vilazodone may decrease the serum concentration of Phenobarbital and Phenobarbital may decrease the metabolism of Cimetidine
Vilazodone may increase the severity of adverse effects when combined with Fluphenazine and Fluphenazine may decrease the metabolism of Cimetidine
Vilazodone may increase the serotonergic activities of Granisetron and Granisetron may decrease the metabolism of Cimetidine
Vilazodone (Compound) resembles Trazodone (Compound) and Vilazodone may increase the severity of adverse effects when combined with Trazodone and Trazodone may decrease the metabolism of Cimetidine
|
DB01551
|
DB04842
| 184 | 954 |
Dihydrocodeine
|
Fluspirilene
|
Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911.
|
A long-acting injectable antipsychotic agent used for chronic schizophrenia.
|
The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Fluspirilene.
| 48 |
[
[
[
184,
71,
954
]
],
[
[
184,
71,
434
],
[
434,
225,
954
]
],
[
[
184,
69,
245
],
[
245,
71,
954
]
],
[
[
184,
38,
405
],
[
405,
192,
954
]
],
[
[
184,
192,
587
],
[
587,
38,
954
]
],
[
[
184,
54,
471
],
[
471,
208,
954
]
],
[
[
184,
251,
495
],
[
495,
55,
954
]
],
[
[
184,
225,
1007
],
[
1007,
71,
954
]
],
[
[
184,
180,
164
],
[
164,
71,
954
]
],
[
[
184,
71,
964
],
[
964,
71,
954
]
]
] |
[
[
[
"Dihydrocodeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluspirilene"
]
],
[
[
"Dihydrocodeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flunarizine"
],
[
"Flunarizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluspirilene"
]
],
[
[
"Dihydrocodeine",
"{u} may decrease the metabolism of {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluspirilene"
]
],
[
[
"Dihydrocodeine",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Fluspirilene"
]
],
[
[
"Dihydrocodeine",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Fluspirilene"
]
],
[
[
"Dihydrocodeine",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Fluspirilene"
]
],
[
[
"Dihydrocodeine",
"{u} may decrease the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Fluspirilene"
]
],
[
[
"Dihydrocodeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluspirilene"
]
],
[
[
"Dihydrocodeine",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluspirilene"
]
],
[
[
"Dihydrocodeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triflupromazine"
],
[
"Triflupromazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluspirilene"
]
]
] |
Dihydrocodeine may increase the severity of adverse effects when combined with Flunarizine and Flunarizine may increase the severity of adverse effects when combined with Fluspirilene
Dihydrocodeine may decrease the metabolism of Haloperidol and Haloperidol may increase the severity of adverse effects when combined with Fluspirilene
Dihydrocodeine may increase the central nervous system depressant activities of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Fluspirilene
Dihydrocodeine may increase the central nervous system depressant activities of Ethanol and Ethanol may increase the central nervous system depressant activities of Fluspirilene
Dihydrocodeine may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Fluspirilene
Dihydrocodeine may decrease the serum concentration of Vemurafenib and Vemurafenib may increase the severity of QTc prolonging effects when combined with Fluspirilene
Dihydrocodeine may increase the severity of adverse effects when combined with Paliperidone and Paliperidone may increase the severity of adverse effects when combined with Fluspirilene
Dihydrocodeine can increase the metabolism of Phenobarbital and Phenobarbital may increase the severity of adverse effects when combined with Fluspirilene
Dihydrocodeine may increase the severity of adverse effects when combined with Triflupromazine and Triflupromazine may increase the severity of adverse effects when combined with Fluspirilene
|
DB00903
|
DB00284
| 893 | 947 |
Etacrynic acid
|
Acarbose
|
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.
|
Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are responsible for the metabolism of complex starches and oligo-, tri-, and disaccharides into absorbable simple sugars.[L31633,A37868] By inhibiting the activity of these enzymes, acarbose limits the absorption of dietary carbohydrates and the subsequent postprandial increase in blood glucose and insulin levels. Acarbose is therefore used in conjunction with diet, exercise, and other pharmacotherapies for the management of blood sugar levels in patients with type 2 diabetes.[L31628,L31633] Acarbose is one of only two approved alpha-glucosidase inhibitors (the other being
|
The therapeutic efficacy of Acarbose can be decreased when used in combination with Etacrynic acid.
| 69 |
[
[
[
893,
92,
947
]
],
[
[
893,
71,
904
],
[
904,
155,
947
]
],
[
[
893,
21,
28593
],
[
28593,
175,
947
]
],
[
[
893,
52,
828
],
[
828,
185,
947
]
],
[
[
893,
92,
423
],
[
423,
31,
947
]
],
[
[
893,
225,
53
],
[
53,
185,
947
]
],
[
[
893,
205,
768
],
[
768,
185,
947
]
],
[
[
893,
71,
955
],
[
955,
92,
947
]
],
[
[
893,
225,
1048
],
[
1048,
92,
947
]
],
[
[
893,
259,
80
],
[
80,
92,
947
]
]
] |
[
[
[
"Etacrynic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Acarbose"
]
],
[
[
"Etacrynic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paromomycin"
],
[
"Paromomycin",
"{u} (Compound) resembles {v} (Compound)",
"Acarbose"
]
],
[
[
"Etacrynic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is caused by {v} (Compound)",
"Acarbose"
]
],
[
[
"Etacrynic acid",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the hypoglycemic activities of {v}",
"Acarbose"
]
],
[
[
"Etacrynic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may increase the hypoglycemic activities of {v}",
"Acarbose"
]
],
[
[
"Etacrynic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} may increase the hypoglycemic activities of {v}",
"Acarbose"
]
],
[
[
"Etacrynic acid",
"{u} may decrease the diuretic activities of {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may increase the hypoglycemic activities of {v}",
"Acarbose"
]
],
[
[
"Etacrynic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may decrease the therapeutic efficacy of {v}",
"Acarbose"
]
],
[
[
"Etacrynic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may decrease the therapeutic efficacy of {v}",
"Acarbose"
]
],
[
[
"Etacrynic acid",
"{u} may increase the hypokalemic activities of {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may decrease the therapeutic efficacy of {v}",
"Acarbose"
]
]
] |
Etacrynic acid may increase the severity of adverse effects when combined with Paromomycin and Paromomycin (Compound) resembles Acarbose (Compound)
Etacrynic acid (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Acarbose (Compound)
Etacrynic acid may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the hypoglycemic activities of Acarbose
Etacrynic acid may decrease the therapeutic efficacy of Repaglinide and Repaglinide may increase the hypoglycemic activities of Acarbose
Etacrynic acid may increase the severity of adverse effects when combined with Phenelzine and Phenelzine may increase the hypoglycemic activities of Acarbose
Etacrynic acid may decrease the diuretic activities of Olsalazine and Olsalazine may increase the hypoglycemic activities of Acarbose
Etacrynic acid may increase the severity of adverse effects when combined with Quetiapine and Quetiapine may decrease the therapeutic efficacy of Acarbose
Etacrynic acid may increase the severity of adverse effects when combined with Chlorothiazide and Chlorothiazide may decrease the therapeutic efficacy of Acarbose
Etacrynic acid may increase the hypokalemic activities of Prednisone and Prednisone may decrease the therapeutic efficacy of Acarbose
|
DB01356
|
DB00875
| 997 | 931 |
Lithium cation
|
Flupentixol
|
Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.
|
Flupentixol is an antipsychotic drug of the thioxanthene group. It exists in two geometric isomers, the trans(E) and pharmacologically active cis(Z) forms. Flupentixol decanoate is one of the active ingredients found in injectable drug formulations: it is produced by esterification of cis(Z)‐flupentixol with decanoic acid. Flupentixol is an antagonist of both D1 and D2 dopamine receptors. Available as oral tablets or long-acting intramuscular injections, flupentixol is marketed under brand names such as Depixol and Fluanxol. It is approved for use in Canada and other countries around the world, but not in the US. It is used for the management of chronic schizophrenia in patients whose main manifestations do not include excitement, agitation or hyperactivity. It has been marketed to manage symptoms of depression in patients who may or may not exhibit signs
|
Lithium cation may increase the neurotoxic activities of Flupentixol.
| 34 |
[
[
[
997,
57,
931
]
],
[
[
997,
57,
1378
],
[
1378,
1,
931
]
],
[
[
997,
57,
1014
],
[
1014,
155,
931
]
],
[
[
997,
57,
971
],
[
971,
225,
931
]
],
[
[
997,
57,
970
],
[
970,
196,
931
]
],
[
[
997,
38,
1262
],
[
1262,
192,
931
]
],
[
[
997,
192,
72
],
[
72,
38,
931
]
],
[
[
997,
57,
543
],
[
543,
38,
931
]
],
[
[
997,
196,
645
],
[
645,
196,
931
]
],
[
[
997,
225,
914
],
[
914,
196,
931
]
]
] |
[
[
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Flupentixol"
]
],
[
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Acetophenazine"
],
[
"Acetophenazine",
"{u} (Compound) resembles {v} (Compound)",
"Flupentixol"
]
],
[
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Fluphenazine"
],
[
"Fluphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Flupentixol"
]
],
[
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Zuclopenthixol"
],
[
"Zuclopenthixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flupentixol"
]
],
[
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Thiothixene"
],
[
"Thiothixene",
"{u} may increase the QTc prolonging activities of {v}",
"Flupentixol"
]
],
[
[
"Lithium cation",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Flupentixol"
]
],
[
[
"Lithium cation",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Flupentixol"
]
],
[
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Flupentixol"
]
],
[
[
"Lithium cation",
"{u} may increase the QTc prolonging activities of {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Flupentixol"
]
],
[
[
"Lithium cation",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desflurane"
],
[
"Desflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Flupentixol"
]
]
] |
Lithium cation may increase the neurotoxic activities of Acetophenazine and Acetophenazine (Compound) resembles Flupentixol (Compound)
Lithium cation may increase the neurotoxic activities of Fluphenazine and Fluphenazine (Compound) resembles Flupentixol (Compound)
Lithium cation may increase the neurotoxic activities of Zuclopenthixol and Zuclopenthixol may increase the severity of adverse effects when combined with Flupentixol
Lithium cation may increase the neurotoxic activities of Thiothixene and Thiothixene may increase the QTc prolonging activities of Flupentixol
Lithium cation may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Flupentixol
Lithium cation may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Flupentixol
Lithium cation may increase the neurotoxic activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Flupentixol
Lithium cation may increase the QTc prolonging activities of Azithromycin and Azithromycin may increase the QTc prolonging activities of Flupentixol
Lithium cation may increase the severity of adverse effects when combined with Desflurane and Desflurane may increase the QTc prolonging activities of Flupentixol
|
DB01325
|
DB00483
| 1,325 | 60 |
Quinethazone
|
Gallamine triethiodide
|
Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.
|
A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of tubocurarine, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)
|
The serum concentration of Gallamine triethiodide can be increased when it is combined with Quinethazone.
| 72 |
[
[
[
1325,
95,
60
]
],
[
[
1325,
95,
26
],
[
26,
24,
60
]
],
[
[
1325,
71,
18
],
[
18,
24,
60
]
],
[
[
1325,
95,
59
],
[
59,
197,
60
]
],
[
[
1325,
248,
997
],
[
997,
197,
60
]
],
[
[
1325,
246,
808
],
[
808,
197,
60
]
],
[
[
1325,
95,
45
],
[
45,
225,
60
]
],
[
[
1325,
225,
184
],
[
184,
225,
60
]
],
[
[
1325,
259,
108
],
[
108,
71,
60
]
],
[
[
1325,
95,
50
],
[
50,
71,
60
]
]
] |
[
[
[
"Quinethazone",
"{u} may increase the serum concentration of {v}",
"Gallamine triethiodide"
]
],
[
[
"Quinethazone",
"{u} may increase the serum concentration of {v}",
"Tiotropium"
],
[
"Tiotropium",
"{u} may increase the anticholinergic activities of {v}",
"Gallamine triethiodide"
]
],
[
[
"Quinethazone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
],
[
"Sulpiride",
"{u} may increase the anticholinergic activities of {v}",
"Gallamine triethiodide"
]
],
[
[
"Quinethazone",
"{u} may increase the serum concentration of {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may increase the neuromuscular blocking activities of {v}",
"Gallamine triethiodide"
]
],
[
[
"Quinethazone",
"{u} may decrease the excretion rate {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the neuromuscular blocking activities of {v}",
"Gallamine triethiodide"
]
],
[
[
"Quinethazone",
"{u} may decrease the therapeutic efficacy of {v}",
"Magnesium salicylate"
],
[
"Magnesium salicylate",
"{u} may increase the neuromuscular blocking activities of {v}",
"Gallamine triethiodide"
]
],
[
[
"Quinethazone",
"{u} may increase the serum concentration of {v}",
"Mecamylamine"
],
[
"Mecamylamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Gallamine triethiodide"
]
],
[
[
"Quinethazone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dihydrocodeine"
],
[
"Dihydrocodeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Gallamine triethiodide"
]
],
[
[
"Quinethazone",
"{u} may increase the hypokalemic activities of {v}",
"Formestane"
],
[
"Formestane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Gallamine triethiodide"
]
],
[
[
"Quinethazone",
"{u} may increase the serum concentration of {v}",
"Propantheline"
],
[
"Propantheline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Gallamine triethiodide"
]
]
] |
Quinethazone may increase the serum concentration of Tiotropium and Tiotropium may increase the anticholinergic activities of Gallamine triethiodide
Quinethazone may increase the severity of adverse effects when combined with Sulpiride and Sulpiride may increase the anticholinergic activities of Gallamine triethiodide
Quinethazone may increase the serum concentration of Quinidine and Quinidine may increase the neuromuscular blocking activities of Gallamine triethiodide
Quinethazone may decrease the excretion rate Lithium cation and Lithium cation may increase the neuromuscular blocking activities of Gallamine triethiodide
Quinethazone may decrease the therapeutic efficacy of Magnesium salicylate and Magnesium salicylate may increase the neuromuscular blocking activities of Gallamine triethiodide
Quinethazone may increase the serum concentration of Mecamylamine and Mecamylamine may increase the severity of adverse effects when combined with Gallamine triethiodide
Quinethazone may increase the severity of adverse effects when combined with Dihydrocodeine and Dihydrocodeine may increase the severity of adverse effects when combined with Gallamine triethiodide
Quinethazone may increase the hypokalemic activities of Formestane and Formestane may increase the severity of adverse effects when combined with Gallamine triethiodide
Quinethazone may increase the serum concentration of Propantheline and Propantheline may increase the severity of adverse effects when combined with Gallamine triethiodide
|
DB01002
|
DB01197
| 214 | 669 |
Levobupivacaine
|
Captopril
|
Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. In particular, the specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and possesses a greater length of action in comparison to bupivacaine. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children. When administered appropriately, the occurrence of adverse effects is not anticipated much if at all. In
|
Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment of hypertension.
|
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Captopril.
| 48 |
[
[
[
214,
71,
669
]
],
[
[
214,
21,
28614
],
[
28614,
175,
669
]
],
[
[
214,
180,
156
],
[
156,
26,
669
]
],
[
[
214,
38,
702
],
[
702,
32,
669
]
],
[
[
214,
52,
968
],
[
968,
206,
669
]
],
[
[
214,
69,
556
],
[
556,
223,
669
]
],
[
[
214,
95,
429
],
[
429,
223,
669
]
],
[
[
214,
71,
411
],
[
411,
223,
669
]
],
[
[
214,
225,
653
],
[
653,
223,
669
]
],
[
[
214,
69,
482
],
[
482,
69,
669
]
]
] |
[
[
[
"Levobupivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Captopril"
]
],
[
[
"Levobupivacaine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Captopril"
]
],
[
[
"Levobupivacaine",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Captopril"
]
],
[
[
"Levobupivacaine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Captopril"
]
],
[
[
"Levobupivacaine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Captopril"
]
],
[
[
"Levobupivacaine",
"{u} may decrease the metabolism of {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may decrease the metabolism of {v}",
"Captopril"
]
],
[
[
"Levobupivacaine",
"{u} may increase the serum concentration of {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} may decrease the metabolism of {v}",
"Captopril"
]
],
[
[
"Levobupivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sertraline"
],
[
"Sertraline",
"{u} may decrease the metabolism of {v}",
"Captopril"
]
],
[
[
"Levobupivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may decrease the metabolism of {v}",
"Captopril"
]
],
[
[
"Levobupivacaine",
"{u} may decrease the metabolism of {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Captopril"
]
]
] |
Levobupivacaine (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Captopril (Compound)
Levobupivacaine can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Captopril
Levobupivacaine may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Captopril
Levobupivacaine may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Captopril
Levobupivacaine may decrease the metabolism of Citalopram and Citalopram may decrease the metabolism of Captopril
Levobupivacaine may increase the serum concentration of Lopinavir and Lopinavir may decrease the metabolism of Captopril
Levobupivacaine may increase the severity of adverse effects when combined with Sertraline and Sertraline may decrease the metabolism of Captopril
Levobupivacaine may increase the severity of adverse effects when combined with Thioridazine and Thioridazine may decrease the metabolism of Captopril
Levobupivacaine may decrease the metabolism of Verapamil and Verapamil may decrease the metabolism of Captopril
|
DB00831
|
DB00771
| 940 | 941 |
Trifluoperazine
|
Clidinium
|
A phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
|
Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
|
The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Clidinium.
| 48 |
[
[
[
940,
71,
941
]
],
[
[
940,
71,
959
],
[
959,
225,
941
]
],
[
[
940,
71,
289
],
[
289,
71,
941
]
],
[
[
940,
184,
674
],
[
674,
30,
941
]
],
[
[
940,
192,
491
],
[
491,
38,
941
]
],
[
[
940,
38,
1265
],
[
1265,
192,
941
]
],
[
[
940,
54,
1046
],
[
1046,
208,
941
]
],
[
[
940,
211,
997
],
[
997,
71,
941
]
],
[
[
940,
225,
397
],
[
397,
71,
941
]
],
[
[
940,
246,
968
],
[
968,
225,
941
]
]
] |
[
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clidinium"
]
],
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clidinium"
]
],
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clidinium"
]
],
[
[
"Trifluoperazine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Clidinium"
]
],
[
[
"Trifluoperazine",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Clidinium"
]
],
[
[
"Trifluoperazine",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Clidinium"
]
],
[
[
"Trifluoperazine",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Clidinium"
]
],
[
[
"Trifluoperazine",
"{u} may increase the neurotoxic activities of {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clidinium"
]
],
[
[
"Trifluoperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Eszopiclone"
],
[
"Eszopiclone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clidinium"
]
],
[
[
"Trifluoperazine",
"{u} may decrease the therapeutic efficacy of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clidinium"
]
]
] |
Trifluoperazine may increase the severity of adverse effects when combined with Fexofenadine and Fexofenadine may increase the severity of adverse effects when combined with Clidinium
Trifluoperazine may increase the severity of adverse effects when combined with Levacetylmethadol and Levacetylmethadol may increase the severity of adverse effects when combined with Clidinium
Trifluoperazine can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Clidinium
Trifluoperazine may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Clidinium
Trifluoperazine may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Clidinium
Trifluoperazine may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Clidinium
Trifluoperazine may increase the neurotoxic activities of Lithium cation and Lithium cation may increase the severity of adverse effects when combined with Clidinium
Trifluoperazine may increase the severity of adverse effects when combined with Eszopiclone and Eszopiclone may increase the severity of adverse effects when combined with Clidinium
Trifluoperazine may decrease the therapeutic efficacy of Levodopa and Levodopa may increase the severity of adverse effects when combined with Clidinium
|
DB04898
|
DB01283
| 363 | 349 |
Ximelagatran
|
Lumiracoxib
|
Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries where the drug had been approved.
|
Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling the drug.
|
Ximelagatran may increase the anticoagulant activities of Lumiracoxib.
| 5 |
[
[
[
363,
28,
349
]
],
[
[
363,
6,
7128
],
[
7128,
160,
349
]
],
[
[
363,
180,
147
],
[
147,
26,
349
]
],
[
[
363,
28,
498
],
[
498,
28,
349
]
],
[
[
363,
182,
677
],
[
677,
28,
349
]
],
[
[
363,
69,
1076
],
[
1076,
223,
349
]
],
[
[
363,
97,
639
],
[
639,
223,
349
]
],
[
[
363,
249,
267
],
[
267,
223,
349
]
],
[
[
363,
28,
584
],
[
584,
71,
349
]
],
[
[
363,
28,
808
],
[
808,
225,
349
]
]
] |
[
[
[
"Ximelagatran",
"{u} may increase the anticoagulant activities of {v}",
"Lumiracoxib"
]
],
[
[
"Ximelagatran",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Lumiracoxib"
]
],
[
[
"Ximelagatran",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Lumiracoxib"
]
],
[
[
"Ximelagatran",
"{u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Lumiracoxib"
]
],
[
[
"Ximelagatran",
"{u} may increase the anticoagulant activities of {v}",
"Dabigatran etexilate"
],
[
"Dabigatran etexilate",
"{u} may increase the anticoagulant activities of {v}",
"Lumiracoxib"
]
],
[
[
"Ximelagatran",
"{u} may decrease the metabolism of {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may decrease the metabolism of {v}",
"Lumiracoxib"
]
],
[
[
"Ximelagatran",
"{u} may decrease the serum concentration of {v}",
"Valproic acid"
],
[
"Valproic acid",
"{u} may decrease the metabolism of {v}",
"Lumiracoxib"
]
],
[
[
"Ximelagatran",
"{u} may increase the serum concentration of {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may decrease the metabolism of {v}",
"Lumiracoxib"
]
],
[
[
"Ximelagatran",
"{u} may increase the anticoagulant activities of {v}",
"Tenoxicam"
],
[
"Tenoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lumiracoxib"
]
],
[
[
"Ximelagatran",
"{u} may increase the anticoagulant activities of {v}",
"Magnesium salicylate"
],
[
"Magnesium salicylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lumiracoxib"
]
]
] |
Ximelagatran (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Lumiracoxib (Compound)
Ximelagatran can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Lumiracoxib
Ximelagatran may increase the anticoagulant activities of Dicoumarol and Dicoumarol may increase the anticoagulant activities of Lumiracoxib
Ximelagatran may increase the anticoagulant activities of Dabigatran etexilate and Dabigatran etexilate may increase the anticoagulant activities of Lumiracoxib
Ximelagatran may decrease the metabolism of Fluconazole and Fluconazole may decrease the metabolism of Lumiracoxib
Ximelagatran may decrease the serum concentration of Valproic acid and Valproic acid may decrease the metabolism of Lumiracoxib
Ximelagatran may increase the serum concentration of Lovastatin and Lovastatin may decrease the metabolism of Lumiracoxib
Ximelagatran may increase the anticoagulant activities of Tenoxicam and Tenoxicam may increase the severity of adverse effects when combined with Lumiracoxib
Ximelagatran may increase the anticoagulant activities of Magnesium salicylate and Magnesium salicylate may increase the severity of adverse effects when combined with Lumiracoxib
|
DB06712
|
DB01397
| 435 | 808 |
Nilvadipine
|
Magnesium salicylate
|
Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.
|
Magnesium salicylate is a non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain. It is available in several over-the-counter (OTC) formulations. Though the recommended doseage is 1160 mg every six hours, per package directions of the Doan's OTC brand (580 mg magnesium salicylate tetrahydrate, equivalent to 934.4 mg anhydrous magnesium salicylate), effective pain relief is often found with a half dosage, with reduced anti-inflammatory results.
|
The risk or severity of adverse effects can be increased when Nilvadipine is combined with Magnesium salicylate.
| 48 |
[
[
[
435,
71,
808
]
],
[
[
435,
180,
156
],
[
156,
1,
808
]
],
[
[
435,
71,
893
],
[
893,
205,
808
]
],
[
[
435,
236,
557
],
[
557,
205,
808
]
],
[
[
435,
236,
1038
],
[
1038,
59,
808
]
],
[
[
435,
82,
1033
],
[
1033,
59,
808
]
],
[
[
435,
71,
1034
],
[
1034,
59,
808
]
],
[
[
435,
225,
1025
],
[
1025,
59,
808
]
],
[
[
435,
225,
605
],
[
605,
71,
808
]
],
[
[
435,
236,
158
],
[
158,
71,
808
]
]
] |
[
[
[
"Nilvadipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium salicylate"
]
],
[
[
"Nilvadipine",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Magnesium salicylate"
]
],
[
[
"Nilvadipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may decrease the diuretic activities of {v}",
"Magnesium salicylate"
]
],
[
[
"Nilvadipine",
"{u} may increase the hypotensive activities of {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may decrease the diuretic activities of {v}",
"Magnesium salicylate"
]
],
[
[
"Nilvadipine",
"{u} may increase the hypotensive activities of {v}",
"Nadolol"
],
[
"Nadolol",
"{u} may decrease the antihypertensive activities of {v}",
"Magnesium salicylate"
]
],
[
[
"Nilvadipine",
"{u} may increase the hypotensive activities of {v}",
"Bupranolol"
],
[
"Bupranolol",
"{u} may decrease the antihypertensive activities of {v}",
"Magnesium salicylate"
]
],
[
[
"Nilvadipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Esmolol"
],
[
"Esmolol",
"{u} may decrease the antihypertensive activities of {v}",
"Magnesium salicylate"
]
],
[
[
"Nilvadipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Arotinolol"
],
[
"Arotinolol",
"{u} may decrease the antihypertensive activities of {v}",
"Magnesium salicylate"
]
],
[
[
"Nilvadipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cilnidipine"
],
[
"Cilnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium salicylate"
]
],
[
[
"Nilvadipine",
"{u} may increase the hypotensive activities of {v}",
"Nicardipine"
],
[
"Nicardipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium salicylate"
]
]
] |
Nilvadipine can increase the metabolism of Carbamazepine and Carbamazepine (Compound) resembles Magnesium salicylate (Compound)
Nilvadipine may increase the severity of adverse effects when combined with Etacrynic acid and Etacrynic acid may decrease the diuretic activities of Magnesium salicylate
Nilvadipine may increase the hypotensive activities of Torasemide and Torasemide may decrease the diuretic activities of Magnesium salicylate
Nilvadipine may increase the hypotensive activities of Nadolol and Nadolol may decrease the antihypertensive activities of Magnesium salicylate
Nilvadipine may increase the hypotensive activities of Bupranolol and Bupranolol may decrease the antihypertensive activities of Magnesium salicylate
Nilvadipine may increase the severity of adverse effects when combined with Esmolol and Esmolol may decrease the antihypertensive activities of Magnesium salicylate
Nilvadipine may increase the severity of adverse effects when combined with Arotinolol and Arotinolol may decrease the antihypertensive activities of Magnesium salicylate
Nilvadipine may increase the severity of adverse effects when combined with Cilnidipine and Cilnidipine may increase the severity of adverse effects when combined with Magnesium salicylate
Nilvadipine may increase the hypotensive activities of Nicardipine and Nicardipine may increase the severity of adverse effects when combined with Magnesium salicylate
|
DB00903
|
DB00476
| 893 | 828 |
Etacrynic acid
|
Duloxetine
|
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.
|
Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
|
Etacrynic acid may increase the orthostatic hypotensive activities of Duloxetine.
| 29 |
[
[
[
893,
52,
828
]
],
[
[
893,
205,
827
],
[
827,
1,
828
]
],
[
[
893,
7,
3107
],
[
3107,
161,
828
]
],
[
[
893,
21,
28676
],
[
28676,
175,
828
]
],
[
[
893,
249,
342
],
[
342,
28,
828
]
],
[
[
893,
92,
947
],
[
947,
31,
828
]
],
[
[
893,
225,
724
],
[
724,
52,
828
]
],
[
[
893,
71,
1028
],
[
1028,
52,
828
]
],
[
[
893,
29,
894
],
[
894,
52,
828
]
],
[
[
893,
52,
968
],
[
968,
52,
828
]
]
] |
[
[
[
"Etacrynic acid",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
]
],
[
[
"Etacrynic acid",
"{u} may decrease the diuretic activities of {v}",
"Naftifine"
],
[
"Naftifine",
"{u} (Compound) resembles {v} (Compound)",
"Duloxetine"
]
],
[
[
"Etacrynic acid",
"{u} (Compound) upregulates {v} (Gene)",
"HMOX1"
],
[
"HMOX1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Duloxetine"
]
],
[
[
"Etacrynic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Dysphagia"
],
[
"Dysphagia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Duloxetine"
]
],
[
[
"Etacrynic acid",
"{u} may increase the serum concentration of {v}",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Duloxetine"
]
],
[
[
"Etacrynic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may increase the hypoglycemic activities of {v}",
"Duloxetine"
]
],
[
[
"Etacrynic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dexmedetomidine"
],
[
"Dexmedetomidine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
]
],
[
[
"Etacrynic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metipranolol"
],
[
"Metipranolol",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
]
],
[
[
"Etacrynic acid",
"{u} may increase the ototoxic activities of {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
]
],
[
[
"Etacrynic acid",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
]
]
] |
Etacrynic acid may decrease the diuretic activities of Naftifine and Naftifine (Compound) resembles Duloxetine (Compound)
Etacrynic acid (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Duloxetine (Compound)
Etacrynic acid (Compound) causes Dysphagia (Side Effect) and Dysphagia (Side Effect) is caused by Duloxetine (Compound)
Etacrynic acid may increase the serum concentration of Acenocoumarol and Acenocoumarol may increase the anticoagulant activities of Duloxetine
Etacrynic acid may decrease the therapeutic efficacy of Acarbose and Acarbose may increase the hypoglycemic activities of Duloxetine
Etacrynic acid may increase the severity of adverse effects when combined with Dexmedetomidine and Dexmedetomidine may increase the orthostatic hypotensive activities of Duloxetine
Etacrynic acid may increase the severity of adverse effects when combined with Metipranolol and Metipranolol may increase the orthostatic hypotensive activities of Duloxetine
Etacrynic acid may increase the ototoxic activities of Furosemide and Furosemide may increase the orthostatic hypotensive activities of Duloxetine
Etacrynic acid may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Duloxetine
|
DB06288
|
DB00950
| 980 | 959 |
Amisulpride
|
Fexofenadine
|
Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysthymia, and major depression. Amisulpride predominantly works in the limbic system, which explains its relatively lower risk of extrapyramidal adverse effects compared to other atypical antipsychotic agents.[A6752, L32764] Oral tablets of amisulpride is used in European countries as a treatment for acute and chronic schizophrenic disorders, as well as secondary negative symptoms in mental health disorders such as affective disorders, depressive mood, and mental retardation. Amisulpride is also used as an antiemetic agent. In the US, the intravenous formulation of amisulpride is used to treat and prevent postoperative nausea
|
Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamines, such as [diphenhydramine], which readily bind to off-targets that contribute to side effects such as sedation. Fexofenadine is the major active metabolite of [terfenadine] and is administered as a racemic mixture in which both enantiomers display approximately equivalent antihistamine activity.
|
The risk or severity of adverse effects can be increased when Amisulpride is combined with Fexofenadine.
| 48 |
[
[
[
980,
71,
959
]
],
[
[
980,
71,
941
],
[
941,
71,
959
]
],
[
[
980,
225,
942
],
[
942,
71,
959
]
],
[
[
980,
71,
918
],
[
918,
225,
959
]
],
[
[
980,
21,
28693
],
[
28693,
175,
959
]
],
[
[
980,
184,
674
],
[
674,
30,
959
]
],
[
[
980,
192,
72
],
[
72,
38,
959
]
],
[
[
980,
38,
1265
],
[
1265,
192,
959
]
],
[
[
980,
54,
1365
],
[
1365,
208,
959
]
],
[
[
980,
58,
955
],
[
955,
71,
959
]
]
] |
[
[
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fexofenadine"
]
],
[
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clidinium"
],
[
"Clidinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fexofenadine"
]
],
[
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diphenoxylate"
],
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fexofenadine"
]
],
[
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Difenoxin"
],
[
"Difenoxin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fexofenadine"
]
],
[
[
"Amisulpride",
"{u} (Compound) causes {v} (Side Effect)",
"Nervousness"
],
[
"Nervousness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fexofenadine"
]
],
[
[
"Amisulpride",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Fexofenadine"
]
],
[
[
"Amisulpride",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Fexofenadine"
]
],
[
[
"Amisulpride",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Fexofenadine"
]
],
[
[
"Amisulpride",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Fexofenadine"
]
],
[
[
"Amisulpride",
"{u} may increase the antipsychotic activities of {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fexofenadine"
]
]
] |
Amisulpride may increase the severity of adverse effects when combined with Clidinium and Clidinium may increase the severity of adverse effects when combined with Fexofenadine
Amisulpride may increase the severity of adverse effects when combined with Diphenoxylate and Diphenoxylate may increase the severity of adverse effects when combined with Fexofenadine
Amisulpride may increase the severity of adverse effects when combined with Difenoxin and Difenoxin may increase the severity of adverse effects when combined with Fexofenadine
Amisulpride (Compound) causes Nervousness (Side Effect) and Nervousness (Side Effect) is caused by Fexofenadine (Compound)
Amisulpride can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Fexofenadine
Amisulpride may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Fexofenadine
Amisulpride may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Fexofenadine
Amisulpride may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Fexofenadine
Amisulpride may increase the antipsychotic activities of Quetiapine and Quetiapine may increase the severity of adverse effects when combined with Fexofenadine
|
DB00974
|
DB13167
| 749 | 796 |
Edetic acid
|
Alclofenac
|
A chelating agent (chelating agents) that sequesters a variety of polyvalent cations. It is used in pharmaceutical manufacturing and as a food additive.
|
Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.
|
Edetic acid may increase the anticoagulant activities of Alclofenac.
| 5 |
[
[
[
749,
28,
796
]
],
[
[
749,
28,
758
],
[
758,
28,
796
]
],
[
[
749,
182,
363
],
[
363,
28,
796
]
],
[
[
749,
28,
844
],
[
844,
71,
796
]
],
[
[
749,
28,
789
],
[
789,
225,
796
]
],
[
[
749,
88,
1351
],
[
1351,
225,
796
]
],
[
[
749,
34,
124
],
[
124,
225,
796
]
],
[
[
749,
28,
768
],
[
768,
79,
796
]
],
[
[
749,
225,
1444
],
[
1444,
246,
796
]
],
[
[
749,
28,
758
],
[
758,
28,
677
],
[
677,
28,
796
]
]
] |
[
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Alclofenac"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Fondaparinux"
],
[
"Fondaparinux",
"{u} may increase the anticoagulant activities of {v}",
"Alclofenac"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Ximelagatran"
],
[
"Ximelagatran",
"{u} may increase the anticoagulant activities of {v}",
"Alclofenac"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may increase the severity of adverse effects when combined with {v}",
"Alclofenac"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Benzydamine"
],
[
"Benzydamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Alclofenac"
]
],
[
[
"Edetic acid",
"{u} may increase bleeding risks when combined with {v}",
"Acemetacin"
],
[
"Acemetacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Alclofenac"
]
],
[
[
"Edetic acid",
"{u} may decrease the anticoagulant activities of {v}",
"Estrone"
],
[
"Estrone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Alclofenac"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may increase the nephrotoxic activities of {v}",
"Alclofenac"
]
],
[
[
"Edetic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Limaprost"
],
[
"Limaprost",
"{u} may decrease the therapeutic efficacy of {v}",
"Alclofenac"
]
],
[
[
"Edetic acid",
"{u} may increase the anticoagulant activities of {v}",
"Fondaparinux"
],
[
"Fondaparinux",
"{u} may increase the anticoagulant activities of {v}",
"Dabigatran etexilate"
],
[
"Dabigatran etexilate",
"{u} may increase the anticoagulant activities of {v}",
"Alclofenac"
]
]
] |
Edetic acid may increase the anticoagulant activities of Fondaparinux and Fondaparinux may increase the anticoagulant activities of Alclofenac
Edetic acid may increase the anticoagulant activities of Ximelagatran and Ximelagatran may increase the anticoagulant activities of Alclofenac
Edetic acid may increase the anticoagulant activities of Diflunisal and Diflunisal may increase the severity of adverse effects when combined with Alclofenac
Edetic acid may increase the anticoagulant activities of Benzydamine and Benzydamine may increase the severity of adverse effects when combined with Alclofenac
Edetic acid may increase bleeding risks when combined with Acemetacin and Acemetacin may increase the severity of adverse effects when combined with Alclofenac
Edetic acid may decrease the anticoagulant activities of Estrone and Estrone may increase the severity of adverse effects when combined with Alclofenac
Edetic acid may increase the anticoagulant activities of Olsalazine and Olsalazine may increase the nephrotoxic activities of Alclofenac
Edetic acid may increase the severity of adverse effects when combined with Limaprost and Limaprost may decrease the therapeutic efficacy of Alclofenac
Edetic acid may increase the anticoagulant activities of Fondaparinux and Fondaparinux may increase the anticoagulant activities of Dabigatran etexilate and Dabigatran etexilate may increase the anticoagulant activities of Alclofenac
|
DB04946
|
DB00501
| 196 | 886 |
Iloperidone
|
Cimetidine
|
Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. On June 9, 2004, Titan Pharmaceuticals gave the Phase III development rights to Vanda Pharmaceuticals. FDA approved on May 9, 2009.
|
A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy.
|
The metabolism of Cimetidine can be decreased when combined with Iloperidone.
| 46 |
[
[
[
196,
69,
886
]
],
[
[
196,
6,
13066
],
[
13066,
160,
886
]
],
[
[
196,
21,
28474
],
[
28474,
175,
886
]
],
[
[
196,
42,
262
],
[
262,
69,
886
]
],
[
[
196,
69,
828
],
[
828,
69,
886
]
],
[
[
196,
95,
476
],
[
476,
69,
886
]
],
[
[
196,
253,
654
],
[
654,
69,
886
]
],
[
[
196,
180,
164
],
[
164,
69,
886
]
],
[
[
196,
192,
1083
],
[
1083,
69,
886
]
],
[
[
196,
225,
194
],
[
194,
69,
886
]
]
] |
[
[
[
"Iloperidone",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
],
[
[
"Iloperidone",
"{u} (Compound) binds {v} (Gene)",
"CYP2E1"
],
[
"CYP2E1",
"{u} (Gene) is bound by {v} (Compound)",
"Cimetidine"
]
],
[
[
"Iloperidone",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cimetidine"
]
],
[
[
"Iloperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
],
[
[
"Iloperidone",
"{u} may decrease the metabolism of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
],
[
[
"Iloperidone",
"{u} may increase the serum concentration of {v}",
"Netupitant"
],
[
"Netupitant",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
],
[
[
"Iloperidone",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Tipranavir"
],
[
"Tipranavir",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
],
[
[
"Iloperidone",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
],
[
[
"Iloperidone",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
],
[
[
"Iloperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methylphenobarbital"
],
[
"Methylphenobarbital",
"{u} may decrease the metabolism of {v}",
"Cimetidine"
]
]
] |
Iloperidone (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Cimetidine (Compound)
Iloperidone (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Cimetidine (Compound)
Iloperidone may increase the QTc prolonging activities of Amitriptyline and Amitriptyline may decrease the metabolism of Cimetidine
Iloperidone may decrease the metabolism of Duloxetine and Duloxetine may decrease the metabolism of Cimetidine
Iloperidone may increase the serum concentration of Netupitant and Netupitant may decrease the metabolism of Cimetidine
Iloperidone may increase the serum concentration of the active metabolites of Tipranavir and Tipranavir may decrease the metabolism of Cimetidine
Iloperidone can increase the metabolism of Phenobarbital and Phenobarbital may decrease the metabolism of Cimetidine
Iloperidone may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may decrease the metabolism of Cimetidine
Iloperidone may increase the severity of adverse effects when combined with Methylphenobarbital and Methylphenobarbital may decrease the metabolism of Cimetidine
|
DB00542
|
DB06268
| 642 | 483 |
Benazepril
|
Sitaxentan
|
Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure[A838,A837]. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.
|
Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan from the market over concerns of hepatotoxicity.
|
Benazepril may increase the hypotensive activities of Sitaxentan.
| 59 |
[
[
[
642,
82,
483
]
],
[
[
642,
21,
28480
],
[
28480,
175,
483
]
],
[
[
642,
236,
164
],
[
164,
26,
483
]
],
[
[
642,
180,
156
],
[
156,
26,
483
]
],
[
[
642,
249,
615
],
[
615,
32,
483
]
],
[
[
642,
186,
344
],
[
344,
32,
483
]
],
[
[
642,
59,
230
],
[
230,
213,
483
]
],
[
[
642,
71,
582
],
[
582,
223,
483
]
],
[
[
642,
249,
267
],
[
267,
223,
483
]
],
[
[
642,
225,
239
],
[
239,
223,
483
]
]
] |
[
[
[
"Benazepril",
"{u} may increase the hypotensive activities of {v}",
"Sitaxentan"
]
],
[
[
"Benazepril",
"{u} (Compound) causes {v} (Side Effect)",
"Alopecia"
],
[
"Alopecia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sitaxentan"
]
],
[
[
"Benazepril",
"{u} may increase the hypotensive activities of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Sitaxentan"
]
],
[
[
"Benazepril",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Sitaxentan"
]
],
[
[
"Benazepril",
"{u} may increase the serum concentration of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Sitaxentan"
]
],
[
[
"Benazepril",
"{u} may increase the antihypertensive activities of {v}",
"Udenafil"
],
[
"Udenafil",
"{u} may increase the antihypertensive activities of {v}",
"Sitaxentan"
]
],
[
[
"Benazepril",
"{u} may decrease the antihypertensive activities of {v}",
"Yohimbine"
],
[
"Yohimbine",
"{u} may decrease the antihypertensive activities of {v}",
"Sitaxentan"
]
],
[
[
"Benazepril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may decrease the metabolism of {v}",
"Sitaxentan"
]
],
[
[
"Benazepril",
"{u} may increase the serum concentration of {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may decrease the metabolism of {v}",
"Sitaxentan"
]
],
[
[
"Benazepril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Valsartan"
],
[
"Valsartan",
"{u} may decrease the metabolism of {v}",
"Sitaxentan"
]
]
] |
Benazepril (Compound) causes Alopecia (Side Effect) and Alopecia (Side Effect) is caused by Sitaxentan (Compound)
Benazepril may increase the hypotensive activities of Phenobarbital and Phenobarbital can increase the metabolism of Sitaxentan
Benazepril can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Sitaxentan
Benazepril may increase the serum concentration of Sildenafil and Sildenafil may increase the antihypertensive activities of Sitaxentan
Benazepril may increase the antihypertensive activities of Udenafil and Udenafil may increase the antihypertensive activities of Sitaxentan
Benazepril may decrease the antihypertensive activities of Yohimbine and Yohimbine may decrease the antihypertensive activities of Sitaxentan
Benazepril may increase the severity of adverse effects when combined with Leflunomide and Leflunomide may decrease the metabolism of Sitaxentan
Benazepril may increase the serum concentration of Lovastatin and Lovastatin may decrease the metabolism of Sitaxentan
Benazepril may increase the severity of adverse effects when combined with Valsartan and Valsartan may decrease the metabolism of Sitaxentan
|
DB00203
|
DB01626
| 615 | 75 |
Sildenafil
|
Pargyline
|
In eliciting its mechanism of action, sildenafil ultimately prevents or minimizes the breakdown of cyclic guanosine monophosphate (cGMP) by inhibiting cGMP specific phosphodiesterase type 5 (PDE5) [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. The result of doing so allows cGMP present in both the penis and pulmonary vasculature to elicit smooth muscle relaxation and vasodilation that subsequently facilitates relief in pulmonary arterial hypertension and the increased flow of blood into the spongy erectile tissue of the penis that consequently allows it to grow in size and become erect and rigid [F3850, F3853, F3856, F3859, F3883, F3886, L5611, L5614]. Interestingly enough, it is precisely via this mechanism why sildenafil was at first researched as a potential treatment
|
Pargyline is a monoamine oxidase inhibitor with antihypertensive properties.
|
Sildenafil may increase the antihypertensive activities of Pargyline.
| 9 |
[
[
[
615,
32,
75
]
],
[
[
615,
223,
39
],
[
39,
82,
75
]
],
[
[
615,
223,
149
],
[
149,
93,
75
]
],
[
[
615,
223,
151
],
[
151,
155,
75
]
],
[
[
615,
69,
41
],
[
41,
24,
75
]
],
[
[
615,
223,
540
],
[
540,
184,
75
]
],
[
[
615,
69,
284
],
[
284,
31,
75
]
],
[
[
615,
223,
514
],
[
514,
31,
75
]
],
[
[
615,
95,
1019
],
[
1019,
31,
75
]
],
[
[
615,
249,
506
],
[
506,
32,
75
]
]
] |
[
[
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Pargyline"
]
],
[
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Selegiline"
],
[
"Selegiline",
"{u} may increase the hypotensive activities of {v}",
"Pargyline"
]
],
[
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Benzphetamine"
],
[
"Benzphetamine",
"{u} may increase the hypertensive activities of {v}",
"Pargyline"
]
],
[
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Benzyl alcohol"
],
[
"Benzyl alcohol",
"{u} (Compound) resembles {v} (Compound)",
"Pargyline"
]
],
[
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may increase the anticholinergic activities of {v}",
"Pargyline"
]
],
[
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Morphine"
],
[
"Morphine",
"{u} can increase the therapeutic efficacy of {v}",
"Pargyline"
]
],
[
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may increase the hypoglycemic activities of {v}",
"Pargyline"
]
],
[
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Rosiglitazone"
],
[
"Rosiglitazone",
"{u} may increase the hypoglycemic activities of {v}",
"Pargyline"
]
],
[
[
"Sildenafil",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the hypoglycemic activities of {v}",
"Pargyline"
]
],
[
[
"Sildenafil",
"{u} may increase the serum concentration of {v}",
"Avanafil"
],
[
"Avanafil",
"{u} may increase the antihypertensive activities of {v}",
"Pargyline"
]
]
] |
Sildenafil may decrease the metabolism of Selegiline and Selegiline may increase the hypotensive activities of Pargyline
Sildenafil may decrease the metabolism of Benzphetamine and Benzphetamine may increase the hypertensive activities of Pargyline
Sildenafil may decrease the metabolism of Benzyl alcohol and Benzyl alcohol (Compound) resembles Pargyline (Compound)
Sildenafil may decrease the metabolism of Clemastine and Clemastine may increase the anticholinergic activities of Pargyline
Sildenafil may decrease the metabolism of Morphine and Morphine can increase the therapeutic efficacy of Pargyline
Sildenafil may decrease the metabolism of Sulfadiazine and Sulfadiazine may increase the hypoglycemic activities of Pargyline
Sildenafil may decrease the metabolism of Rosiglitazone and Rosiglitazone may increase the hypoglycemic activities of Pargyline
Sildenafil may increase the serum concentration of Mifepristone and Mifepristone may increase the hypoglycemic activities of Pargyline
Sildenafil may increase the serum concentration of Avanafil and Avanafil may increase the antihypertensive activities of Pargyline
|
DB08875
|
DB08816
| 688 | 795 |
Cabozantinib
|
Ticagrelor
|
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133]
|
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
|
The metabolism of Ticagrelor can be decreased when combined with Cabozantinib.
| 46 |
[
[
[
688,
69,
795
]
],
[
[
688,
95,
429
],
[
429,
33,
795
]
],
[
[
688,
251,
119
],
[
119,
33,
795
]
],
[
[
688,
69,
508
],
[
508,
223,
795
]
],
[
[
688,
69,
284
],
[
284,
69,
795
]
],
[
[
688,
191,
243
],
[
243,
69,
795
]
],
[
[
688,
225,
292
],
[
292,
69,
795
]
],
[
[
688,
95,
631
],
[
631,
249,
795
]
],
[
[
688,
251,
225
],
[
225,
95,
795
]
],
[
[
688,
80,
457
],
[
457,
95,
795
]
]
] |
[
[
[
"Cabozantinib",
"{u} may decrease the metabolism of {v}",
"Ticagrelor"
]
],
[
[
"Cabozantinib",
"{u} may increase the serum concentration of {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Ticagrelor"
]
],
[
[
"Cabozantinib",
"{u} may decrease the serum concentration of {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Ticagrelor"
]
],
[
[
"Cabozantinib",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may decrease the metabolism of {v}",
"Ticagrelor"
]
],
[
[
"Cabozantinib",
"{u} may decrease the metabolism of {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may decrease the metabolism of {v}",
"Ticagrelor"
]
],
[
[
"Cabozantinib",
"{u} may increase the cardiotoxic activities of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may decrease the metabolism of {v}",
"Ticagrelor"
]
],
[
[
"Cabozantinib",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may decrease the metabolism of {v}",
"Ticagrelor"
]
],
[
[
"Cabozantinib",
"{u} may increase the serum concentration of {v}",
"Simeprevir"
],
[
"Simeprevir",
"{u} may increase the serum concentration of {v}",
"Ticagrelor"
]
],
[
[
"Cabozantinib",
"{u} may decrease the serum concentration of {v}",
"Bosentan"
],
[
"Bosentan",
"{u} may increase the serum concentration of {v}",
"Ticagrelor"
]
],
[
[
"Cabozantinib",
"{u} may decrease the cardiotoxic activities of {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may increase the serum concentration of {v}",
"Ticagrelor"
]
]
] |
Cabozantinib may increase the serum concentration of Lopinavir and Lopinavir may reduce the serum concentration of the active metabolites of Ticagrelor
Cabozantinib may decrease the serum concentration of Dexamethasone and Dexamethasone may reduce the serum concentration of the active metabolites of Ticagrelor
Cabozantinib may decrease the metabolism of Delavirdine and Delavirdine may decrease the metabolism of Ticagrelor
Cabozantinib may decrease the metabolism of Sulfadiazine and Sulfadiazine may decrease the metabolism of Ticagrelor
Cabozantinib may increase the cardiotoxic activities of Cyclophosphamide and Cyclophosphamide may decrease the metabolism of Ticagrelor
Cabozantinib may increase the severity of adverse effects when combined with Paclitaxel and Paclitaxel may decrease the metabolism of Ticagrelor
Cabozantinib may increase the serum concentration of Simeprevir and Simeprevir may increase the serum concentration of Ticagrelor
Cabozantinib may decrease the serum concentration of Bosentan and Bosentan may increase the serum concentration of Ticagrelor
Cabozantinib may decrease the cardiotoxic activities of Digoxin and Digoxin may increase the serum concentration of Ticagrelor
|
DB01244
|
DB00373
| 190 | 647 |
Bepridil
|
Timolol
|
A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).
|
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
|
The risk or severity of adverse effects can be increased when Bepridil is combined with Timolol.
| 48 |
[
[
[
190,
71,
647
]
],
[
[
190,
5,
17090
],
[
17090,
159,
647
]
],
[
[
190,
6,
18777
],
[
18777,
160,
647
]
],
[
[
190,
21,
28395
],
[
28395,
175,
647
]
],
[
[
190,
249,
150
],
[
150,
26,
647
]
],
[
[
190,
251,
147
],
[
147,
26,
647
]
],
[
[
190,
186,
702
],
[
702,
32,
647
]
],
[
[
190,
71,
730
],
[
730,
47,
647
]
],
[
[
190,
236,
643
],
[
643,
47,
647
]
],
[
[
190,
1,
149
],
[
149,
47,
647
]
]
] |
[
[
[
"Bepridil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Timolol"
]
],
[
[
"Bepridil",
"{u} (Compound) treats {v} (Disease)",
"hypertension"
],
[
"hypertension",
"{u} (Disease) is treated by {v} (Compound)",
"Timolol"
]
],
[
[
"Bepridil",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Timolol"
]
],
[
[
"Bepridil",
"{u} (Compound) causes {v} (Side Effect)",
"Tension"
],
[
"Tension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Timolol"
]
],
[
[
"Bepridil",
"{u} may increase the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Timolol"
]
],
[
[
"Bepridil",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Timolol"
]
],
[
[
"Bepridil",
"{u} may increase the antihypertensive activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Timolol"
]
],
[
[
"Bepridil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Timolol"
]
],
[
[
"Bepridil",
"{u} may increase the hypotensive activities of {v}",
"Guanfacine"
],
[
"Guanfacine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Timolol"
]
],
[
[
"Bepridil",
"{u} (Compound) resembles {v} (Compound)",
"Benzphetamine"
],
[
"Benzphetamine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Timolol"
]
]
] |
Bepridil (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Timolol (Compound)
Bepridil (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Timolol (Compound)
Bepridil (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Timolol (Compound)
Bepridil may increase the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Timolol
Bepridil may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Timolol
Bepridil may increase the antihypertensive activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Timolol
Bepridil may increase the severity of adverse effects when combined with Tizanidine and Tizanidine may increase the atrioventricular blocking activities of Timolol
Bepridil may increase the hypotensive activities of Guanfacine and Guanfacine may increase the atrioventricular blocking activities of Timolol
Bepridil (Compound) resembles Benzphetamine (Compound) and Benzphetamine may increase the atrioventricular blocking activities of Timolol
|
DB01100
|
DB09080
| 413 | 638 |
Pimozide
|
Olodaterol
|
A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403)
|
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated
|
Pimozide may increase the QTc-prolonging activities of Olodaterol.
| 19 |
[
[
[
413,
42,
638
]
],
[
[
413,
180,
161
],
[
161,
26,
638
]
],
[
[
413,
95,
191
],
[
191,
26,
638
]
],
[
[
413,
42,
278
],
[
278,
27,
638
]
],
[
[
413,
71,
911
],
[
911,
36,
638
]
],
[
[
413,
249,
576
],
[
576,
36,
638
]
],
[
[
413,
209,
1322
],
[
1322,
42,
638
]
],
[
[
413,
42,
1318
],
[
1318,
42,
638
]
],
[
[
413,
71,
955
],
[
955,
42,
638
]
],
[
[
413,
95,
653
],
[
653,
42,
638
]
]
] |
[
[
[
"Pimozide",
"{u} may increase the QTc prolonging activities of {v}",
"Olodaterol"
]
],
[
[
"Pimozide",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Olodaterol"
]
],
[
[
"Pimozide",
"{u} may increase the serum concentration of {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} can increase the metabolism of {v}",
"Olodaterol"
]
],
[
[
"Pimozide",
"{u} may increase the QTc prolonging activities of {v}",
"Alfuzosin"
],
[
"Alfuzosin",
"{u} may decrease the vasoconstricting activities of {v}",
"Olodaterol"
]
],
[
[
"Pimozide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may decrease the bronchodilatory activities of {v}",
"Olodaterol"
]
],
[
[
"Pimozide",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may decrease the bronchodilatory activities of {v}",
"Olodaterol"
]
],
[
[
"Pimozide",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Procainamide"
],
[
"Procainamide",
"{u} may increase the QTc prolonging activities of {v}",
"Olodaterol"
]
],
[
[
"Pimozide",
"{u} may increase the QTc prolonging activities of {v}",
"Propafenone"
],
[
"Propafenone",
"{u} may increase the QTc prolonging activities of {v}",
"Olodaterol"
]
],
[
[
"Pimozide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may increase the QTc prolonging activities of {v}",
"Olodaterol"
]
],
[
[
"Pimozide",
"{u} may increase the serum concentration of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the QTc prolonging activities of {v}",
"Olodaterol"
]
]
] |
Pimozide can increase the metabolism of Primidone and Primidone can increase the metabolism of Olodaterol
Pimozide may increase the serum concentration of Aprepitant and Aprepitant can increase the metabolism of Olodaterol
Pimozide may increase the QTc prolonging activities of Alfuzosin and Alfuzosin may decrease the vasoconstricting activities of Olodaterol
Pimozide may increase the severity of adverse effects when combined with Oxprenolol and Oxprenolol may decrease the bronchodilatory activities of Olodaterol
Pimozide may increase the serum concentration of Metoprolol and Metoprolol may decrease the bronchodilatory activities of Olodaterol
Pimozide may increase the severity of QTc prolonging effects when combined with Procainamide and Procainamide may increase the QTc prolonging activities of Olodaterol
Pimozide may increase the QTc prolonging activities of Propafenone and Propafenone may increase the QTc prolonging activities of Olodaterol
Pimozide may increase the severity of adverse effects when combined with Quetiapine and Quetiapine may increase the QTc prolonging activities of Olodaterol
Pimozide may increase the serum concentration of Thioridazine and Thioridazine may increase the QTc prolonging activities of Olodaterol
|
DB01178
|
DB01114
| 928 | 281 |
Chlormezanone
|
Chlorpheniramine
|
A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.
|
A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine.
|
The risk or severity of adverse effects can be increased when Chlormezanone is combined with Chlorpheniramine.
| 48 |
[
[
[
928,
71,
281
]
],
[
[
928,
71,
979
],
[
979,
155,
281
]
],
[
[
928,
192,
72
],
[
72,
1,
281
]
],
[
[
928,
225,
392
],
[
392,
1,
281
]
],
[
[
928,
71,
161
],
[
161,
26,
281
]
],
[
[
928,
225,
156
],
[
156,
26,
281
]
],
[
[
928,
38,
1264
],
[
1264,
192,
281
]
],
[
[
928,
192,
287
],
[
287,
38,
281
]
],
[
[
928,
54,
1365
],
[
1365,
208,
281
]
],
[
[
928,
71,
556
],
[
556,
223,
281
]
]
] |
[
[
[
"Chlormezanone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorpheniramine"
]
],
[
[
"Chlormezanone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpheniramine"
]
],
[
[
"Chlormezanone",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpheniramine"
]
],
[
[
"Chlormezanone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpheniramine"
]
],
[
[
"Chlormezanone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Chlorpheniramine"
]
],
[
[
"Chlormezanone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Chlorpheniramine"
]
],
[
[
"Chlormezanone",
"{u} may increase the central nervous system depressant activities of {v}",
"Sodium oxybate"
],
[
"Sodium oxybate",
"{u} may increase the central nervous system depressant activities of {v}",
"Chlorpheniramine"
]
],
[
[
"Chlormezanone",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Chlorpheniramine"
]
],
[
[
"Chlormezanone",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Chlorpheniramine"
]
],
[
[
"Chlormezanone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may decrease the metabolism of {v}",
"Chlorpheniramine"
]
]
] |
Chlormezanone may increase the severity of adverse effects when combined with Dexbrompheniramine and Dexbrompheniramine (Compound) resembles Chlorpheniramine (Compound)
Chlormezanone may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine (Compound) resembles Chlorpheniramine (Compound)
Chlormezanone may increase the severity of adverse effects when combined with Chlorpromazine and Chlorpromazine (Compound) resembles Chlorpheniramine (Compound)
Chlormezanone may increase the severity of adverse effects when combined with Primidone and Primidone can increase the metabolism of Chlorpheniramine
Chlormezanone may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Chlorpheniramine
Chlormezanone may increase the central nervous system depressant activities of Sodium oxybate and Sodium oxybate may increase the central nervous system depressant activities of Chlorpheniramine
Chlormezanone may increase the central nervous system depressant activities of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Chlorpheniramine
Chlormezanone may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Chlorpheniramine
Chlormezanone may increase the severity of adverse effects when combined with Citalopram and Citalopram may decrease the metabolism of Chlorpheniramine
|
DB00388
|
DB00696
| 711 | 563 |
Phenylephrine
|
Ergotamine
|
Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939.
|
A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.
|
Phenylephrine may increase the hypertensive activities of Ergotamine.
| 70 |
[
[
[
711,
93,
563
]
],
[
[
711,
93,
1303
],
[
1303,
1,
563
]
],
[
[
711,
6,
7680
],
[
7680,
160,
563
]
],
[
[
711,
21,
28506
],
[
28506,
175,
563
]
],
[
[
711,
181,
278
],
[
278,
27,
563
]
],
[
[
711,
181,
248
],
[
248,
201,
563
]
],
[
[
711,
71,
519
],
[
519,
201,
563
]
],
[
[
711,
260,
486
],
[
486,
213,
563
]
],
[
[
711,
93,
610
],
[
610,
223,
563
]
],
[
[
711,
261,
1021
],
[
1021,
225,
563
]
]
] |
[
[
[
"Phenylephrine",
"{u} may increase the hypertensive activities of {v}",
"Ergotamine"
]
],
[
[
"Phenylephrine",
"{u} may increase the hypertensive activities of {v}",
"Methylergometrine"
],
[
"Methylergometrine",
"{u} (Compound) resembles {v} (Compound)",
"Ergotamine"
]
],
[
[
"Phenylephrine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1D"
],
[
"ADRA1D",
"{u} (Gene) is bound by {v} (Compound)",
"Ergotamine"
]
],
[
[
"Phenylephrine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ergotamine"
]
],
[
[
"Phenylephrine",
"{u} may decrease the vasoconstricting activities of {v}",
"Alfuzosin"
],
[
"Alfuzosin",
"{u} may decrease the vasoconstricting activities of {v}",
"Ergotamine"
]
],
[
[
"Phenylephrine",
"{u} may decrease the vasoconstricting activities of {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Ergotamine"
]
],
[
[
"Phenylephrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Celiprolol"
],
[
"Celiprolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Ergotamine"
]
],
[
[
"Phenylephrine",
"{u} may increase the vasopressor activities of {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may decrease the antihypertensive activities of {v}",
"Ergotamine"
]
],
[
[
"Phenylephrine",
"{u} may increase the hypertensive activities of {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may decrease the metabolism of {v}",
"Ergotamine"
]
],
[
[
"Phenylephrine",
"{u} may increase the tachycardic activities of {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ergotamine"
]
]
] |
Phenylephrine may increase the hypertensive activities of Methylergometrine and Methylergometrine (Compound) resembles Ergotamine (Compound)
Phenylephrine (Compound) binds ADRA1D (Gene) and ADRA1D (Gene) is bound by Ergotamine (Compound)
Phenylephrine (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Ergotamine (Compound)
Phenylephrine may decrease the vasoconstricting activities of Alfuzosin and Alfuzosin may decrease the vasoconstricting activities of Ergotamine
Phenylephrine may decrease the vasoconstricting activities of Carvedilol and Carvedilol may increase the atrioventricular blocking activities of Ergotamine
Phenylephrine may increase the severity of adverse effects when combined with Celiprolol and Celiprolol may increase the atrioventricular blocking activities of Ergotamine
Phenylephrine may increase the vasopressor activities of Doxepin and Doxepin may decrease the antihypertensive activities of Ergotamine
Phenylephrine may increase the hypertensive activities of Atomoxetine and Atomoxetine may decrease the metabolism of Ergotamine
Phenylephrine may increase the tachycardic activities of Milnacipran and Milnacipran may increase the severity of adverse effects when combined with Ergotamine
|
DB00663
|
DB00255
| 105 | 574 |
Flumethasone
|
Diethylstilbestrol
|
Flumethasone is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application. This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching.
|
A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.
|
The serum concentration of Diethylstilbestrol can be increased when it is combined with Flumethasone.
| 72 |
[
[
[
105,
95,
574
]
],
[
[
105,
95,
291
],
[
291,
1,
574
]
],
[
[
105,
96,
811
],
[
811,
223,
574
]
],
[
[
105,
251,
156
],
[
156,
92,
574
]
],
[
[
105,
225,
785
],
[
785,
92,
574
]
],
[
[
105,
155,
111
],
[
111,
95,
574
]
],
[
[
105,
97,
1092
],
[
1092,
97,
574
]
],
[
[
105,
95,
269
],
[
269,
97,
574
]
],
[
[
105,
251,
177
],
[
177,
97,
574
]
],
[
[
105,
71,
686
],
[
686,
97,
574
]
]
] |
[
[
[
"Flumethasone",
"{u} may increase the serum concentration of {v}",
"Diethylstilbestrol"
]
],
[
[
"Flumethasone",
"{u} may increase the serum concentration of {v}",
"Dienestrol"
],
[
"Dienestrol",
"{u} (Compound) resembles {v} (Compound)",
"Diethylstilbestrol"
]
],
[
[
"Flumethasone",
"{u} may increase the fluid retaining activities of {v}",
"Testosterone propionate"
],
[
"Testosterone propionate",
"{u} may decrease the metabolism of {v}",
"Diethylstilbestrol"
]
],
[
[
"Flumethasone",
"{u} may decrease the serum concentration of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may decrease the therapeutic efficacy of {v}",
"Diethylstilbestrol"
]
],
[
[
"Flumethasone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Adapalene"
],
[
"Adapalene",
"{u} may decrease the therapeutic efficacy of {v}",
"Diethylstilbestrol"
]
],
[
[
"Flumethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fluticasone furoate"
],
[
"Fluticasone furoate",
"{u} may increase the serum concentration of {v}",
"Diethylstilbestrol"
]
],
[
[
"Flumethasone",
"{u} may decrease the serum concentration of {v}",
"Telaprevir"
],
[
"Telaprevir",
"{u} may decrease the serum concentration of {v}",
"Diethylstilbestrol"
]
],
[
[
"Flumethasone",
"{u} may increase the serum concentration of {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may decrease the serum concentration of {v}",
"Diethylstilbestrol"
]
],
[
[
"Flumethasone",
"{u} may decrease the serum concentration of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} may decrease the serum concentration of {v}",
"Diethylstilbestrol"
]
],
[
[
"Flumethasone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isoflurophate"
],
[
"Isoflurophate",
"{u} may decrease the serum concentration of {v}",
"Diethylstilbestrol"
]
]
] |
Flumethasone may increase the serum concentration of Dienestrol and Dienestrol (Compound) resembles Diethylstilbestrol (Compound)
Flumethasone may increase the fluid retaining activities of Testosterone propionate and Testosterone propionate may decrease the metabolism of Diethylstilbestrol
Flumethasone may decrease the serum concentration of Carbamazepine and Carbamazepine may decrease the therapeutic efficacy of Diethylstilbestrol
Flumethasone may increase the severity of adverse effects when combined with Adapalene and Adapalene may decrease the therapeutic efficacy of Diethylstilbestrol
Flumethasone (Compound) resembles Fluticasone furoate (Compound) and Fluticasone furoate may increase the serum concentration of Diethylstilbestrol
Flumethasone may decrease the serum concentration of Telaprevir and Telaprevir may decrease the serum concentration of Diethylstilbestrol
Flumethasone may increase the serum concentration of Nelfinavir and Nelfinavir may decrease the serum concentration of Diethylstilbestrol
Flumethasone may decrease the serum concentration of Rifapentine and Rifapentine may decrease the serum concentration of Diethylstilbestrol
Flumethasone may increase the severity of adverse effects when combined with Isoflurophate and Isoflurophate may decrease the serum concentration of Diethylstilbestrol
|
DB01282
|
DB09026
| 1,353 | 306 |
Carbetocin
|
Aliskiren
|
Carbetocin is a drug used to control postpartum hemorrhage, bleeding after giving birth. It is an analogue of oxytocin, and its action is similar to that of oxytocin -- it causes contraction of the uterus.
|
Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension. It was developed by Speedel and Novartis and initially approved by the FDA in early 2007. Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.
|
The risk or severity of adverse effects can be increased when Carbetocin is combined with Aliskiren.
| 48 |
[
[
[
1353,
71,
306
]
],
[
[
1353,
236,
164
],
[
164,
26,
306
]
],
[
[
1353,
71,
702
],
[
702,
32,
306
]
],
[
[
1353,
52,
828
],
[
828,
206,
306
]
],
[
[
1353,
225,
227
],
[
227,
223,
306
]
],
[
[
1353,
71,
512
],
[
512,
71,
306
]
],
[
[
1353,
225,
146
],
[
146,
71,
306
]
],
[
[
1353,
71,
953
],
[
953,
225,
306
]
],
[
[
1353,
236,
194
],
[
194,
82,
306
]
],
[
[
1353,
225,
1360
],
[
1360,
236,
306
]
]
] |
[
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aliskiren"
]
],
[
[
"Carbetocin",
"{u} may increase the hypotensive activities of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Aliskiren"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Aliskiren"
]
],
[
[
"Carbetocin",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Aliskiren"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may decrease the metabolism of {v}",
"Aliskiren"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nisoldipine"
],
[
"Nisoldipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aliskiren"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Barnidipine"
],
[
"Barnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aliskiren"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aliskiren"
]
],
[
[
"Carbetocin",
"{u} may increase the hypotensive activities of {v}",
"Methylphenobarbital"
],
[
"Methylphenobarbital",
"{u} may increase the hypotensive activities of {v}",
"Aliskiren"
]
],
[
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amifostine"
],
[
"Amifostine",
"{u} may increase the hypotensive activities of {v}",
"Aliskiren"
]
]
] |
Carbetocin may increase the hypotensive activities of Phenobarbital and Phenobarbital can increase the metabolism of Aliskiren
Carbetocin may increase the severity of adverse effects when combined with Brimonidine and Brimonidine may increase the antihypertensive activities of Aliskiren
Carbetocin may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Aliskiren
Carbetocin may increase the severity of adverse effects when combined with Bortezomib and Bortezomib may decrease the metabolism of Aliskiren
Carbetocin may increase the severity of adverse effects when combined with Nisoldipine and Nisoldipine may increase the severity of adverse effects when combined with Aliskiren
Carbetocin may increase the severity of adverse effects when combined with Barnidipine and Barnidipine may increase the severity of adverse effects when combined with Aliskiren
Carbetocin may increase the severity of adverse effects when combined with Empagliflozin and Empagliflozin may increase the severity of adverse effects when combined with Aliskiren
Carbetocin may increase the hypotensive activities of Methylphenobarbital and Methylphenobarbital may increase the hypotensive activities of Aliskiren
Carbetocin may increase the severity of adverse effects when combined with Amifostine and Amifostine may increase the hypotensive activities of Aliskiren
|
DB01045
|
DB01192
| 147 | 327 |
Rifampicin
|
Oxymorphone
|
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
|
An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092). On June 8, 2017, FDA requested Endo Pharmaceuticals to remove the medication from the market due to opioid misuse and abuse risks associated with the product's injectable reformulation.
|
The metabolism of Oxymorphone can be increased when combined with Rifampicin.
| 3 |
[
[
[
147,
26,
327
]
],
[
[
147,
26,
260
],
[
260,
1,
327
]
],
[
[
147,
97,
1083
],
[
1083,
155,
327
]
],
[
[
147,
26,
184
],
[
184,
225,
327
]
],
[
[
147,
6,
4590
],
[
4590,
160,
327
]
],
[
[
147,
180,
161
],
[
161,
26,
327
]
],
[
[
147,
97,
150
],
[
150,
26,
327
]
],
[
[
147,
26,
156
],
[
156,
26,
327
]
],
[
[
147,
26,
72
],
[
72,
38,
327
]
],
[
[
147,
97,
1261
],
[
1261,
192,
327
]
]
] |
[
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Oxymorphone"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Hydromorphone"
],
[
"Hydromorphone",
"{u} (Compound) resembles {v} (Compound)",
"Oxymorphone"
]
],
[
[
"Rifampicin",
"{u} may decrease the serum concentration of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} (Compound) resembles {v} (Compound)",
"Oxymorphone"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Dihydrocodeine"
],
[
"Dihydrocodeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxymorphone"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Oxymorphone"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Oxymorphone"
]
],
[
[
"Rifampicin",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Oxymorphone"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Oxymorphone"
]
],
[
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Oxymorphone"
]
],
[
[
"Rifampicin",
"{u} may decrease the serum concentration of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Oxymorphone"
]
]
] |
Rifampicin can increase the metabolism of Hydromorphone and Hydromorphone (Compound) resembles Oxymorphone (Compound)
Rifampicin may decrease the serum concentration of Hydrocodone and Hydrocodone (Compound) resembles Oxymorphone (Compound)
Rifampicin can increase the metabolism of Dihydrocodeine and Dihydrocodeine may increase the severity of adverse effects when combined with Oxymorphone
Rifampicin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Oxymorphone (Compound)
Rifampicin can increase the metabolism of Primidone and Primidone can increase the metabolism of Oxymorphone
Rifampicin may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Oxymorphone
Rifampicin can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Oxymorphone
Rifampicin can increase the metabolism of Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Oxymorphone
Rifampicin may decrease the serum concentration of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Oxymorphone
|
DB09071
|
DB09118
| 1,013 | 1,269 |
Tasimelteon
|
Stiripentol
|
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
|
Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood. Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit.
|
The serum concentration of Stiripentol can be increased when it is combined with Tasimelteon.
| 72 |
[
[
[
1013,
95,
1269
]
],
[
[
1013,
192,
679
],
[
679,
38,
1269
]
],
[
[
1013,
38,
702
],
[
702,
192,
1269
]
],
[
[
1013,
192,
587
],
[
587,
208,
1269
]
],
[
[
1013,
54,
1046
],
[
1046,
208,
1269
]
],
[
[
1013,
225,
639
],
[
639,
69,
1269
]
],
[
[
1013,
95,
861
],
[
861,
69,
1269
]
],
[
[
1013,
251,
150
],
[
150,
69,
1269
]
],
[
[
1013,
225,
925
],
[
925,
71,
1269
]
],
[
[
1013,
71,
1021
],
[
1021,
225,
1269
]
]
] |
[
[
[
"Tasimelteon",
"{u} may increase the serum concentration of {v}",
"Stiripentol"
]
],
[
[
"Tasimelteon",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Stiripentol"
]
],
[
[
"Tasimelteon",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Stiripentol"
]
],
[
[
"Tasimelteon",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the sedative activities of {v}",
"Stiripentol"
]
],
[
[
"Tasimelteon",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Stiripentol"
]
],
[
[
"Tasimelteon",
"{u} may increase the severity of adverse effects when combined with {v}",
"Valproic acid"
],
[
"Valproic acid",
"{u} may decrease the metabolism of {v}",
"Stiripentol"
]
],
[
[
"Tasimelteon",
"{u} may increase the serum concentration of {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may decrease the metabolism of {v}",
"Stiripentol"
]
],
[
[
"Tasimelteon",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may decrease the metabolism of {v}",
"Stiripentol"
]
],
[
[
"Tasimelteon",
"{u} may increase the severity of adverse effects when combined with {v}",
"Reserpine"
],
[
"Reserpine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Stiripentol"
]
],
[
[
"Tasimelteon",
"{u} may increase the severity of adverse effects when combined with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} may increase the severity of adverse effects when combined with {v}",
"Stiripentol"
]
]
] |
Tasimelteon may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Stiripentol
Tasimelteon may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Stiripentol
Tasimelteon may increase the central nervous system depressant activities of Ethanol and Ethanol may increase the sedative activities of Stiripentol
Tasimelteon may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Stiripentol
Tasimelteon may increase the severity of adverse effects when combined with Valproic acid and Valproic acid may decrease the metabolism of Stiripentol
Tasimelteon may increase the serum concentration of Fluvoxamine and Fluvoxamine may decrease the metabolism of Stiripentol
Tasimelteon may decrease the serum concentration of Fosphenytoin and Fosphenytoin may decrease the metabolism of Stiripentol
Tasimelteon may increase the severity of adverse effects when combined with Reserpine and Reserpine may increase the severity of adverse effects when combined with Stiripentol
Tasimelteon may increase the severity of adverse effects when combined with Milnacipran and Milnacipran may increase the severity of adverse effects when combined with Stiripentol
|
DB01090
|
DB09236
| 21 | 185 |
Pentolinium
|
Lacidipine
|
Pentolinium is a nicotinic antagonist that has been used as a ganglionic blocking agent in hypertension.
|
Lacidipine is a lipophilic dihydropyridine calcium antagonist with an intrinsically slow onset of activity. Due to its long duration of action, lacidipine does not lead to reflex tachycardia. It displays specificity in the vascular smooth muscle, where it acts as an antihypertensive agent to dilate peripheral arterioles and reduce blood pressure. Compared to other dihydropyridine calcium antagonists, lacidipine exhibits a greater antioxidant activity which may confer potentially beneficial antiatherosclerotic effects. Lacidipine is a highly lipophilic molecule that interacts with the biological membranes. Through radiotracer analysis, it was determined that lacidipine displays a high membrane partition coefficient leading to accumulation of the drug in the membrane and slow rate of membrane washout. When visualized by small-angle X-ray diffraction with angstrom resolution to examine its location within the membranes, lacidipine was
|
Pentolinium may increase the hypotensive activities of Lacidipine.
| 59 |
[
[
[
21,
82,
185
]
],
[
[
21,
186,
344
],
[
344,
32,
185
]
],
[
[
21,
107,
1265
],
[
1265,
225,
185
]
],
[
[
21,
71,
510
],
[
510,
225,
185
]
],
[
[
21,
236,
650
],
[
650,
82,
185
]
],
[
[
21,
82,
1028
],
[
1028,
82,
185
]
],
[
[
21,
236,
504
],
[
504,
236,
185
]
],
[
[
21,
249,
1041
],
[
1041,
82,
185
]
],
[
[
21,
82,
1063
],
[
1063,
236,
185
]
],
[
[
21,
246,
31
],
[
31,
82,
185
]
]
] |
[
[
[
"Pentolinium",
"{u} may increase the hypotensive activities of {v}",
"Lacidipine"
]
],
[
[
"Pentolinium",
"{u} may increase the antihypertensive activities of {v}",
"Udenafil"
],
[
"Udenafil",
"{u} may increase the antihypertensive activities of {v}",
"Lacidipine"
]
],
[
[
"Pentolinium",
"{u} may increase the tachycardic activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lacidipine"
]
],
[
[
"Pentolinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sufentanil"
],
[
"Sufentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lacidipine"
]
],
[
[
"Pentolinium",
"{u} may increase the hypotensive activities of {v}",
"Moexipril"
],
[
"Moexipril",
"{u} may increase the hypotensive activities of {v}",
"Lacidipine"
]
],
[
[
"Pentolinium",
"{u} may increase the hypotensive activities of {v}",
"Metipranolol"
],
[
"Metipranolol",
"{u} may increase the hypotensive activities of {v}",
"Lacidipine"
]
],
[
[
"Pentolinium",
"{u} may increase the hypotensive activities of {v}",
"Propranolol"
],
[
"Propranolol",
"{u} may increase the hypotensive activities of {v}",
"Lacidipine"
]
],
[
[
"Pentolinium",
"{u} may increase the serum concentration of {v}",
"Chlorthalidone"
],
[
"Chlorthalidone",
"{u} may increase the hypotensive activities of {v}",
"Lacidipine"
]
],
[
[
"Pentolinium",
"{u} may increase the hypotensive activities of {v}",
"Deserpidine"
],
[
"Deserpidine",
"{u} may increase the hypotensive activities of {v}",
"Lacidipine"
]
],
[
[
"Pentolinium",
"{u} may decrease the therapeutic efficacy of {v}",
"Minaprine"
],
[
"Minaprine",
"{u} may increase the hypotensive activities of {v}",
"Lacidipine"
]
]
] |
Pentolinium may increase the antihypertensive activities of Udenafil and Udenafil may increase the antihypertensive activities of Lacidipine
Pentolinium may increase the tachycardic activities of Nabilone and Nabilone may increase the severity of adverse effects when combined with Lacidipine
Pentolinium may increase the severity of adverse effects when combined with Sufentanil and Sufentanil may increase the severity of adverse effects when combined with Lacidipine
Pentolinium may increase the hypotensive activities of Moexipril and Moexipril may increase the hypotensive activities of Lacidipine
Pentolinium may increase the hypotensive activities of Metipranolol and Metipranolol may increase the hypotensive activities of Lacidipine
Pentolinium may increase the hypotensive activities of Propranolol and Propranolol may increase the hypotensive activities of Lacidipine
Pentolinium may increase the serum concentration of Chlorthalidone and Chlorthalidone may increase the hypotensive activities of Lacidipine
Pentolinium may increase the hypotensive activities of Deserpidine and Deserpidine may increase the hypotensive activities of Lacidipine
Pentolinium may decrease the therapeutic efficacy of Minaprine and Minaprine may increase the hypotensive activities of Lacidipine
|
DB01196
|
DB08933
| 629 | 1,114 |
Estramustine
|
Luliconazole
|
A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.
|
Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes. It was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan.
|
The serum concentration of Luliconazole can be increased when it is combined with Estramustine.
| 72 |
[
[
[
629,
95,
1114
]
],
[
[
629,
6,
4590
],
[
4590,
160,
1114
]
],
[
[
629,
251,
1113
],
[
1113,
95,
1114
]
],
[
[
629,
69,
613
],
[
613,
95,
1114
]
],
[
[
629,
249,
1475
],
[
1475,
95,
1114
]
],
[
[
629,
246,
298
],
[
298,
95,
1114
]
],
[
[
629,
155,
124
],
[
124,
95,
1114
]
],
[
[
629,
180,
147
],
[
147,
95,
1114
]
],
[
[
629,
56,
340
],
[
340,
95,
1114
]
],
[
[
629,
225,
331
],
[
331,
95,
1114
]
]
] |
[
[
[
"Estramustine",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Estramustine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Luliconazole"
]
],
[
[
"Estramustine",
"{u} may decrease the serum concentration of {v}",
"Boceprevir"
],
[
"Boceprevir",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Estramustine",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Estramustine",
"{u} may increase the serum concentration of {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Estramustine",
"{u} may decrease the therapeutic efficacy of {v}",
"Hexobarbital"
],
[
"Hexobarbital",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Estramustine",
"{u} (Compound) resembles {v} (Compound)",
"Estrone"
],
[
"Estrone",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Estramustine",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Estramustine",
"{u} may increase the immunosuppressive activities of {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
],
[
[
"Estramustine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pimecrolimus"
],
[
"Pimecrolimus",
"{u} may increase the serum concentration of {v}",
"Luliconazole"
]
]
] |
Estramustine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Luliconazole (Compound)
Estramustine may decrease the serum concentration of Boceprevir and Boceprevir may increase the serum concentration of Luliconazole
Estramustine may decrease the metabolism of Ticlopidine and Ticlopidine may increase the serum concentration of Luliconazole
Estramustine may increase the serum concentration of Naloxegol and Naloxegol may increase the serum concentration of Luliconazole
Estramustine may decrease the therapeutic efficacy of Hexobarbital and Hexobarbital may increase the serum concentration of Luliconazole
Estramustine (Compound) resembles Estrone (Compound) and Estrone may increase the serum concentration of Luliconazole
Estramustine can increase the metabolism of Rifampicin and Rifampicin may increase the serum concentration of Luliconazole
Estramustine may increase the immunosuppressive activities of Fingolimod and Fingolimod may increase the serum concentration of Luliconazole
Estramustine may increase the severity of adverse effects when combined with Pimecrolimus and Pimecrolimus may increase the serum concentration of Luliconazole
|
DB00861
|
DB00779
| 844 | 879 |
Diflunisal
|
Nalidixic acid
|
Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway. Diflunisal is used to relieve pain accompanied with inflammation and in the symptomatic treatment of rheumatoid arthritis and osteoarthritis.
|
Nalidixic acid is a synthetic 1,8-naphthyridine antimicrobial agent with a limited bacteriocidal spectrum. It is an inhibitor of the A subunit of bacterial DNA gyrase.
|
Diflunisal may increase the neuroexcitatory activities of Nalidixic acid.
| 26 |
[
[
[
844,
49,
879
]
],
[
[
844,
49,
850
],
[
850,
1,
879
]
],
[
[
844,
49,
818
],
[
818,
155,
879
]
],
[
[
844,
6,
4817
],
[
4817,
160,
879
]
],
[
[
844,
21,
28585
],
[
28585,
175,
879
]
],
[
[
844,
182,
219
],
[
219,
28,
879
]
],
[
[
844,
185,
575
],
[
575,
31,
879
]
],
[
[
844,
71,
514
],
[
514,
31,
879
]
],
[
[
844,
225,
620
],
[
620,
49,
879
]
],
[
[
844,
71,
211
],
[
211,
49,
879
]
]
] |
[
[
[
"Diflunisal",
"{u} may increase the neuroexcitatory activities of {v}",
"Nalidixic acid"
]
],
[
[
"Diflunisal",
"{u} may increase the neuroexcitatory activities of {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Nalidixic acid"
]
],
[
[
"Diflunisal",
"{u} may increase the neuroexcitatory activities of {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Nalidixic acid"
]
],
[
[
"Diflunisal",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compound)",
"Nalidixic acid"
]
],
[
[
"Diflunisal",
"{u} (Compound) causes {v} (Side Effect)",
"Thrombocytopenia"
],
[
"Thrombocytopenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nalidixic acid"
]
],
[
[
"Diflunisal",
"{u} may increase the anticoagulant activities of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Nalidixic acid"
]
],
[
[
"Diflunisal",
"{u} may increase the hypoglycemic activities of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may increase the hypoglycemic activities of {v}",
"Nalidixic acid"
]
],
[
[
"Diflunisal",
"{u} may increase the severity of adverse effects when combined with {v}",
"Rosiglitazone"
],
[
"Rosiglitazone",
"{u} may increase the hypoglycemic activities of {v}",
"Nalidixic acid"
]
],
[
[
"Diflunisal",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} may increase the neuroexcitatory activities of {v}",
"Nalidixic acid"
]
],
[
[
"Diflunisal",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} may increase the neuroexcitatory activities of {v}",
"Nalidixic acid"
]
]
] |
Diflunisal may increase the neuroexcitatory activities of Enoxacin and Enoxacin (Compound) resembles Nalidixic acid (Compound)
Diflunisal may increase the neuroexcitatory activities of Norfloxacin and Norfloxacin (Compound) resembles Nalidixic acid (Compound)
Diflunisal (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Nalidixic acid (Compound)
Diflunisal (Compound) causes Thrombocytopenia (Side Effect) and Thrombocytopenia (Side Effect) is caused by Nalidixic acid (Compound)
Diflunisal may increase the anticoagulant activities of Warfarin and Warfarin may increase the anticoagulant activities of Nalidixic acid
Diflunisal may increase the hypoglycemic activities of Sulfisoxazole and Sulfisoxazole may increase the hypoglycemic activities of Nalidixic acid
Diflunisal may increase the severity of adverse effects when combined with Rosiglitazone and Rosiglitazone may increase the hypoglycemic activities of Nalidixic acid
Diflunisal may increase the severity of adverse effects when combined with Mycophenolate mofetil and Mycophenolate mofetil may increase the neuroexcitatory activities of Nalidixic acid
Diflunisal may increase the severity of adverse effects when combined with Ketoprofen and Ketoprofen may increase the neuroexcitatory activities of Nalidixic acid
|
DB01037
|
DB01170
| 39 | 1,047 |
Selegiline
|
Guanethidine
|
A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl.
|
An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues. [PubChem]
|
Selegiline may increase the hypotensive activities of Guanethidine.
| 59 |
[
[
[
39,
82,
1047
]
],
[
[
39,
6,
4590
],
[
4590,
160,
1047
]
],
[
[
39,
82,
1072
],
[
1072,
82,
1047
]
],
[
[
39,
82,
454
],
[
454,
236,
1047
]
],
[
[
39,
69,
239
],
[
239,
82,
1047
]
],
[
[
39,
71,
139
],
[
139,
82,
1047
]
],
[
[
39,
207,
715
],
[
715,
82,
1047
]
],
[
[
39,
225,
1360
],
[
1360,
236,
1047
]
],
[
[
39,
71,
1038
],
[
1038,
236,
1047
]
],
[
[
39,
247,
71
],
[
71,
82,
1047
]
]
] |
[
[
[
"Selegiline",
"{u} may increase the hypotensive activities of {v}",
"Guanethidine"
]
],
[
[
"Selegiline",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Guanethidine"
]
],
[
[
"Selegiline",
"{u} may increase the hypotensive activities of {v}",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may increase the hypotensive activities of {v}",
"Guanethidine"
]
],
[
[
"Selegiline",
"{u} may increase the hypotensive activities of {v}",
"Selexipag"
],
[
"Selexipag",
"{u} may increase the hypotensive activities of {v}",
"Guanethidine"
]
],
[
[
"Selegiline",
"{u} may decrease the metabolism of {v}",
"Valsartan"
],
[
"Valsartan",
"{u} may increase the hypotensive activities of {v}",
"Guanethidine"
]
],
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Atenolol"
],
[
"Atenolol",
"{u} may increase the hypotensive activities of {v}",
"Guanethidine"
]
],
[
[
"Selegiline",
"{u} may increase the hypertensive effects of {v}",
"Methyldopa"
],
[
"Methyldopa",
"{u} may increase the hypotensive activities of {v}",
"Guanethidine"
]
],
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amifostine"
],
[
"Amifostine",
"{u} may increase the hypotensive activities of {v}",
"Guanethidine"
]
],
[
[
"Selegiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nadolol"
],
[
"Nadolol",
"{u} may increase the hypotensive activities of {v}",
"Guanethidine"
]
],
[
[
"Selegiline",
"{u} may increase the hypertensive activities of {v}",
"Toloxatone"
],
[
"Toloxatone",
"{u} may increase the hypotensive activities of {v}",
"Guanethidine"
]
]
] |
Selegiline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Guanethidine (Compound)
Selegiline may increase the hypotensive activities of Hydroflumethiazide and Hydroflumethiazide may increase the hypotensive activities of Guanethidine
Selegiline may increase the hypotensive activities of Selexipag and Selexipag may increase the hypotensive activities of Guanethidine
Selegiline may decrease the metabolism of Valsartan and Valsartan may increase the hypotensive activities of Guanethidine
Selegiline may increase the severity of adverse effects when combined with Atenolol and Atenolol may increase the hypotensive activities of Guanethidine
Selegiline may increase the hypertensive effects of Methyldopa and Methyldopa may increase the hypotensive activities of Guanethidine
Selegiline may increase the severity of adverse effects when combined with Amifostine and Amifostine may increase the hypotensive activities of Guanethidine
Selegiline may increase the severity of adverse effects when combined with Nadolol and Nadolol may increase the hypotensive activities of Guanethidine
Selegiline may increase the hypertensive activities of Toloxatone and Toloxatone may increase the hypotensive activities of Guanethidine
|
DB04898
|
DB00495
| 363 | 162 |
Ximelagatran
|
Zidovudine
|
Ximelagatran is an anticoagulant intended to become a replacement for warfarin by overcoming the dietary restrictions, drug interaction, and monitoring issues associated with the former. In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries where the drug had been approved.
|
A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. [PubChem]
|
The serum concentration of Zidovudine can be decreased when it is combined with Ximelagatran.
| 74 |
[
[
[
363,
97,
162
]
],
[
[
363,
6,
7128
],
[
7128,
160,
162
]
],
[
[
363,
180,
150
],
[
150,
26,
162
]
],
[
[
363,
69,
422
],
[
422,
223,
162
]
],
[
[
363,
249,
615
],
[
615,
223,
162
]
],
[
[
363,
223,
482
],
[
482,
223,
162
]
],
[
[
363,
28,
514
],
[
514,
223,
162
]
],
[
[
363,
97,
508
],
[
508,
223,
162
]
],
[
[
363,
95,
1019
],
[
1019,
249,
162
]
],
[
[
363,
28,
764
],
[
764,
249,
162
]
]
] |
[
[
[
"Ximelagatran",
"{u} may decrease the serum concentration of {v}",
"Zidovudine"
]
],
[
[
"Ximelagatran",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Zidovudine"
]
],
[
[
"Ximelagatran",
"{u} can increase the metabolism of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Zidovudine"
]
],
[
[
"Ximelagatran",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may decrease the metabolism of {v}",
"Zidovudine"
]
],
[
[
"Ximelagatran",
"{u} may increase the serum concentration of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Zidovudine"
]
],
[
[
"Ximelagatran",
"{u} may decrease the metabolism of {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Zidovudine"
]
],
[
[
"Ximelagatran",
"{u} may increase the anticoagulant activities of {v}",
"Rosiglitazone"
],
[
"Rosiglitazone",
"{u} may decrease the metabolism of {v}",
"Zidovudine"
]
],
[
[
"Ximelagatran",
"{u} may decrease the serum concentration of {v}",
"Delavirdine"
],
[
"Delavirdine",
"{u} may decrease the metabolism of {v}",
"Zidovudine"
]
],
[
[
"Ximelagatran",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the serum concentration of {v}",
"Zidovudine"
]
],
[
[
"Ximelagatran",
"{u} may increase the anticoagulant activities of {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may increase the serum concentration of {v}",
"Zidovudine"
]
]
] |
Ximelagatran (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Zidovudine (Compound)
Ximelagatran can increase the metabolism of Fosphenytoin and Fosphenytoin can increase the metabolism of Zidovudine
Ximelagatran may decrease the metabolism of Midostaurin and Midostaurin may decrease the metabolism of Zidovudine
Ximelagatran may increase the serum concentration of Sildenafil and Sildenafil may decrease the metabolism of Zidovudine
Ximelagatran may decrease the metabolism of Verapamil and Verapamil may decrease the metabolism of Zidovudine
Ximelagatran may increase the anticoagulant activities of Rosiglitazone and Rosiglitazone may decrease the metabolism of Zidovudine
Ximelagatran may decrease the serum concentration of Delavirdine and Delavirdine may decrease the metabolism of Zidovudine
Ximelagatran may increase the serum concentration of Mifepristone and Mifepristone may increase the serum concentration of Zidovudine
Ximelagatran may increase the anticoagulant activities of Dasatinib and Dasatinib may increase the serum concentration of Zidovudine
|
DB01173
|
DB08883
| 72 | 1,257 |
Orphenadrine
|
Perampanel
|
A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
|
Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™.
|
Orphenadrine may increase the central nervous system depressant (CNS depressant) activities of Perampanel.
| 15 |
[
[
[
72,
38,
1257
]
],
[
[
72,
38,
988
],
[
988,
38,
1257
]
],
[
[
72,
122,
976
],
[
976,
38,
1257
]
],
[
[
72,
1,
979
],
[
979,
38,
1257
]
],
[
[
72,
249,
730
],
[
730,
38,
1257
]
],
[
[
72,
95,
1269
],
[
1269,
38,
1257
]
],
[
[
72,
155,
288
],
[
288,
38,
1257
]
],
[
[
72,
192,
287
],
[
287,
38,
1257
]
],
[
[
72,
54,
1046
],
[
1046,
208,
1257
]
],
[
[
72,
69,
1099
],
[
1099,
223,
1257
]
]
] |
[
[
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Melperone"
],
[
"Melperone",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the central nervous system depressant activities of {v}",
"Dimenhydrinate"
],
[
"Dimenhydrinate",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound)",
"Dexbrompheniramine"
],
[
"Dexbrompheniramine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Orphenadrine",
"{u} may increase the serum concentration of {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Orphenadrine",
"{u} may increase the serum concentration of {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound)",
"Promazine"
],
[
"Promazine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
]
],
[
[
"Orphenadrine",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Perampanel"
]
],
[
[
"Orphenadrine",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may decrease the metabolism of {v}",
"Perampanel"
]
]
] |
Orphenadrine may increase the central nervous system depressant activities of Melperone and Melperone may increase the central nervous system depressant activities of Perampanel
Orphenadrine (Compound) resembles Dimenhydrinate (Compound) and Orphenadrine may increase the central nervous system depressant activities of Dimenhydrinate and Dimenhydrinate may increase the central nervous system depressant activities of Perampanel
Orphenadrine (Compound) resembles Dexbrompheniramine (Compound) and Dexbrompheniramine may increase the central nervous system depressant activities of Perampanel
Orphenadrine may increase the serum concentration of Tizanidine and Tizanidine may increase the central nervous system depressant activities of Perampanel
Orphenadrine may increase the serum concentration of Stiripentol and Stiripentol may increase the central nervous system depressant activities of Perampanel
Orphenadrine (Compound) resembles Promazine (Compound) and Promazine may increase the central nervous system depressant activities of Perampanel
Orphenadrine may increase the central nervous system depressant activities of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Perampanel
Orphenadrine may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Perampanel
Orphenadrine may decrease the metabolism of Idelalisib and Idelalisib may decrease the metabolism of Perampanel
|
DB00925
|
DB00697
| 355 | 730 |
Phenoxybenzamine
|
Tizanidine
|
An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.
|
Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debilitating condition. Initially approved by the FDA in 1996, tizanidine is an Alpha-2 adrenergic receptor agonist reducing spasticity by the presynaptic inhibition of excitatory neurotransmitters that cause firing of neurons promoting muscle spasm [FDA label].
|
The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Tizanidine.
| 48 |
[
[
[
355,
71,
730
]
],
[
[
355,
186,
702
],
[
702,
192,
730
]
],
[
[
355,
6,
14697
],
[
14697,
160,
730
]
],
[
[
355,
18,
9188
],
[
9188,
172,
730
]
],
[
[
355,
21,
28384
],
[
28384,
175,
730
]
],
[
[
355,
225,
1265
],
[
1265,
192,
730
]
],
[
[
355,
71,
679
],
[
679,
38,
730
]
],
[
[
355,
69,
429
],
[
429,
42,
730
]
],
[
[
355,
236,
640
],
[
640,
42,
730
]
],
[
[
355,
71,
955
],
[
955,
42,
730
]
]
] |
[
[
[
"Phenoxybenzamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tizanidine"
]
],
[
[
"Phenoxybenzamine",
"{u} may increase the antihypertensive activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Tizanidine"
]
],
[
[
"Phenoxybenzamine",
"{u} (Compound) binds {v} (Gene)",
"ADRA2B"
],
[
"ADRA2B",
"{u} (Gene) is bound by {v} (Compound)",
"Tizanidine"
]
],
[
[
"Phenoxybenzamine",
"{u} (Compound) downregulates {v} (Gene)",
"CCNB2"
],
[
"CCNB2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Tizanidine"
]
],
[
[
"Phenoxybenzamine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tizanidine"
]
],
[
[
"Phenoxybenzamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Tizanidine"
]
],
[
[
"Phenoxybenzamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Tizanidine"
]
],
[
[
"Phenoxybenzamine",
"{u} may decrease the metabolism of {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} may increase the QTc prolonging activities of {v}",
"Tizanidine"
]
],
[
[
"Phenoxybenzamine",
"{u} may increase the hypotensive activities of {v}",
"Quinine"
],
[
"Quinine",
"{u} may increase the QTc prolonging activities of {v}",
"Tizanidine"
]
],
[
[
"Phenoxybenzamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may increase the QTc prolonging activities of {v}",
"Tizanidine"
]
]
] |
Phenoxybenzamine may increase the antihypertensive activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Tizanidine
Phenoxybenzamine (Compound) binds ADRA2B (Gene) and ADRA2B (Gene) is bound by Tizanidine (Compound)
Phenoxybenzamine (Compound) downregulates CCNB2 (Gene) and CCNB2 (Gene) is downregulated by Tizanidine (Compound)
Phenoxybenzamine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Tizanidine (Compound)
Phenoxybenzamine may increase the severity of adverse effects when combined with Nabilone and Nabilone may increase the central nervous system depressant activities of Tizanidine
Phenoxybenzamine may increase the severity of adverse effects when combined with Thalidomide and Thalidomide may increase the central nervous system depressant activities of Tizanidine
Phenoxybenzamine may decrease the metabolism of Lopinavir and Lopinavir may increase the QTc prolonging activities of Tizanidine
Phenoxybenzamine may increase the hypotensive activities of Quinine and Quinine may increase the QTc prolonging activities of Tizanidine
Phenoxybenzamine may increase the severity of adverse effects when combined with Quetiapine and Quetiapine may increase the QTc prolonging activities of Tizanidine
|
DB00796
|
DB01050
| 304 | 334 |
Candesartan cilexetil
|
Ibuprofen
|
Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension. It is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. Candesartan lowers blood pressure by antagonizing the renin-angiotensin-aldosterone system (RAAS); it competes with angiotensin II for binding to the type-1 angiotensin II receptor (AT1) subtype and prevents the blood pressure increasing effects of angiotensin II. Unlike angiotensin-converting enzyme (ACE) inhibitors, ARBs do not have the adverse effect of dry cough. Candesartan may be used to treat hypertension, isolated systolic hypertension, left ventricular hypertrophy and diabetic nephropathy. It may also be used as an alternative agent for
|
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than
|
The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Ibuprofen.
| 48 |
[
[
[
304,
71,
334
]
],
[
[
304,
236,
23
],
[
23,
1,
334
]
],
[
[
304,
225,
1034
],
[
1034,
1,
334
]
],
[
[
304,
82,
1046
],
[
1046,
155,
334
]
],
[
[
304,
6,
8339
],
[
8339,
160,
334
]
],
[
[
304,
21,
28780
],
[
28780,
175,
334
]
],
[
[
304,
180,
164
],
[
164,
26,
334
]
],
[
[
304,
71,
687
],
[
687,
28,
334
]
],
[
[
304,
78,
894
],
[
894,
205,
334
]
],
[
[
304,
225,
1037
],
[
1037,
59,
334
]
]
] |
[
[
[
"Candesartan cilexetil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ibuprofen"
]
],
[
[
"Candesartan cilexetil",
"{u} may increase the hypotensive activities of {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} (Compound) resembles {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Candesartan cilexetil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Esmolol"
],
[
"Esmolol",
"{u} (Compound) resembles {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Candesartan cilexetil",
"{u} may increase the hypotensive activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} (Compound) resembles {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Candesartan cilexetil",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Candesartan cilexetil",
"{u} (Compound) causes {v} (Side Effect)",
"Musculoskeletal discomfort"
],
[
"Musculoskeletal discomfort",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Candesartan cilexetil",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Ibuprofen"
]
],
[
[
"Candesartan cilexetil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the anticoagulant activities of {v}",
"Ibuprofen"
]
],
[
[
"Candesartan cilexetil",
"{u} may increase the hypotensive effects when combined with {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may decrease the diuretic activities of {v}",
"Ibuprofen"
]
],
[
[
"Candesartan cilexetil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may decrease the antihypertensive activities of {v}",
"Ibuprofen"
]
]
] |
Candesartan cilexetil may increase the hypotensive activities of Procarbazine and Procarbazine (Compound) resembles Ibuprofen (Compound)
Candesartan cilexetil may increase the severity of adverse effects when combined with Esmolol and Esmolol (Compound) resembles Ibuprofen (Compound)
Candesartan cilexetil may increase the hypotensive activities of Metyrosine and Metyrosine (Compound) resembles Ibuprofen (Compound)
Candesartan cilexetil (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ibuprofen (Compound)
Candesartan cilexetil (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Ibuprofen (Compound)
Candesartan cilexetil can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Ibuprofen
Candesartan cilexetil may increase the severity of adverse effects when combined with Nafamostat and Nafamostat may increase the anticoagulant activities of Ibuprofen
Candesartan cilexetil may increase the hypotensive effects when combined with Furosemide and Furosemide may decrease the diuretic activities of Ibuprofen
Candesartan cilexetil may increase the severity of adverse effects when combined with Betaxolol and Betaxolol may decrease the antihypertensive activities of Ibuprofen
|
DB00402
|
DB00980
| 397 | 250 |
Eszopiclone
|
Ramelteon
|
Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a safer alternative to other drugs used for insomnia. One major benefit of eszopiclone is that it is approved by the FDA for the long-term treatment of insomnia. This sets it apart from many other hypnotic sedatives, which are generally approved only for the relief of short-term (6-8 weeks) insomnia. Eszopiclone was initially approved by the FDA in 2004.
|
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
|
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Ramelteon.
| 48 |
[
[
[
397,
71,
250
]
],
[
[
397,
6,
4590
],
[
4590,
160,
250
]
],
[
[
397,
21,
28575
],
[
28575,
175,
250
]
],
[
[
397,
180,
164
],
[
164,
26,
250
]
],
[
[
397,
192,
72
],
[
72,
38,
250
]
],
[
[
397,
38,
1261
],
[
1261,
192,
250
]
],
[
[
397,
54,
471
],
[
471,
208,
250
]
],
[
[
397,
69,
1077
],
[
1077,
223,
250
]
],
[
[
397,
71,
611
],
[
611,
223,
250
]
],
[
[
397,
71,
586
],
[
586,
71,
250
]
]
] |
[
[
[
"Eszopiclone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ramelteon"
]
],
[
[
"Eszopiclone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Eszopiclone",
"{u} (Compound) causes {v} (Side Effect)",
"Influenza"
],
[
"Influenza",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Eszopiclone",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Ramelteon"
]
],
[
[
"Eszopiclone",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Ramelteon"
]
],
[
[
"Eszopiclone",
"{u} may increase the central nervous system depressant activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Ramelteon"
]
],
[
[
"Eszopiclone",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Ramelteon"
]
],
[
[
"Eszopiclone",
"{u} may decrease the metabolism of {v}",
"Isavuconazonium"
],
[
"Isavuconazonium",
"{u} may decrease the metabolism of {v}",
"Ramelteon"
]
],
[
[
"Eszopiclone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may decrease the metabolism of {v}",
"Ramelteon"
]
],
[
[
"Eszopiclone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triazolam"
],
[
"Triazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ramelteon"
]
]
] |
Eszopiclone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ramelteon (Compound)
Eszopiclone (Compound) causes Influenza (Side Effect) and Influenza (Side Effect) is caused by Ramelteon (Compound)
Eszopiclone can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Ramelteon
Eszopiclone may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Ramelteon
Eszopiclone may increase the central nervous system depressant activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Ramelteon
Eszopiclone may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Ramelteon
Eszopiclone may decrease the metabolism of Isavuconazonium and Isavuconazonium may decrease the metabolism of Ramelteon
Eszopiclone may increase the severity of adverse effects when combined with Lidocaine and Lidocaine may decrease the metabolism of Ramelteon
Eszopiclone may increase the severity of adverse effects when combined with Triazolam and Triazolam may increase the severity of adverse effects when combined with Ramelteon
|
DB01021
|
DB00392
| 1,045 | 69 |
Trichlormethiazide
|
Profenamine
|
A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830)
|
Profenamine (also known as ethopropazine) is a medication derived from phenothiazine. It is primarily used as an antidyskinetic to treat Parkinsonism. It is sold under the trade name Parsitan in Canada. In the US, the marketing of profenamine has been discontinued.
|
The serum concentration of Profenamine can be increased when it is combined with Trichlormethiazide.
| 72 |
[
[
[
1045,
95,
69
]
],
[
[
1045,
236,
355
],
[
355,
155,
69
]
],
[
[
1045,
95,
28
],
[
28,
24,
69
]
],
[
[
1045,
95,
44
],
[
44,
225,
69
]
],
[
[
1045,
225,
1015
],
[
1015,
225,
69
]
],
[
[
1045,
95,
43
],
[
43,
71,
69
]
],
[
[
1045,
105,
1108
],
[
1108,
225,
69
]
],
[
[
1045,
71,
45
],
[
45,
225,
69
]
],
[
[
1045,
236,
31
],
[
31,
92,
69
]
],
[
[
1045,
1,
1049
],
[
1049,
95,
69
]
]
] |
[
[
[
"Trichlormethiazide",
"{u} may increase the serum concentration of {v}",
"Profenamine"
]
],
[
[
"Trichlormethiazide",
"{u} may increase the hypotensive activities of {v}",
"Phenoxybenzamine"
],
[
"Phenoxybenzamine",
"{u} (Compound) resembles {v} (Compound)",
"Profenamine"
]
],
[
[
"Trichlormethiazide",
"{u} may increase the serum concentration of {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may increase the anticholinergic activities of {v}",
"Profenamine"
]
],
[
[
"Trichlormethiazide",
"{u} may increase the serum concentration of {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Profenamine"
]
],
[
[
"Trichlormethiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levorphanol"
],
[
"Levorphanol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Profenamine"
]
],
[
[
"Trichlormethiazide",
"{u} may increase the serum concentration of {v}",
"Procyclidine"
],
[
"Procyclidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Profenamine"
]
],
[
[
"Trichlormethiazide",
"{u} may increase the hypokalemic activities of {v}",
"Topiramate"
],
[
"Topiramate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Profenamine"
]
],
[
[
"Trichlormethiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mecamylamine"
],
[
"Mecamylamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Profenamine"
]
],
[
[
"Trichlormethiazide",
"{u} may increase the hypotensive activities of {v}",
"Minaprine"
],
[
"Minaprine",
"{u} may decrease the therapeutic efficacy of {v}",
"Profenamine"
]
],
[
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may increase the serum concentration of {v}",
"Profenamine"
]
]
] |
Trichlormethiazide may increase the hypotensive activities of Phenoxybenzamine and Phenoxybenzamine (Compound) resembles Profenamine (Compound)
Trichlormethiazide may increase the serum concentration of Glycopyrronium and Glycopyrronium may increase the anticholinergic activities of Profenamine
Trichlormethiazide may increase the serum concentration of Tolterodine and Tolterodine may increase the severity of adverse effects when combined with Profenamine
Trichlormethiazide may increase the severity of adverse effects when combined with Levorphanol and Levorphanol may increase the severity of adverse effects when combined with Profenamine
Trichlormethiazide may increase the serum concentration of Procyclidine and Procyclidine may increase the severity of adverse effects when combined with Profenamine
Trichlormethiazide may increase the hypokalemic activities of Topiramate and Topiramate may increase the severity of adverse effects when combined with Profenamine
Trichlormethiazide may increase the severity of adverse effects when combined with Mecamylamine and Mecamylamine may increase the severity of adverse effects when combined with Profenamine
Trichlormethiazide may increase the hypotensive activities of Minaprine and Minaprine may decrease the therapeutic efficacy of Profenamine
Trichlormethiazide (Compound) resembles Bendroflumethiazide (Compound) and Bendroflumethiazide may increase the serum concentration of Profenamine
|
DB00359
|
DB00614
| 284 | 58 |
Sulfadiazine
|
Furazolidone
|
One of the short-acting sulfonamides used in combination with pyrimethamine to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.
|
A nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase. (From Martindale, The Extra Pharmacopoeia, 30th ed, p514)
|
Sulfadiazine may increase the hypoglycemic activities of Furazolidone.
| 8 |
[
[
[
284,
31,
58
]
],
[
[
284,
69,
41
],
[
41,
24,
58
]
],
[
[
284,
69,
297
],
[
297,
31,
58
]
],
[
[
284,
31,
947
],
[
947,
31,
58
]
],
[
[
284,
223,
526
],
[
526,
31,
58
]
],
[
[
284,
95,
1019
],
[
1019,
31,
58
]
],
[
[
284,
185,
423
],
[
423,
31,
58
]
],
[
[
284,
69,
610
],
[
610,
220,
58
]
],
[
[
284,
223,
253
],
[
253,
225,
58
]
],
[
[
284,
223,
491
],
[
491,
71,
58
]
]
] |
[
[
[
"Sulfadiazine",
"{u} may increase the hypoglycemic activities of {v}",
"Furazolidone"
]
],
[
[
"Sulfadiazine",
"{u} may decrease the metabolism of {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may increase the anticholinergic activities of {v}",
"Furazolidone"
]
],
[
[
"Sulfadiazine",
"{u} may decrease the metabolism of {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may increase the hypoglycemic activities of {v}",
"Furazolidone"
]
],
[
[
"Sulfadiazine",
"{u} may increase the hypoglycemic activities of {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may increase the hypoglycemic activities of {v}",
"Furazolidone"
]
],
[
[
"Sulfadiazine",
"{u} may decrease the metabolism of {v}",
"Glyburide"
],
[
"Glyburide",
"{u} may increase the hypoglycemic activities of {v}",
"Furazolidone"
]
],
[
[
"Sulfadiazine",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the hypoglycemic activities of {v}",
"Furazolidone"
]
],
[
[
"Sulfadiazine",
"{u} may increase the hypoglycemic activities of {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may increase the hypoglycemic activities of {v}",
"Furazolidone"
]
],
[
[
"Sulfadiazine",
"{u} may decrease the metabolism of {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may increase the central neurotoxic activities of {v}",
"Furazolidone"
]
],
[
[
"Sulfadiazine",
"{u} may decrease the metabolism of {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Furazolidone"
]
],
[
[
"Sulfadiazine",
"{u} may decrease the metabolism of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Furazolidone"
]
]
] |
Sulfadiazine may decrease the metabolism of Clemastine and Clemastine may increase the anticholinergic activities of Furazolidone
Sulfadiazine may decrease the metabolism of Tolbutamide and Tolbutamide may increase the hypoglycemic activities of Furazolidone
Sulfadiazine may increase the hypoglycemic activities of Acarbose and Acarbose may increase the hypoglycemic activities of Furazolidone
Sulfadiazine may decrease the metabolism of Glyburide and Glyburide may increase the hypoglycemic activities of Furazolidone
Sulfadiazine may increase the serum concentration of Mifepristone and Mifepristone may increase the hypoglycemic activities of Furazolidone
Sulfadiazine may increase the hypoglycemic activities of Repaglinide and Repaglinide may increase the hypoglycemic activities of Furazolidone
Sulfadiazine may decrease the metabolism of Atomoxetine and Atomoxetine may increase the central neurotoxic activities of Furazolidone
Sulfadiazine may decrease the metabolism of Formoterol and Formoterol may increase the severity of adverse effects when combined with Furazolidone
Sulfadiazine may decrease the metabolism of Buprenorphine and Buprenorphine may increase the severity of adverse effects when combined with Furazolidone
|
DB00647
|
DB00903
| 469 | 893 |
Dextropropoxyphene
|
Etacrynic acid
|
Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect.
|
A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.
|
The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Etacrynic acid.
| 48 |
[
[
[
469,
71,
893
]
],
[
[
469,
18,
5353
],
[
5353,
172,
893
]
],
[
[
469,
21,
28593
],
[
28593,
175,
893
]
],
[
[
469,
71,
894
],
[
894,
183,
893
]
],
[
[
469,
225,
54
],
[
54,
193,
893
]
],
[
[
469,
180,
142
],
[
142,
51,
893
]
],
[
[
469,
240,
828
],
[
828,
206,
893
]
],
[
[
469,
71,
968
],
[
968,
206,
893
]
],
[
[
469,
225,
579
],
[
579,
71,
893
]
],
[
[
469,
69,
461
],
[
461,
71,
893
]
]
] |
[
[
[
"Dextropropoxyphene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
]
],
[
[
"Dextropropoxyphene",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Etacrynic acid"
]
],
[
[
"Dextropropoxyphene",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is caused by {v} (Compound)",
"Etacrynic acid"
]
],
[
[
"Dextropropoxyphene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may increase the ototoxic activities of {v}",
"Etacrynic acid"
]
],
[
[
"Dextropropoxyphene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tubocurarine"
],
[
"Tubocurarine",
"{u} may decrease the neuromuscular blocking activities of {v}",
"Etacrynic acid"
]
],
[
[
"Dextropropoxyphene",
"{u} can increase the metabolism of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may decrease the diuretic activities of {v}",
"Etacrynic acid"
]
],
[
[
"Dextropropoxyphene",
"{u} may increase the serotonergic activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Etacrynic acid"
]
],
[
[
"Dextropropoxyphene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Etacrynic acid"
]
],
[
[
"Dextropropoxyphene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Codeine"
],
[
"Codeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
]
],
[
[
"Dextropropoxyphene",
"{u} may decrease the metabolism of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
]
]
] |
Dextropropoxyphene (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Etacrynic acid (Compound)
Dextropropoxyphene (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Etacrynic acid (Compound)
Dextropropoxyphene may increase the severity of adverse effects when combined with Furosemide and Furosemide may increase the ototoxic activities of Etacrynic acid
Dextropropoxyphene may increase the severity of adverse effects when combined with Tubocurarine and Tubocurarine may decrease the neuromuscular blocking activities of Etacrynic acid
Dextropropoxyphene can increase the metabolism of Phenytoin and Phenytoin may decrease the diuretic activities of Etacrynic acid
Dextropropoxyphene may increase the serotonergic activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Etacrynic acid
Dextropropoxyphene may increase the severity of adverse effects when combined with Levodopa and Levodopa may increase the orthostatic hypotensive activities of Etacrynic acid
Dextropropoxyphene may increase the severity of adverse effects when combined with Codeine and Codeine may increase the severity of adverse effects when combined with Etacrynic acid
Dextropropoxyphene may decrease the metabolism of Diltiazem and Diltiazem may increase the severity of adverse effects when combined with Etacrynic acid
|
DB11921
|
DB01026
| 95 | 496 |
Deflazacort
|
Ketoconazole
|
Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A
|
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
|
The metabolism of Ketoconazole can be decreased when combined with Deflazacort.
| 46 |
[
[
[
95,
69,
496
]
],
[
[
95,
69,
479
],
[
479,
69,
496
]
],
[
[
95,
180,
177
],
[
177,
26,
496
]
],
[
[
95,
69,
575
],
[
575,
42,
496
]
],
[
[
95,
71,
863
],
[
863,
42,
496
]
],
[
[
95,
71,
1293
],
[
1293,
69,
496
]
],
[
[
95,
225,
334
],
[
334,
69,
496
]
],
[
[
95,
105,
183
],
[
183,
69,
496
]
],
[
[
95,
69,
1086
],
[
1086,
223,
496
]
],
[
[
95,
95,
622
],
[
622,
69,
496
]
]
] |
[
[
[
"Deflazacort",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Deflazacort",
"{u} may decrease the metabolism of {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Deflazacort",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Deflazacort",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may increase the QTc prolonging activities of {v}",
"Ketoconazole"
]
],
[
[
"Deflazacort",
"{u} may increase the severity of adverse effects when combined with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Ketoconazole"
]
],
[
[
"Deflazacort",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Deflazacort",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Deflazacort",
"{u} may increase the hypokalemic activities of {v}",
"Indapamide"
],
[
"Indapamide",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Deflazacort",
"{u} may decrease the metabolism of {v}",
"Clotrimazole"
],
[
"Clotrimazole",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Deflazacort",
"{u} may increase the serum concentration of {v}",
"Mestranol"
],
[
"Mestranol",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
]
]
] |
Deflazacort may decrease the metabolism of Posaconazole and Posaconazole may decrease the metabolism of Ketoconazole
Deflazacort can increase the metabolism of Rifapentine and Rifapentine can increase the metabolism of Ketoconazole
Deflazacort may decrease the metabolism of Sulfisoxazole and Sulfisoxazole may increase the QTc prolonging activities of Ketoconazole
Deflazacort may increase the severity of adverse effects when combined with Gemifloxacin and Gemifloxacin may increase the QTc prolonging activities of Ketoconazole
Deflazacort may increase the severity of adverse effects when combined with Metoclopramide and Metoclopramide may decrease the metabolism of Ketoconazole
Deflazacort may increase the severity of adverse effects when combined with Ibuprofen and Ibuprofen may decrease the metabolism of Ketoconazole
Deflazacort may increase the hypokalemic activities of Indapamide and Indapamide may decrease the metabolism of Ketoconazole
Deflazacort may decrease the metabolism of Clotrimazole and Clotrimazole may decrease the metabolism of Ketoconazole
Deflazacort may increase the serum concentration of Mestranol and Mestranol may decrease the metabolism of Ketoconazole
|
DB09049
|
DB00590
| 1,475 | 678 |
Naloxegol
|
Doxazosin
|
Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier.
|
Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 1990.
|
The serum concentration of Doxazosin can be increased when it is combined with Naloxegol.
| 72 |
[
[
[
1475,
95,
678
]
],
[
[
1475,
95,
147
],
[
147,
26,
678
]
],
[
[
1475,
251,
150
],
[
150,
26,
678
]
],
[
[
1475,
95,
563
],
[
563,
181,
678
]
],
[
[
1475,
249,
576
],
[
576,
52,
678
]
],
[
[
1475,
95,
248
],
[
248,
52,
678
]
],
[
[
1475,
95,
657
],
[
657,
223,
678
]
],
[
[
1475,
249,
653
],
[
653,
223,
678
]
],
[
[
1475,
95,
461
],
[
461,
71,
678
]
],
[
[
1475,
95,
516
],
[
516,
225,
678
]
]
] |
[
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Doxazosin"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Doxazosin"
]
],
[
[
"Naloxegol",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Doxazosin"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Ergotamine"
],
[
"Ergotamine",
"{u} may decrease the vasoconstricting activities of {v}",
"Doxazosin"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Doxazosin"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Doxazosin"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may decrease the metabolism of {v}",
"Doxazosin"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may decrease the metabolism of {v}",
"Doxazosin"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may increase the severity of adverse effects when combined with {v}",
"Doxazosin"
]
],
[
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Doxazosin"
]
]
] |
Naloxegol may increase the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Doxazosin
Naloxegol may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Doxazosin
Naloxegol may increase the serum concentration of Ergotamine and Ergotamine may decrease the vasoconstricting activities of Doxazosin
Naloxegol may increase the serum concentration of Metoprolol and Metoprolol may increase the orthostatic hypotensive activities of Doxazosin
Naloxegol may increase the serum concentration of Carvedilol and Carvedilol may increase the orthostatic hypotensive activities of Doxazosin
Naloxegol may increase the serum concentration of Voriconazole and Voriconazole may decrease the metabolism of Doxazosin
Naloxegol may increase the serum concentration of Thioridazine and Thioridazine may decrease the metabolism of Doxazosin
Naloxegol may increase the serum concentration of Diltiazem and Diltiazem may increase the severity of adverse effects when combined with Doxazosin
Naloxegol may increase the serum concentration of Felodipine and Felodipine may increase the severity of adverse effects when combined with Doxazosin
|
DB12026
|
DB06717
| 470 | 1,106 |
Voxilaprevir
|
Fosaprepitant
|
Voxilaprevir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Voxilaprevir exerts its antiviral action by reversibly binding and inhibiting the NS3/4A serine protease of Hepatitis C Virus (HCV) [FDA Label]. Following viral replication of HCV genetic material and translation into a single polypeptide, Nonstructural Protein 3 (NS3) and its activating cofactor Nonstructural Protein 4A (NS4A) are responsible for cleaving genetic material into the following structural and nonstructural proteins required for assembly into mature virus: NS
|
Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
|
The serum concentration of Fosaprepitant can be increased when it is combined with Voxilaprevir.
| 72 |
[
[
[
470,
95,
1106
]
],
[
[
470,
251,
1110
],
[
1110,
95,
1106
]
],
[
[
470,
69,
266
],
[
266,
95,
1106
]
],
[
[
470,
180,
142
],
[
142,
95,
1106
]
],
[
[
470,
249,
1475
],
[
1475,
95,
1106
]
],
[
[
470,
95,
495
],
[
495,
95,
1106
]
],
[
[
470,
180,
147
],
[
147,
97,
1106
]
],
[
[
470,
95,
191
],
[
191,
119,
1106
]
],
[
[
470,
251,
1110
],
[
1110,
21,
28506
],
[
28506,
175,
1106
]
],
[
[
470,
69,
266
],
[
266,
21,
28495
],
[
28495,
175,
1106
]
]
] |
[
[
[
"Voxilaprevir",
"{u} may increase the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Voxilaprevir",
"{u} may decrease the serum concentration of {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may increase the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Voxilaprevir",
"{u} may decrease the metabolism of {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may increase the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Voxilaprevir",
"{u} can increase the metabolism of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may increase the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Voxilaprevir",
"{u} may increase the serum concentration of {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may increase the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Voxilaprevir",
"{u} may increase the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Voxilaprevir",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} may decrease the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Voxilaprevir",
"{u} may increase the serum concentration of {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the serum concentration of {v}",
"Fosaprepitant"
]
],
[
[
"Voxilaprevir",
"{u} may decrease the serum concentration of {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosaprepitant"
]
],
[
[
"Voxilaprevir",
"{u} may decrease the metabolism of {v}",
"Indinavir"
],
[
"Indinavir",
"{u} (Compound) causes {v} (Side Effect)",
"Oedema"
],
[
"Oedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosaprepitant"
]
]
] |
Voxilaprevir may decrease the serum concentration of Enzalutamide and Enzalutamide may increase the serum concentration of Fosaprepitant
Voxilaprevir may decrease the metabolism of Indinavir and Indinavir may increase the serum concentration of Fosaprepitant
Voxilaprevir can increase the metabolism of Phenytoin and Phenytoin may increase the serum concentration of Fosaprepitant
Voxilaprevir may increase the serum concentration of Naloxegol and Naloxegol may increase the serum concentration of Fosaprepitant
Voxilaprevir may increase the serum concentration of Vemurafenib and Vemurafenib may increase the serum concentration of Fosaprepitant
Voxilaprevir can increase the metabolism of Rifampicin and Rifampicin may decrease the serum concentration of Fosaprepitant
Voxilaprevir may increase the serum concentration of Aprepitant and Aprepitant (Compound) resembles Fosaprepitant (Compound) and Aprepitant may increase the serum concentration of Fosaprepitant
Voxilaprevir may decrease the serum concentration of Enzalutamide and Enzalutamide (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Fosaprepitant (Compound)
Voxilaprevir may decrease the metabolism of Indinavir and Indinavir (Compound) causes Oedema (Side Effect) and Oedema (Side Effect) is caused by Fosaprepitant (Compound)
|
DB08865
|
DB00358
| 1,079 | 285 |
Crizotinib
|
Mefloquine
|
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used
|
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196
|
Crizotinib may increase the QTc-prolonging activities of Mefloquine.
| 19 |
[
[
[
1079,
42,
285
]
],
[
[
1079,
6,
4590
],
[
4590,
160,
285
]
],
[
[
1079,
18,
5427
],
[
5427,
161,
285
]
],
[
[
1079,
7,
3107
],
[
3107,
161,
285
]
],
[
[
1079,
18,
5353
],
[
5353,
172,
285
]
],
[
[
1079,
21,
28474
],
[
28474,
175,
285
]
],
[
[
1079,
251,
171
],
[
171,
26,
285
]
],
[
[
1079,
196,
1322
],
[
1322,
42,
285
]
],
[
[
1079,
42,
383
],
[
383,
42,
285
]
],
[
[
1079,
249,
971
],
[
971,
42,
285
]
]
] |
[
[
[
"Crizotinib",
"{u} may increase the QTc prolonging activities of {v}",
"Mefloquine"
]
],
[
[
"Crizotinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Crizotinib",
"{u} (Compound) downregulates {v} (Gene)",
"PHGDH"
],
[
"PHGDH",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Crizotinib",
"{u} (Compound) upregulates {v} (Gene)",
"HMOX1"
],
[
"HMOX1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Crizotinib",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Crizotinib",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mefloquine"
]
],
[
[
"Crizotinib",
"{u} may decrease the serum concentration of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Mefloquine"
]
],
[
[
"Crizotinib",
"{u} may increase the QTc prolonging activities of {v}",
"Procainamide"
],
[
"Procainamide",
"{u} may increase the QTc prolonging activities of {v}",
"Mefloquine"
]
],
[
[
"Crizotinib",
"{u} may increase the QTc prolonging activities of {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may increase the QTc prolonging activities of {v}",
"Mefloquine"
]
],
[
[
"Crizotinib",
"{u} may increase the serum concentration of {v}",
"Zuclopenthixol"
],
[
"Zuclopenthixol",
"{u} may increase the QTc prolonging activities of {v}",
"Mefloquine"
]
]
] |
Crizotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mefloquine (Compound)
Crizotinib (Compound) downregulates PHGDH (Gene) and PHGDH (Gene) is upregulated by Mefloquine (Compound)
Crizotinib (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Mefloquine (Compound)
Crizotinib (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Mefloquine (Compound)
Crizotinib (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Mefloquine (Compound)
Crizotinib may decrease the serum concentration of Pentobarbital and Pentobarbital can increase the metabolism of Mefloquine
Crizotinib may increase the QTc prolonging activities of Procainamide and Procainamide may increase the QTc prolonging activities of Mefloquine
Crizotinib may increase the QTc prolonging activities of Granisetron and Granisetron may increase the QTc prolonging activities of Mefloquine
Crizotinib may increase the serum concentration of Zuclopenthixol and Zuclopenthixol may increase the QTc prolonging activities of Mefloquine
|
DB00623
|
DB00622
| 1,014 | 158 |
Fluphenazine
|
Nicardipine
|
A phenothiazine used in the treatment of psychoses. Its properties and uses are generally similar to those of chlorpromazine.
|
A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem]
|
The metabolism of Nicardipine can be decreased when combined with Fluphenazine.
| 46 |
[
[
[
1014,
69,
158
]
],
[
[
1014,
6,
13066
],
[
13066,
160,
158
]
],
[
[
1014,
21,
28392
],
[
28392,
175,
158
]
],
[
[
1014,
225,
156
],
[
156,
26,
158
]
],
[
[
1014,
71,
161
],
[
161,
26,
158
]
],
[
[
1014,
38,
702
],
[
702,
32,
158
]
],
[
[
1014,
71,
196
],
[
196,
42,
158
]
],
[
[
1014,
95,
539
],
[
539,
42,
158
]
],
[
[
1014,
82,
1027
],
[
1027,
42,
158
]
],
[
[
1014,
69,
392
],
[
392,
42,
158
]
]
] |
[
[
[
"Fluphenazine",
"{u} may decrease the metabolism of {v}",
"Nicardipine"
]
],
[
[
"Fluphenazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2E1"
],
[
"CYP2E1",
"{u} (Gene) is bound by {v} (Compound)",
"Nicardipine"
]
],
[
[
"Fluphenazine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nicardipine"
]
],
[
[
"Fluphenazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Nicardipine"
]
],
[
[
"Fluphenazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Nicardipine"
]
],
[
[
"Fluphenazine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Nicardipine"
]
],
[
[
"Fluphenazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Iloperidone"
],
[
"Iloperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Nicardipine"
]
],
[
[
"Fluphenazine",
"{u} may increase the serum concentration of {v}",
"Artemether"
],
[
"Artemether",
"{u} may increase the QTc prolonging activities of {v}",
"Nicardipine"
]
],
[
[
"Fluphenazine",
"{u} may increase the hypotensive activities of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the QTc prolonging activities of {v}",
"Nicardipine"
]
],
[
[
"Fluphenazine",
"{u} may decrease the metabolism of {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may increase the QTc prolonging activities of {v}",
"Nicardipine"
]
]
] |
Fluphenazine (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is bound by Nicardipine (Compound)
Fluphenazine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Nicardipine (Compound)
Fluphenazine may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Nicardipine
Fluphenazine may increase the severity of adverse effects when combined with Primidone and Primidone can increase the metabolism of Nicardipine
Fluphenazine may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Nicardipine
Fluphenazine may increase the severity of adverse effects when combined with Iloperidone and Iloperidone may increase the QTc prolonging activities of Nicardipine
Fluphenazine may increase the serum concentration of Artemether and Artemether may increase the QTc prolonging activities of Nicardipine
Fluphenazine may increase the hypotensive activities of Sotalol and Sotalol may increase the QTc prolonging activities of Nicardipine
Fluphenazine may decrease the metabolism of Chlorpromazine and Chlorpromazine may increase the QTc prolonging activities of Nicardipine
|
DB00283
|
DB00765
| 41 | 1,046 |
Clemastine
|
Metyrosine
|
An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.
|
An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed)
|
Clemastine may increase the sedative activities of Metyrosine.
| 31 |
[
[
[
41,
54,
1046
]
],
[
[
41,
223,
228
],
[
228,
1,
1046
]
],
[
[
41,
21,
29036
],
[
29036,
175,
1046
]
],
[
[
41,
223,
1040
],
[
1040,
32,
1046
]
],
[
[
41,
225,
936
],
[
936,
54,
1046
]
],
[
[
41,
223,
273
],
[
273,
54,
1046
]
],
[
[
41,
71,
963
],
[
963,
54,
1046
]
],
[
[
41,
24,
63
],
[
63,
54,
1046
]
],
[
[
41,
192,
1083
],
[
1083,
54,
1046
]
],
[
[
41,
38,
1257
],
[
1257,
54,
1046
]
]
] |
[
[
[
"Clemastine",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
]
],
[
[
"Clemastine",
"{u} may decrease the metabolism of {v}",
"Acetaminophen"
],
[
"Acetaminophen",
"{u} (Compound) resembles {v} (Compound)",
"Metyrosine"
]
],
[
[
"Clemastine",
"{u} (Compound) causes {v} (Side Effect)",
"Nasal congestion"
],
[
"Nasal congestion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metyrosine"
]
],
[
[
"Clemastine",
"{u} may decrease the metabolism of {v}",
"Tadalafil"
],
[
"Tadalafil",
"{u} may increase the antihypertensive activities of {v}",
"Metyrosine"
]
],
[
[
"Clemastine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tiapride"
],
[
"Tiapride",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
]
],
[
[
"Clemastine",
"{u} may decrease the metabolism of {v}",
"Dantrolene"
],
[
"Dantrolene",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
]
],
[
[
"Clemastine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Gabapentin enacarbil"
],
[
"Gabapentin enacarbil",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
]
],
[
[
"Clemastine",
"{u} may increase the anticholinergic activities of {v}",
"Tranylcypromine"
],
[
"Tranylcypromine",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
]
],
[
[
"Clemastine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
]
],
[
[
"Clemastine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
]
]
] |
Clemastine may decrease the metabolism of Acetaminophen and Acetaminophen (Compound) resembles Metyrosine (Compound)
Clemastine (Compound) causes Nasal congestion (Side Effect) and Nasal congestion (Side Effect) is caused by Metyrosine (Compound)
Clemastine may decrease the metabolism of Tadalafil and Tadalafil may increase the antihypertensive activities of Metyrosine
Clemastine may increase the severity of adverse effects when combined with Tiapride and Tiapride may increase the sedative activities of Metyrosine
Clemastine may decrease the metabolism of Dantrolene and Dantrolene may increase the sedative activities of Metyrosine
Clemastine may increase the severity of adverse effects when combined with Gabapentin enacarbil and Gabapentin enacarbil may increase the sedative activities of Metyrosine
Clemastine may increase the anticholinergic activities of Tranylcypromine and Tranylcypromine may increase the sedative activities of Metyrosine
Clemastine may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the sedative activities of Metyrosine
Clemastine may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the sedative activities of Metyrosine
|
DB00908
|
DB00502
| 59 | 245 |
Quinidine
|
Haloperidol
|
Quinidine is a D-isomer of [quinine] present in the bark of the Cinchona tree and similar plant species. This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication.[A38016,A250050] Quinidine is considered the first antiarrhythmic drug (class Ia) and is moderately efficacious in the acute conversion of atrial fibrillation to normal sinus rhythm. It prolongs cellular action potential by blocking sodium and potassium currents. A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug. Due to its side effects and increased risk of mortality, the use of quinidine was reduced over the next few decades. However, it continues to be used in the treatment of Brugada syndrome, short QT syndrome and idiopathic ventricular fibrillation.
|
Haloperidol is a high potency first-generation (typical) antipsychotic and one of the most frequently used antipsychotic medications used worldwide. While haloperidol has demonstrated pharmacologic activity at a number of receptors in the brain, it exerts its antipsychotic effect through its strong antagonism of the dopamine receptor (mainly D2), particularly within the mesolimbic and mesocortical systems of the brain. Haloperidol is indicated for the treatment of the manifestations of several psychotic disorders including schizophrenia, acute psychosis, Tourette syndrome, and other severe behavioural states. It is also used off-label for the management of chorea associated with Huntington's disease and for the treatment of intractable hiccups as it is a potent antiemetic. Dopamine-antagonizing medications such as haloperidol are though to improve psychotic symptoms and states that are caused by an over-production of dopamine, such as schizophrenia, which is
|
Quinidine may increase the QTc-prolonging activities of Haloperidol.
| 19 |
[
[
[
59,
42,
245
]
],
[
[
59,
223,
55
],
[
55,
155,
245
]
],
[
[
59,
6,
7128
],
[
7128,
160,
245
]
],
[
[
59,
21,
28509
],
[
28509,
175,
245
]
],
[
[
59,
251,
161
],
[
161,
26,
245
]
],
[
[
59,
102,
164
],
[
164,
26,
245
]
],
[
[
59,
180,
173
],
[
173,
26,
245
]
],
[
[
59,
42,
543
],
[
543,
38,
245
]
],
[
[
59,
107,
1261
],
[
1261,
192,
245
]
],
[
[
59,
33,
1083
],
[
1083,
38,
245
]
]
] |
[
[
[
"Quinidine",
"{u} may increase the QTc prolonging activities of {v}",
"Haloperidol"
]
],
[
[
"Quinidine",
"{u} may decrease the metabolism of {v}",
"Moclobemide"
],
[
"Moclobemide",
"{u} (Compound) resembles {v} (Compound)",
"Haloperidol"
]
],
[
[
"Quinidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Haloperidol"
]
],
[
[
"Quinidine",
"{u} (Compound) causes {v} (Side Effect)",
"Mediastinal disorder"
],
[
"Mediastinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Haloperidol"
]
],
[
[
"Quinidine",
"{u} may decrease the serum concentration of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Haloperidol"
]
],
[
[
"Quinidine",
"{u} may increase the hepatotoxic activities of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Haloperidol"
]
],
[
[
"Quinidine",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Haloperidol"
]
],
[
[
"Quinidine",
"{u} may increase the QTc prolonging activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Haloperidol"
]
],
[
[
"Quinidine",
"{u} may increase the tachycardic activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Haloperidol"
]
],
[
[
"Quinidine",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Haloperidol"
]
]
] |
Quinidine may decrease the metabolism of Moclobemide and Moclobemide (Compound) resembles Haloperidol (Compound)
Quinidine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Haloperidol (Compound)
Quinidine (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Haloperidol (Compound)
Quinidine may decrease the serum concentration of Primidone and Primidone can increase the metabolism of Haloperidol
Quinidine may increase the hepatotoxic activities of Phenobarbital and Phenobarbital can increase the metabolism of Haloperidol
Quinidine can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Haloperidol
Quinidine may increase the QTc prolonging activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Haloperidol
Quinidine may increase the tachycardic activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Haloperidol
Quinidine may reduce the serum concentration of the active metabolites of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Haloperidol
|
DB00326
|
DB00884
| 1,501 | 421 |
Calcium glucoheptonate
|
Risedronic acid
|
Calcium supplements such as calcium gluceptate are taken by individuals who are unable to get enough calcium in their regular diet or who have a need for more calcium. They are used to prevent or treat several conditions that may cause hypocalcemia (not enough calcium in the blood). The body needs calcium to make strong bones. Calcium is also needed for the heart, muscles, and nervous system to work properly.
|
Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. It functions by preventing resorption of bone[FDA Label].
|
The serum concentration of Risedronic acid can be decreased when it is combined with Calcium glucoheptonate.
| 74 |
[
[
[
1501,
97,
421
]
],
[
[
1501,
97,
1338
],
[
1338,
1,
421
]
],
[
[
1501,
21,
28448
],
[
28448,
175,
421
]
],
[
[
1501,
92,
238
],
[
238,
71,
421
]
],
[
[
1501,
97,
1338
],
[
1338,
1,
1320
],
[
1320,
1,
421
]
],
[
[
1501,
97,
1320
],
[
1320,
155,
1338
],
[
1338,
1,
421
]
],
[
[
1501,
21,
28448
],
[
28448,
175,
1338
],
[
1338,
1,
421
]
],
[
[
1501,
1,
16968
],
[
16968,
21,
28390
],
[
28390,
175,
421
]
],
[
[
1501,
92,
238
],
[
238,
71,
1338
],
[
1338,
1,
421
]
],
[
[
1501,
21,
28510
],
[
28510,
175,
164
],
[
164,
26,
421
]
]
] |
[
[
[
"Calcium glucoheptonate",
"{u} may decrease the serum concentration of {v}",
"Risedronic acid"
]
],
[
[
"Calcium glucoheptonate",
"{u} may decrease the serum concentration of {v}",
"Zoledronic acid"
],
[
"Zoledronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Risedronic acid"
]
],
[
[
"Calcium glucoheptonate",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Risedronic acid"
]
],
[
[
"Calcium glucoheptonate",
"{u} may decrease the therapeutic efficacy of {v}",
"Nimesulide"
],
[
"Nimesulide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Risedronic acid"
]
],
[
[
"Calcium glucoheptonate",
"{u} may decrease the serum concentration of {v}",
"Zoledronic acid"
],
[
"Zoledronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Ibandronate"
],
[
"Ibandronate",
"{u} (Compound) resembles {v} (Compound)",
"Risedronic acid"
]
],
[
[
"Calcium glucoheptonate",
"{u} may decrease the serum concentration of {v}",
"Ibandronate"
],
[
"Ibandronate",
"{u} (Compound) resembles {v} (Compound)",
"Zoledronic acid"
],
[
"Zoledronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Risedronic acid"
]
],
[
[
"Calcium glucoheptonate",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zoledronic acid"
],
[
"Zoledronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Risedronic acid"
]
],
[
[
"Calcium glucoheptonate",
"{u} (Compound) resembles {v} (Compound)",
"Gadopentetate dimeglumine"
],
[
"Gadopentetate dimeglumine",
"{u} (Compound) causes {v} (Side Effect)",
"Urinary tract disorder"
],
[
"Urinary tract disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Risedronic acid"
]
],
[
[
"Calcium glucoheptonate",
"{u} may decrease the therapeutic efficacy of {v}",
"Nimesulide"
],
[
"Nimesulide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zoledronic acid"
],
[
"Zoledronic acid",
"{u} (Compound) resembles {v} (Compound)",
"Risedronic acid"
]
],
[
[
"Calcium glucoheptonate",
"{u} (Compound) causes {v} (Side Effect)",
"Syncope"
],
[
"Syncope",
"{u} (Side Effect) is caused by {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Risedronic acid"
]
]
] |
Calcium glucoheptonate may decrease the serum concentration of Zoledronic acid and Zoledronic acid (Compound) resembles Risedronic acid (Compound)
Calcium glucoheptonate (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Risedronic acid (Compound)
Calcium glucoheptonate may decrease the therapeutic efficacy of Nimesulide and Nimesulide may increase the severity of adverse effects when combined with Risedronic acid
Calcium glucoheptonate may decrease the serum concentration of Zoledronic acid and Zoledronic acid (Compound) resembles Ibandronate (Compound) and Ibandronate (Compound) resembles Risedronic acid (Compound)
Calcium glucoheptonate may decrease the serum concentration of Ibandronate and Ibandronate (Compound) resembles Zoledronic acid (Compound) and Zoledronic acid (Compound) resembles Risedronic acid (Compound)
Calcium glucoheptonate (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Zoledronic acid (Compound) and Zoledronic acid (Compound) resembles Risedronic acid (Compound)
Calcium glucoheptonate (Compound) resembles Gadopentetate dimeglumine (Compound) and Gadopentetate dimeglumine (Compound) causes Urinary tract disorder (Side Effect) and Urinary tract disorder (Side Effect) is caused by Risedronic acid (Compound)
Calcium glucoheptonate may decrease the therapeutic efficacy of Nimesulide and Nimesulide may increase the severity of adverse effects when combined with Zoledronic acid and Zoledronic acid (Compound) resembles Risedronic acid (Compound)
Calcium glucoheptonate (Compound) causes Syncope (Side Effect) and Syncope (Side Effect) is caused by Phenobarbital (Compound) and Phenobarbital can increase the metabolism of Risedronic acid
|
DB01224
|
DB00745
| 955 | 488 |
Quetiapine
|
Modafinil
|
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as [clozapine] and [olanzapine].
|
Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactivation and euphoria. The exact mechanism of action is unclear, although in vitro studies have shown it to inhibit the reuptake of dopamine by binding to the dopamine reuptake pump, and lead to an increase in extracellular dopamine. Modafinil activates glutamatergic circuits while inhibiting GABA.
|
The metabolism of Modafinil can be decreased when combined with Quetiapine.
| 46 |
[
[
[
955,
69,
488
]
],
[
[
955,
225,
355
],
[
355,
155,
488
]
],
[
[
955,
192,
72
],
[
72,
155,
488
]
],
[
[
955,
71,
984
],
[
984,
155,
488
]
],
[
[
955,
251,
150
],
[
150,
26,
488
]
],
[
[
955,
99,
156
],
[
156,
155,
488
]
],
[
[
955,
6,
8607
],
[
8607,
160,
488
]
],
[
[
955,
21,
29454
],
[
29454,
175,
488
]
],
[
[
955,
92,
526
],
[
526,
69,
488
]
],
[
[
955,
69,
396
],
[
396,
69,
488
]
]
] |
[
[
[
"Quetiapine",
"{u} may decrease the metabolism of {v}",
"Modafinil"
]
],
[
[
"Quetiapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenoxybenzamine"
],
[
"Phenoxybenzamine",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
]
],
[
[
"Quetiapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
]
],
[
[
"Quetiapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methadyl acetate"
],
[
"Methadyl acetate",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
]
],
[
[
"Quetiapine",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Modafinil"
]
],
[
[
"Quetiapine",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
]
],
[
[
"Quetiapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Modafinil"
]
],
[
[
"Quetiapine",
"{u} (Compound) causes {v} (Side Effect)",
"Mental disability"
],
[
"Mental disability",
"{u} (Side Effect) is caused by {v} (Compound)",
"Modafinil"
]
],
[
[
"Quetiapine",
"{u} may decrease the therapeutic efficacy of {v}",
"Glyburide"
],
[
"Glyburide",
"{u} may decrease the metabolism of {v}",
"Modafinil"
]
],
[
[
"Quetiapine",
"{u} may decrease the metabolism of {v}",
"Terbinafine"
],
[
"Terbinafine",
"{u} may decrease the metabolism of {v}",
"Modafinil"
]
]
] |
Quetiapine may increase the severity of adverse effects when combined with Phenoxybenzamine and Phenoxybenzamine (Compound) resembles Modafinil (Compound)
Quetiapine may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine (Compound) resembles Modafinil (Compound)
Quetiapine may increase the severity of adverse effects when combined with Methadyl acetate and Methadyl acetate (Compound) resembles Modafinil (Compound)
Quetiapine may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Modafinil
Quetiapine may increase the serum concentration of the active metabolites of Carbamazepine and Carbamazepine (Compound) resembles Modafinil (Compound)
Quetiapine (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Modafinil (Compound)
Quetiapine (Compound) causes Mental disability (Side Effect) and Mental disability (Side Effect) is caused by Modafinil (Compound)
Quetiapine may decrease the therapeutic efficacy of Glyburide and Glyburide may decrease the metabolism of Modafinil
Quetiapine may decrease the metabolism of Terbinafine and Terbinafine may decrease the metabolism of Modafinil
|
DB00870
|
DB00880
| 628 | 1,048 |
Suprofen
|
Chlorothiazide
|
An ibuprofen-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic. It is no longer approved for use in the United States.
|
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)
|
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Suprofen.
| 69 |
[
[
[
628,
92,
1048
]
],
[
[
628,
92,
1325
],
[
1325,
1,
1048
]
],
[
[
628,
92,
1066
],
[
1066,
236,
1048
]
],
[
[
628,
21,
28490
],
[
28490,
175,
1048
]
],
[
[
628,
180,
164
],
[
164,
52,
1048
]
],
[
[
628,
69,
535
],
[
535,
225,
1048
]
],
[
[
628,
213,
1029
],
[
1029,
225,
1048
]
],
[
[
628,
225,
650
],
[
650,
71,
1048
]
],
[
[
628,
213,
139
],
[
139,
71,
1048
]
],
[
[
628,
69,
239
],
[
239,
71,
1048
]
]
] |
[
[
[
"Suprofen",
"{u} may decrease the therapeutic efficacy of {v}",
"Chlorothiazide"
]
],
[
[
"Suprofen",
"{u} may decrease the therapeutic efficacy of {v}",
"Quinethazone"
],
[
"Quinethazone",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
]
],
[
[
"Suprofen",
"{u} may decrease the therapeutic efficacy of {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} may increase the hypotensive activities of {v}",
"Chlorothiazide"
]
],
[
[
"Suprofen",
"{u} (Compound) causes {v} (Side Effect)",
"Erythema"
],
[
"Erythema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Chlorothiazide"
]
],
[
[
"Suprofen",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Chlorothiazide"
]
],
[
[
"Suprofen",
"{u} may decrease the metabolism of {v}",
"Irbesartan"
],
[
"Irbesartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorothiazide"
]
],
[
[
"Suprofen",
"{u} may decrease the antihypertensive activities of {v}",
"Levobunolol"
],
[
"Levobunolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorothiazide"
]
],
[
[
"Suprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Moexipril"
],
[
"Moexipril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorothiazide"
]
],
[
[
"Suprofen",
"{u} may decrease the antihypertensive activities of {v}",
"Atenolol"
],
[
"Atenolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorothiazide"
]
],
[
[
"Suprofen",
"{u} may decrease the metabolism of {v}",
"Valsartan"
],
[
"Valsartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorothiazide"
]
]
] |
Suprofen may decrease the therapeutic efficacy of Quinethazone and Quinethazone (Compound) resembles Chlorothiazide (Compound)
Suprofen may decrease the therapeutic efficacy of Polythiazide and Polythiazide may increase the hypotensive activities of Chlorothiazide
Suprofen (Compound) causes Erythema (Side Effect) and Erythema (Side Effect) is caused by Chlorothiazide (Compound)
Suprofen can increase the metabolism of Phenobarbital and Phenobarbital may increase the orthostatic hypotensive activities of Chlorothiazide
Suprofen may decrease the metabolism of Irbesartan and Irbesartan may increase the severity of adverse effects when combined with Chlorothiazide
Suprofen may decrease the antihypertensive activities of Levobunolol and Levobunolol may increase the severity of adverse effects when combined with Chlorothiazide
Suprofen may increase the severity of adverse effects when combined with Moexipril and Moexipril may increase the severity of adverse effects when combined with Chlorothiazide
Suprofen may decrease the antihypertensive activities of Atenolol and Atenolol may increase the severity of adverse effects when combined with Chlorothiazide
Suprofen may decrease the metabolism of Valsartan and Valsartan may increase the severity of adverse effects when combined with Chlorothiazide
|
DB00780
|
DB00797
| 53 | 1,070 |
Phenelzine
|
Tolazoline
|
Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name of Nardil.
|
A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn.
|
Phenelzine may increase the hypotensive activities of Tolazoline.
| 59 |
[
[
[
53,
123,
1070
]
],
[
[
53,
1,
34
],
[
34,
155,
1070
]
],
[
[
53,
247,
707
],
[
707,
155,
1070
]
],
[
[
53,
1,
1298
],
[
1298,
1,
1070
]
],
[
[
53,
52,
828
],
[
828,
206,
1070
]
],
[
[
53,
225,
605
],
[
605,
71,
1070
]
],
[
[
53,
71,
1326
],
[
1326,
225,
1070
]
],
[
[
53,
225,
975
],
[
975,
225,
1070
]
],
[
[
53,
71,
541
],
[
541,
71,
1070
]
],
[
[
53,
30,
540
],
[
540,
71,
1070
]
]
] |
[
[
[
"Phenelzine",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the hypotensive activities of {v}",
"Tolazoline"
]
],
[
[
"Phenelzine",
"{u} (Compound) resembles {v} (Compound)",
"Amphetamine"
],
[
"Amphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Tolazoline"
]
],
[
[
"Phenelzine",
"{u} may increase the hypertensive activities of {v}",
"Mephentermine"
],
[
"Mephentermine",
"{u} (Compound) resembles {v} (Compound)",
"Tolazoline"
]
],
[
[
"Phenelzine",
"{u} (Compound) resembles {v} (Compound)",
"Dextroamphetamine"
],
[
"Dextroamphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Tolazoline"
]
],
[
[
"Phenelzine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Tolazoline"
]
],
[
[
"Phenelzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cilnidipine"
],
[
"Cilnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolazoline"
]
],
[
[
"Phenelzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methyclothiazide"
],
[
"Methyclothiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolazoline"
]
],
[
[
"Phenelzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolcapone"
],
[
"Tolcapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolazoline"
]
],
[
[
"Phenelzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ropivacaine"
],
[
"Ropivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolazoline"
]
],
[
[
"Phenelzine",
"{u} can increase the therapeutic efficacy of {v}",
"Morphine"
],
[
"Morphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolazoline"
]
]
] |
Phenelzine (Compound) resembles Tolazoline (Compound) and
Phenelzine (Compound) resembles Amphetamine (Compound) and Amphetamine (Compound) resembles Tolazoline (Compound)
Phenelzine may increase the hypertensive activities of Mephentermine and Mephentermine (Compound) resembles Tolazoline (Compound)
Phenelzine (Compound) resembles Dextroamphetamine (Compound) and Dextroamphetamine (Compound) resembles Tolazoline (Compound)
Phenelzine may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Tolazoline
Phenelzine may increase the severity of adverse effects when combined with Cilnidipine and Cilnidipine may increase the severity of adverse effects when combined with Tolazoline
Phenelzine may increase the severity of adverse effects when combined with Methyclothiazide and Methyclothiazide may increase the severity of adverse effects when combined with Tolazoline
Phenelzine may increase the severity of adverse effects when combined with Tolcapone and Tolcapone may increase the severity of adverse effects when combined with Tolazoline
Phenelzine may increase the severity of adverse effects when combined with Ropivacaine and Ropivacaine may increase the severity of adverse effects when combined with Tolazoline
Phenelzine can increase the therapeutic efficacy of Morphine and Morphine may increase the severity of adverse effects when combined with Tolazoline
|
DB00682
|
DB00446
| 219 | 658 |
Warfarin
|
Chloramphenicol
|
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
|
An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022]
|
Warfarin may increase the anticoagulant activities of Chloramphenicol.
| 5 |
[
[
[
219,
28,
658
]
],
[
[
219,
6,
7128
],
[
7128,
160,
658
]
],
[
[
219,
251,
156
],
[
156,
26,
658
]
],
[
[
219,
180,
147
],
[
147,
26,
658
]
],
[
[
219,
131,
498
],
[
498,
28,
658
]
],
[
[
219,
1,
342
],
[
342,
28,
658
]
],
[
[
219,
182,
384
],
[
384,
28,
658
]
],
[
[
219,
28,
597
],
[
597,
187,
658
]
],
[
[
219,
28,
44
],
[
44,
69,
658
]
],
[
[
219,
69,
554
],
[
554,
69,
658
]
]
] |
[
[
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Chloramphenicol"
]
],
[
[
"Warfarin",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Chloramphenicol"
]
],
[
[
"Warfarin",
"{u} may decrease the serum concentration of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Chloramphenicol"
]
],
[
[
"Warfarin",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Chloramphenicol"
]
],
[
[
"Warfarin",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Chloramphenicol"
]
],
[
[
"Warfarin",
"{u} (Compound) resembles {v} (Compound)",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Chloramphenicol"
]
],
[
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Chloramphenicol"
]
],
[
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Chloramphenicol"
]
],
[
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may decrease the metabolism of {v}",
"Chloramphenicol"
]
],
[
[
"Warfarin",
"{u} may decrease the metabolism of {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may decrease the metabolism of {v}",
"Chloramphenicol"
]
]
] |
Warfarin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Chloramphenicol (Compound)
Warfarin may decrease the serum concentration of Carbamazepine and Carbamazepine can increase the metabolism of Chloramphenicol
Warfarin can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Chloramphenicol
Warfarin (Compound) resembles Dicoumarol (Compound) and Warfarin may increase the anticoagulant activities of Dicoumarol and Dicoumarol may increase the anticoagulant activities of Chloramphenicol
Warfarin (Compound) resembles Acenocoumarol (Compound) and Acenocoumarol may increase the anticoagulant activities of Chloramphenicol
Warfarin may increase the anticoagulant activities of Phenprocoumon and Phenprocoumon may increase the anticoagulant activities of Chloramphenicol
Warfarin may increase the anticoagulant activities of Clopidogrel and Clopidogrel may reduce the serum concentration of the active metabolites of Chloramphenicol
Warfarin may increase the anticoagulant activities of Tolterodine and Tolterodine may decrease the metabolism of Chloramphenicol
Warfarin may decrease the metabolism of Pantoprazole and Pantoprazole may decrease the metabolism of Chloramphenicol
|
DB01043
|
DB00387
| 1,120 | 43 |
Memantine
|
Procyclidine
|
Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease. Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease. In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050. In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or
|
A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.
|
The therapeutic efficacy of Procyclidine can be decreased when used in combination with Memantine.
| 69 |
[
[
[
1120,
92,
43
]
],
[
[
1120,
92,
28
],
[
28,
24,
43
]
],
[
[
1120,
92,
37
],
[
37,
225,
43
]
],
[
[
1120,
10,
17031
],
[
17031,
164,
43
]
],
[
[
1120,
92,
62
],
[
62,
116,
43
]
],
[
[
1120,
92,
28
],
[
28,
24,
37
],
[
37,
225,
43
]
],
[
[
1120,
92,
37
],
[
37,
178,
28
],
[
28,
24,
43
]
],
[
[
1120,
10,
17031
],
[
17031,
164,
27
],
[
27,
225,
43
]
],
[
[
1120,
92,
26
],
[
26,
24,
28
],
[
28,
24,
43
]
],
[
[
1120,
92,
13
],
[
13,
225,
65
],
[
65,
225,
43
]
]
] |
[
[
[
"Memantine",
"{u} may decrease the therapeutic efficacy of {v}",
"Procyclidine"
]
],
[
[
"Memantine",
"{u} may decrease the therapeutic efficacy of {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may increase the anticholinergic activities of {v}",
"Procyclidine"
]
],
[
[
"Memantine",
"{u} may decrease the therapeutic efficacy of {v}",
"Oxyphenonium"
],
[
"Oxyphenonium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Procyclidine"
]
],
[
[
"Memantine",
"{u} (Compound) palliates {v} (Disease)",
"Parkinson's disease"
],
[
"Parkinson's disease",
"{u} (Disease) is palliated by {v} (Compound)",
"Procyclidine"
]
],
[
[
"Memantine",
"{u} may decrease the therapeutic efficacy of {v}",
"Trihexyphenidyl"
],
[
"Trihexyphenidyl",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Procyclidine"
]
],
[
[
"Memantine",
"{u} may decrease the therapeutic efficacy of {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may increase the anticholinergic activities of {v}",
"Oxyphenonium"
],
[
"Oxyphenonium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Procyclidine"
]
],
[
[
"Memantine",
"{u} may decrease the therapeutic efficacy of {v}",
"Oxyphenonium"
],
[
"Oxyphenonium",
"{u} may increase the anticholinergic activities of {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may increase the anticholinergic activities of {v}",
"Procyclidine"
]
],
[
[
"Memantine",
"{u} (Compound) palliates {v} (Disease)",
"Parkinson's disease"
],
[
"Parkinson's disease",
"{u} (Disease) is palliated by {v} (Compound)",
"Biperiden"
],
[
"Biperiden",
"{u} may increase the severity of adverse effects when combined with {v}",
"Procyclidine"
]
],
[
[
"Memantine",
"{u} may decrease the therapeutic efficacy of {v}",
"Tiotropium"
],
[
"Tiotropium",
"{u} may increase the anticholinergic activities of {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may increase the anticholinergic activities of {v}",
"Procyclidine"
]
],
[
[
"Memantine",
"{u} may decrease the therapeutic efficacy of {v}",
"Methscopolamine"
],
[
"Methscopolamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxybutynin"
],
[
"Oxybutynin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Procyclidine"
]
]
] |
Memantine may decrease the therapeutic efficacy of Glycopyrronium and Glycopyrronium may increase the anticholinergic activities of Procyclidine
Memantine may decrease the therapeutic efficacy of Oxyphenonium and Oxyphenonium may increase the severity of adverse effects when combined with Procyclidine
Memantine (Compound) palliates Parkinson's disease (Disease) and Parkinson's disease (Disease) is palliated by Procyclidine (Compound)
Memantine may decrease the therapeutic efficacy of Trihexyphenidyl and Trihexyphenidyl (Compound) resembles Procyclidine (Compound) and Trihexyphenidyl may increase the severity of adverse effects when combined with Procyclidine
Memantine may decrease the therapeutic efficacy of Glycopyrronium and Glycopyrronium may increase the anticholinergic activities of Oxyphenonium and Oxyphenonium may increase the severity of adverse effects when combined with Procyclidine
Memantine may decrease the therapeutic efficacy of Oxyphenonium and Oxyphenonium may increase the anticholinergic activities of Glycopyrronium and Glycopyrronium may increase the anticholinergic activities of Procyclidine
Memantine (Compound) palliates Parkinson's disease (Disease) and Parkinson's disease (Disease) is palliated by Biperiden (Compound) and Biperiden may increase the severity of adverse effects when combined with Procyclidine
Memantine may decrease the therapeutic efficacy of Tiotropium and Tiotropium may increase the anticholinergic activities of Glycopyrronium and Glycopyrronium may increase the anticholinergic activities of Procyclidine
Memantine may decrease the therapeutic efficacy of Methscopolamine and Methscopolamine may increase the severity of adverse effects when combined with Oxybutynin and Oxybutynin may increase the severity of adverse effects when combined with Procyclidine
|
DB00227
|
DB00701
| 267 | 431 |
Lovastatin
|
Amprenavir
|
Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered
|
Amprenavir is a protease inhibitor used to treat HIV infection.
|
The serum concentration of Amprenavir can be increased when it is combined with Lovastatin.
| 72 |
[
[
[
267,
95,
431
]
],
[
[
267,
6,
8339
],
[
8339,
160,
431
]
],
[
[
267,
21,
28501
],
[
28501,
175,
431
]
],
[
[
267,
180,
171
],
[
171,
26,
431
]
],
[
[
267,
251,
142
],
[
142,
26,
431
]
],
[
[
267,
95,
657
],
[
657,
223,
431
]
],
[
[
267,
223,
422
],
[
422,
223,
431
]
],
[
[
267,
95,
482
],
[
482,
69,
431
]
],
[
[
267,
69,
1086
],
[
1086,
223,
431
]
],
[
[
267,
249,
1085
],
[
1085,
223,
431
]
]
] |
[
[
[
"Lovastatin",
"{u} may increase the serum concentration of {v}",
"Amprenavir"
]
],
[
[
"Lovastatin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Amprenavir"
]
],
[
[
"Lovastatin",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amprenavir"
]
],
[
[
"Lovastatin",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Lovastatin",
"{u} may decrease the serum concentration of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Lovastatin",
"{u} may increase the serum concentration of {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may decrease the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Lovastatin",
"{u} may decrease the metabolism of {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may decrease the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Lovastatin",
"{u} may increase the serum concentration of {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Lovastatin",
"{u} may decrease the metabolism of {v}",
"Clotrimazole"
],
[
"Clotrimazole",
"{u} may decrease the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Lovastatin",
"{u} may increase the serum concentration of {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may decrease the metabolism of {v}",
"Amprenavir"
]
]
] |
Lovastatin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Amprenavir (Compound)
Lovastatin (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Amprenavir (Compound)
Lovastatin can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Amprenavir
Lovastatin may decrease the serum concentration of Phenytoin and Phenytoin can increase the metabolism of Amprenavir
Lovastatin may increase the serum concentration of Voriconazole and Voriconazole may decrease the metabolism of Amprenavir
Lovastatin may decrease the metabolism of Midostaurin and Midostaurin may decrease the metabolism of Amprenavir
Lovastatin may increase the serum concentration of Verapamil and Verapamil may decrease the metabolism of Amprenavir
Lovastatin may decrease the metabolism of Clotrimazole and Clotrimazole may decrease the metabolism of Amprenavir
Lovastatin may increase the serum concentration of Olaparib and Olaparib may decrease the metabolism of Amprenavir
|
DB00708
|
DB00594
| 510 | 1,358 |
Sufentanil
|
Amiloride
|
Sufentanil is an opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. It is administered by the intravenous, epidural and sublingual routes. Also known as _Dsuvia_, the sublingual form is used for the management of acute pain in adults that is severe to warrant the use of an opioid analgesic in certified medically supervised healthcare settings, including hospitals, surgical centers, and emergency departments. Consideration may be made in the future for the use of the sublingual form in the US military in cases where analgesia is required immediately. The sublingual form, manufactured by AcelRx Pharmaceuticals, Inc. (AcelRx), was approved on November 2, 2018. This route of administration is intended to be a simple, effective, non-invasive analgesic option to enable healthcare professionals to rapidly manage acute pain without difficult intravenous or epidural
|
A pyrazine compound inhibiting sodium reabsorption through sodium channels in renal epithelial cells. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with diuretics to spare potassium loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705)
|
The risk or severity of adverse effects can be increased when Sufentanil is combined with Amiloride.
| 48 |
[
[
[
510,
71,
1358
]
],
[
[
510,
21,
28392
],
[
28392,
175,
1358
]
],
[
[
510,
52,
828
],
[
828,
206,
1358
]
],
[
[
510,
71,
438
],
[
438,
71,
1358
]
],
[
[
510,
230,
1034
],
[
1034,
71,
1358
]
],
[
[
510,
116,
419
],
[
419,
71,
1358
]
],
[
[
510,
71,
426
],
[
426,
225,
1358
]
],
[
[
510,
192,
679
],
[
679,
71,
1358
]
],
[
[
510,
225,
579
],
[
579,
71,
1358
]
],
[
[
510,
38,
1265
],
[
1265,
71,
1358
]
]
] |
[
[
[
"Sufentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amiloride"
]
],
[
[
"Sufentanil",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amiloride"
]
],
[
[
"Sufentanil",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Amiloride"
]
],
[
[
"Sufentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Imipramine"
],
[
"Imipramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amiloride"
]
],
[
[
"Sufentanil",
"{u} may increase the bradycardic activities of {v}",
"Esmolol"
],
[
"Esmolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amiloride"
]
],
[
[
"Sufentanil",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Alfentanil"
],
[
"Alfentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amiloride"
]
],
[
[
"Sufentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amiloride"
]
],
[
[
"Sufentanil",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amiloride"
]
],
[
[
"Sufentanil",
"{u} may increase the severity of adverse effects when combined with {v}",
"Codeine"
],
[
"Codeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amiloride"
]
],
[
[
"Sufentanil",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amiloride"
]
]
] |
Sufentanil (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Amiloride (Compound)
Sufentanil may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Amiloride
Sufentanil may increase the severity of adverse effects when combined with Imipramine and Imipramine may increase the severity of adverse effects when combined with Amiloride
Sufentanil may increase the bradycardic activities of Esmolol and Esmolol may increase the severity of adverse effects when combined with Amiloride
Sufentanil (Compound) resembles Alfentanil (Compound) and Sufentanil may increase the severity of adverse effects when combined with Alfentanil and Alfentanil may increase the severity of adverse effects when combined with Amiloride
Sufentanil may increase the severity of adverse effects when combined with Dapagliflozin and Dapagliflozin may increase the severity of adverse effects when combined with Amiloride
Sufentanil may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the severity of adverse effects when combined with Amiloride
Sufentanil may increase the severity of adverse effects when combined with Codeine and Codeine may increase the severity of adverse effects when combined with Amiloride
Sufentanil may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the severity of adverse effects when combined with Amiloride
|
DB01600
|
DB00287
| 4 | 1,051 |
Tiaprofenic acid
|
Travoprost
|
Tiaprofenic acid is a non-steroidal anti-inflammatory drug employed in the treatment of pain, particularly arthritis pain. It belongs to the _arylpropionic acid_ (profen) group of nonsteroidal anti-inflammatory drugs (NSAIDs).
|
Travoprost is a synthetic isopropyl ester prodrug of a prostaglandin F2alpha (F2α) analogue and selective FP prostanoid receptor agonist. It is used to decrease intraocular pressure in open-angle glaucoma and ocular hypertension. Unlike other prostaglandin analogues, travoprost demonstrates full agonism and high selectivity at the prostanoid receptor, reporting a higher efficacy in reducing intraocular pressure and a reduced risk for developing off-target side effects.
|
The therapeutic efficacy of Travoprost can be decreased when used in combination with Tiaprofenic acid.
| 69 |
[
[
[
4,
92,
1051
]
],
[
[
4,
92,
1537
],
[
1537,
155,
1051
]
],
[
[
4,
92,
1489
],
[
1489,
1,
1051
]
],
[
[
4,
21,
28463
],
[
28463,
175,
1051
]
],
[
[
4,
225,
1071
],
[
1071,
236,
1051
]
],
[
[
4,
92,
1045
],
[
1045,
236,
1051
]
],
[
[
4,
213,
1026
],
[
1026,
236,
1051
]
],
[
[
4,
225,
239
],
[
239,
82,
1051
]
],
[
[
4,
213,
576
],
[
576,
82,
1051
]
],
[
[
4,
51,
557
],
[
557,
82,
1051
]
]
] |
[
[
[
"Tiaprofenic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Travoprost"
]
],
[
[
"Tiaprofenic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Dinoprost tromethamine"
],
[
"Dinoprost tromethamine",
"{u} (Compound) resembles {v} (Compound)",
"Travoprost"
]
],
[
[
"Tiaprofenic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Carboprost tromethamine"
],
[
"Carboprost tromethamine",
"{u} (Compound) resembles {v} (Compound)",
"Travoprost"
]
],
[
[
"Tiaprofenic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Travoprost"
]
],
[
[
"Tiaprofenic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Telmisartan"
],
[
"Telmisartan",
"{u} may increase the hypotensive activities of {v}",
"Travoprost"
]
],
[
[
"Tiaprofenic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} may increase the hypotensive activities of {v}",
"Travoprost"
]
],
[
[
"Tiaprofenic acid",
"{u} may decrease the antihypertensive activities of {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} may increase the hypotensive activities of {v}",
"Travoprost"
]
],
[
[
"Tiaprofenic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Valsartan"
],
[
"Valsartan",
"{u} may increase the hypotensive activities of {v}",
"Travoprost"
]
],
[
[
"Tiaprofenic acid",
"{u} may decrease the antihypertensive activities of {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may increase the hypotensive activities of {v}",
"Travoprost"
]
],
[
[
"Tiaprofenic acid",
"{u} may decrease the diuretic activities of {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may increase the hypotensive activities of {v}",
"Travoprost"
]
]
] |
Tiaprofenic acid may decrease the therapeutic efficacy of Dinoprost tromethamine and Dinoprost tromethamine (Compound) resembles Travoprost (Compound)
Tiaprofenic acid may decrease the therapeutic efficacy of Carboprost tromethamine and Carboprost tromethamine (Compound) resembles Travoprost (Compound)
Tiaprofenic acid (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Travoprost (Compound)
Tiaprofenic acid may increase the severity of adverse effects when combined with Telmisartan and Telmisartan may increase the hypotensive activities of Travoprost
Tiaprofenic acid may decrease the therapeutic efficacy of Trichlormethiazide and Trichlormethiazide may increase the hypotensive activities of Travoprost
Tiaprofenic acid may decrease the antihypertensive activities of Acebutolol and Acebutolol may increase the hypotensive activities of Travoprost
Tiaprofenic acid may increase the severity of adverse effects when combined with Valsartan and Valsartan may increase the hypotensive activities of Travoprost
Tiaprofenic acid may decrease the antihypertensive activities of Metoprolol and Metoprolol may increase the hypotensive activities of Travoprost
Tiaprofenic acid may decrease the diuretic activities of Torasemide and Torasemide may increase the hypotensive activities of Travoprost
|
DB09212
|
DB06786
| 810 | 122 |
Loxoprofen
|
Halcinonide
|
Loxoprofen is a propionic acid derivative non-steroidal anti-inflammatory drug. It is marketed under the trade name Loxonin in Brazil, Mexico and Japan by Sankyo, as Loxomac in India, and as Oxeno in Argentina. A transdermal preparation was approved for use in Japan in January 2006.
|
Halcinonide is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and is distributed as a cream and ointment. Halcinonide is marketed under the brand name Halog® by Ranbaxy Laboratories Inc. Research suggests that clobetasol propionate demonstrates superior pharmacologic efficacy in the treatment of psoriasis when compared to halcinonide.
|
The risk or severity of adverse effects can be increased when Loxoprofen is combined with Halcinonide.
| 48 |
[
[
[
810,
71,
122
]
],
[
[
810,
49,
879
],
[
879,
225,
122
]
],
[
[
810,
225,
11
],
[
11,
71,
122
]
],
[
[
810,
71,
796
],
[
796,
71,
122
]
],
[
[
810,
182,
687
],
[
687,
71,
122
]
],
[
[
810,
233,
768
],
[
768,
71,
122
]
],
[
[
810,
71,
124
],
[
124,
249,
122
]
],
[
[
810,
92,
183
],
[
183,
259,
122
]
],
[
[
810,
51,
893
],
[
893,
259,
122
]
],
[
[
810,
49,
879
],
[
879,
89,
94
],
[
94,
25,
122
]
]
] |
[
[
[
"Loxoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Loxoprofen",
"{u} may increase the neuroexcitatory activities of {v}",
"Nalidixic acid"
],
[
"Nalidixic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Loxoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carprofen"
],
[
"Carprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Loxoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Alclofenac"
],
[
"Alclofenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Loxoprofen",
"{u} may increase the anticoagulant activities of {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Loxoprofen",
"{u} may increase the nephrotoxic activities of {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halcinonide"
]
],
[
[
"Loxoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Estrone"
],
[
"Estrone",
"{u} may increase the serum concentration of {v}",
"Halcinonide"
]
],
[
[
"Loxoprofen",
"{u} may decrease the therapeutic efficacy of {v}",
"Indapamide"
],
[
"Indapamide",
"{u} may increase the hypokalemic activities of {v}",
"Halcinonide"
]
],
[
[
"Loxoprofen",
"{u} may decrease the diuretic activities of {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may increase the hypokalemic activities of {v}",
"Halcinonide"
]
],
[
[
"Loxoprofen",
"{u} may increase the neuroexcitatory activities of {v}",
"Nalidixic acid"
],
[
"Nalidixic acid",
"{u} may decrease the absorption and serum concentration of {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} can decrease the bioavailability of {v}",
"Halcinonide"
]
]
] |
Loxoprofen may increase the neuroexcitatory activities of Nalidixic acid and Nalidixic acid may increase the severity of adverse effects when combined with Halcinonide
Loxoprofen may increase the severity of adverse effects when combined with Carprofen and Carprofen may increase the severity of adverse effects when combined with Halcinonide
Loxoprofen may increase the severity of adverse effects when combined with Alclofenac and Alclofenac may increase the severity of adverse effects when combined with Halcinonide
Loxoprofen may increase the anticoagulant activities of Nafamostat and Nafamostat may increase the severity of adverse effects when combined with Halcinonide
Loxoprofen may increase the nephrotoxic activities of Olsalazine and Olsalazine may increase the severity of adverse effects when combined with Halcinonide
Loxoprofen may increase the severity of adverse effects when combined with Estrone and Estrone may increase the serum concentration of Halcinonide
Loxoprofen may decrease the therapeutic efficacy of Indapamide and Indapamide may increase the hypokalemic activities of Halcinonide
Loxoprofen may decrease the diuretic activities of Etacrynic acid and Etacrynic acid may increase the hypokalemic activities of Halcinonide
Loxoprofen may increase the neuroexcitatory activities of Nalidixic acid and Nalidixic acid may decrease the absorption and serum concentration of Magnesium oxide and Magnesium oxide can decrease the bioavailability of Halcinonide
|
DB00860
|
DB09048
| 82 | 476 |
Prednisolone
|
Netupitant
|
Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955.
|
Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.
|
The serum concentration of Netupitant can be increased when it is combined with Prednisolone.
| 72 |
[
[
[
82,
95,
476
]
],
[
[
82,
97,
1093
],
[
1093,
223,
476
]
],
[
[
82,
92,
297
],
[
297,
223,
476
]
],
[
[
82,
69,
41
],
[
41,
223,
476
]
],
[
[
82,
95,
1269
],
[
1269,
223,
476
]
],
[
[
82,
225,
1303
],
[
1303,
71,
476
]
],
[
[
82,
92,
481
],
[
481,
95,
476
]
],
[
[
82,
69,
143
],
[
143,
95,
476
]
],
[
[
82,
97,
1092
],
[
1092,
95,
476
]
],
[
[
82,
225,
369
],
[
369,
95,
476
]
]
] |
[
[
[
"Prednisolone",
"{u} may increase the serum concentration of {v}",
"Netupitant"
]
],
[
[
"Prednisolone",
"{u} may decrease the serum concentration of {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may decrease the metabolism of {v}",
"Netupitant"
]
],
[
[
"Prednisolone",
"{u} may decrease the therapeutic efficacy of {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may decrease the metabolism of {v}",
"Netupitant"
]
],
[
[
"Prednisolone",
"{u} may decrease the metabolism of {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may decrease the metabolism of {v}",
"Netupitant"
]
],
[
[
"Prednisolone",
"{u} may increase the serum concentration of {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may decrease the metabolism of {v}",
"Netupitant"
]
],
[
[
"Prednisolone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methylergometrine"
],
[
"Methylergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Netupitant"
]
],
[
[
"Prednisolone",
"{u} may decrease the therapeutic efficacy of {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may increase the serum concentration of {v}",
"Netupitant"
]
],
[
[
"Prednisolone",
"{u} may decrease the metabolism of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may increase the serum concentration of {v}",
"Netupitant"
]
],
[
[
"Prednisolone",
"{u} may decrease the serum concentration of {v}",
"Telaprevir"
],
[
"Telaprevir",
"{u} may increase the serum concentration of {v}",
"Netupitant"
]
],
[
[
"Prednisolone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pergolide"
],
[
"Pergolide",
"{u} may increase the serum concentration of {v}",
"Netupitant"
]
]
] |
Prednisolone may decrease the serum concentration of Isoniazid and Isoniazid may decrease the metabolism of Netupitant
Prednisolone may decrease the therapeutic efficacy of Tolbutamide and Tolbutamide may decrease the metabolism of Netupitant
Prednisolone may decrease the metabolism of Clemastine and Clemastine may decrease the metabolism of Netupitant
Prednisolone may increase the serum concentration of Stiripentol and Stiripentol may decrease the metabolism of Netupitant
Prednisolone may increase the severity of adverse effects when combined with Methylergometrine and Methylergometrine may increase the severity of adverse effects when combined with Netupitant
Prednisolone may decrease the therapeutic efficacy of Sitagliptin and Sitagliptin may increase the serum concentration of Netupitant
Prednisolone may decrease the metabolism of Erythromycin and Erythromycin may increase the serum concentration of Netupitant
Prednisolone may decrease the serum concentration of Telaprevir and Telaprevir may increase the serum concentration of Netupitant
Prednisolone may increase the severity of adverse effects when combined with Pergolide and Pergolide may increase the serum concentration of Netupitant
|
DB01081
|
DB00849
| 942 | 194 |
Diphenoxylate
|
Methylphenobarbital
|
A meperidine congener used as an antidiarrheal, usually in combination with atropine. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity. This medication is classified as a Schedule V under the Controlled Substances Act by the Food and Drug Administration (FDA) and the DEA in the United States when used in preparations. When diphenoxylate is used alone, it is classified as a Schedule II.
|
A barbiturate that is metabolized to phenobarbital. It has been used for similar purposes, especially in epilepsy, but there is no evidence mephobarbital offers any advantage over phenobarbital.
|
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methylphenobarbital.
| 48 |
[
[
[
942,
71,
194
]
],
[
[
942,
225,
465
],
[
465,
38,
194
]
],
[
[
942,
71,
150
],
[
150,
1,
194
]
],
[
[
942,
71,
164
],
[
164,
155,
194
]
],
[
[
942,
71,
821
],
[
821,
225,
194
]
],
[
[
942,
71,
221
],
[
221,
180,
194
]
],
[
[
942,
225,
156
],
[
156,
26,
194
]
],
[
[
942,
155,
403
],
[
403,
180,
194
]
],
[
[
942,
225,
195
],
[
195,
180,
194
]
],
[
[
942,
192,
1266
],
[
1266,
38,
194
]
]
] |
[
[
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methylphenobarbital"
]
],
[
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Meperidine"
],
[
"Meperidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Methylphenobarbital"
]
],
[
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Methylphenobarbital"
]
],
[
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Methylphenobarbital"
]
],
[
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethotoin"
],
[
"Ethotoin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methylphenobarbital"
]
],
[
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nortriptyline"
],
[
"Nortriptyline",
"{u} can increase the metabolism of {v}",
"Methylphenobarbital"
]
],
[
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Methylphenobarbital"
]
],
[
[
"Diphenoxylate",
"{u} (Compound) resembles {v} (Compound)",
"Cinnarizine"
],
[
"Cinnarizine",
"{u} can increase the metabolism of {v}",
"Methylphenobarbital"
]
],
[
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} can increase the metabolism of {v}",
"Methylphenobarbital"
]
],
[
[
"Diphenoxylate",
"{u} may increase the central nervous system depressant activities of {v}",
"Paraldehyde"
],
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Methylphenobarbital"
]
]
] |
Diphenoxylate may increase the severity of adverse effects when combined with Meperidine and Meperidine may increase the central nervous system depressant activities of Methylphenobarbital
Diphenoxylate may increase the severity of adverse effects when combined with Fosphenytoin and Fosphenytoin (Compound) resembles Methylphenobarbital (Compound)
Diphenoxylate may increase the severity of adverse effects when combined with Phenobarbital and Phenobarbital (Compound) resembles Methylphenobarbital (Compound)
Diphenoxylate may increase the severity of adverse effects when combined with Ethotoin and Ethotoin may increase the severity of adverse effects when combined with Methylphenobarbital
Diphenoxylate may increase the severity of adverse effects when combined with Nortriptyline and Nortriptyline can increase the metabolism of Methylphenobarbital
Diphenoxylate may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Methylphenobarbital
Diphenoxylate (Compound) resembles Cinnarizine (Compound) and Cinnarizine can increase the metabolism of Methylphenobarbital
Diphenoxylate may increase the severity of adverse effects when combined with Cyclobenzaprine and Cyclobenzaprine can increase the metabolism of Methylphenobarbital
Diphenoxylate may increase the central nervous system depressant activities of Paraldehyde and Paraldehyde may increase the central nervous system depressant activities of Methylphenobarbital
|
DB00211
|
DB00368
| 713 | 721 |
Midodrine
|
Norepinephrine
|
An ethanolamine derivative that is an adrenergic alpha agonist. It is used as a vasoconstrictor agent in the treatment of hypotension.
|
Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.
|
The risk or severity of adverse effects can be increased when Midodrine is combined with Norepinephrine.
| 48 |
[
[
[
713,
71,
721
]
],
[
[
713,
71,
726
],
[
726,
225,
721
]
],
[
[
713,
247,
694
],
[
694,
1,
721
]
],
[
[
713,
6,
11891
],
[
11891,
160,
721
]
],
[
[
713,
21,
28725
],
[
28725,
175,
721
]
],
[
[
713,
181,
678
],
[
678,
27,
721
]
],
[
[
713,
230,
1031
],
[
1031,
201,
721
]
],
[
[
713,
260,
221
],
[
221,
213,
721
]
],
[
[
713,
225,
712
],
[
712,
71,
721
]
],
[
[
713,
92,
1165
],
[
1165,
246,
721
]
]
] |
[
[
[
"Midodrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Norepinephrine"
]
],
[
[
"Midodrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Norepinephrine"
]
],
[
[
"Midodrine",
"{u} may increase the hypertensive activities of {v}",
"Droxidopa"
],
[
"Droxidopa",
"{u} (Compound) resembles {v} (Compound)",
"Norepinephrine"
]
],
[
[
"Midodrine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is bound by {v} (Compound)",
"Norepinephrine"
]
],
[
[
"Midodrine",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspnoea"
],
[
"Dyspnoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Norepinephrine"
]
],
[
[
"Midodrine",
"{u} may decrease the vasoconstricting activities of {v}",
"Doxazosin"
],
[
"Doxazosin",
"{u} may decrease the vasoconstricting activities of {v}",
"Norepinephrine"
]
],
[
[
"Midodrine",
"{u} may increase the bradycardic activities of {v}",
"Bevantolol"
],
[
"Bevantolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Norepinephrine"
]
],
[
[
"Midodrine",
"{u} may increase the vasopressor activities of {v}",
"Nortriptyline"
],
[
"Nortriptyline",
"{u} may decrease the antihypertensive activities of {v}",
"Norepinephrine"
]
],
[
[
"Midodrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Norepinephrine"
]
],
[
[
"Midodrine",
"{u} may decrease the therapeutic efficacy of {v}",
"Iobenguane"
],
[
"Iobenguane",
"{u} may decrease the therapeutic efficacy of {v}",
"Norepinephrine"
]
]
] |
Midodrine may increase the severity of adverse effects when combined with Isoprenaline and Isoprenaline may increase the severity of adverse effects when combined with Norepinephrine
Midodrine may increase the hypertensive activities of Droxidopa and Droxidopa (Compound) resembles Norepinephrine (Compound)
Midodrine (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Norepinephrine (Compound)
Midodrine (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Norepinephrine (Compound)
Midodrine may decrease the vasoconstricting activities of Doxazosin and Doxazosin may decrease the vasoconstricting activities of Norepinephrine
Midodrine may increase the bradycardic activities of Bevantolol and Bevantolol may increase the atrioventricular blocking activities of Norepinephrine
Midodrine may increase the vasopressor activities of Nortriptyline and Nortriptyline may decrease the antihypertensive activities of Norepinephrine
Midodrine may increase the severity of adverse effects when combined with Phenylpropanolamine and Phenylpropanolamine may increase the severity of adverse effects when combined with Norepinephrine
Midodrine may decrease the therapeutic efficacy of Iobenguane and Iobenguane may decrease the therapeutic efficacy of Norepinephrine
|
DB01365
|
DB00850
| 707 | 525 |
Mephentermine
|
Perphenazine
|
A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1248)
|
An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine.
|
Mephentermine may decrease the stimulatory activities of Perphenazine.
| 60 |
[
[
[
707,
83,
525
]
],
[
[
707,
83,
971
],
[
971,
225,
525
]
],
[
[
707,
83,
1378
],
[
1378,
155,
525
]
],
[
[
707,
98,
69
],
[
69,
1,
525
]
],
[
[
707,
83,
270
],
[
270,
71,
525
]
],
[
[
707,
83,
1379
],
[
1379,
1,
525
]
],
[
[
707,
83,
653
],
[
653,
95,
525
]
],
[
[
707,
98,
1448
],
[
1448,
155,
525
]
],
[
[
707,
97,
164
],
[
164,
26,
525
]
],
[
[
707,
260,
543
],
[
543,
38,
525
]
]
] |
[
[
[
"Mephentermine",
"{u} may decrease the stimulatory activities of {v}",
"Perphenazine"
]
],
[
[
"Mephentermine",
"{u} may decrease the stimulatory activities of {v}",
"Zuclopenthixol"
],
[
"Zuclopenthixol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perphenazine"
]
],
[
[
"Mephentermine",
"{u} may decrease the stimulatory activities of {v}",
"Acetophenazine"
],
[
"Acetophenazine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Mephentermine",
"{u} may decrease the sedative activities of {v}",
"Profenamine"
],
[
"Profenamine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Mephentermine",
"{u} may decrease the stimulatory activities of {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perphenazine"
]
],
[
[
"Mephentermine",
"{u} may decrease the stimulatory activities of {v}",
"Periciazine"
],
[
"Periciazine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Mephentermine",
"{u} may decrease the stimulatory activities of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Perphenazine"
]
],
[
[
"Mephentermine",
"{u} may decrease the sedative activities of {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
]
],
[
[
"Mephentermine",
"{u} may decrease the serum concentration of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Perphenazine"
]
],
[
[
"Mephentermine",
"{u} may increase the vasopressor activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perphenazine"
]
]
] |
Mephentermine may decrease the stimulatory activities of Zuclopenthixol and Zuclopenthixol may increase the severity of adverse effects when combined with Perphenazine
Mephentermine may decrease the stimulatory activities of Acetophenazine and Acetophenazine (Compound) resembles Perphenazine (Compound)
Mephentermine may decrease the sedative activities of Profenamine and Profenamine (Compound) resembles Perphenazine (Compound)
Mephentermine may decrease the stimulatory activities of Prochlorperazine and Prochlorperazine may increase the severity of adverse effects when combined with Perphenazine
Mephentermine may decrease the stimulatory activities of Periciazine and Periciazine (Compound) resembles Perphenazine (Compound)
Mephentermine may decrease the stimulatory activities of Thioridazine and Thioridazine may increase the serum concentration of Perphenazine
Mephentermine may decrease the sedative activities of Alimemazine and Alimemazine (Compound) resembles Perphenazine (Compound)
Mephentermine may decrease the serum concentration of Phenobarbital and Phenobarbital can increase the metabolism of Perphenazine
Mephentermine may increase the vasopressor activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Perphenazine
|
DB00176
|
DB09085
| 861 | 952 |
Fluvoxamine
|
Tetracaine
|
Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
|
Tetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.
|
The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tetracaine.
| 48 |
[
[
[
861,
71,
952
]
],
[
[
861,
184,
674
],
[
674,
30,
952
]
],
[
[
861,
225,
587
],
[
587,
38,
952
]
],
[
[
861,
38,
1261
],
[
1261,
192,
952
]
],
[
[
861,
71,
543
],
[
543,
38,
952
]
],
[
[
861,
192,
491
],
[
491,
38,
952
]
],
[
[
861,
54,
1046
],
[
1046,
208,
952
]
],
[
[
861,
223,
161
],
[
161,
225,
952
]
],
[
[
861,
223,
354
],
[
354,
71,
952
]
],
[
[
861,
86,
254
],
[
254,
71,
952
]
]
] |
[
[
[
"Fluvoxamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tetracaine"
]
],
[
[
"Fluvoxamine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Tetracaine"
]
],
[
[
"Fluvoxamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Tetracaine"
]
],
[
[
"Fluvoxamine",
"{u} may increase the central nervous system depressant activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Tetracaine"
]
],
[
[
"Fluvoxamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Tetracaine"
]
],
[
[
"Fluvoxamine",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Tetracaine"
]
],
[
[
"Fluvoxamine",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Tetracaine"
]
],
[
[
"Fluvoxamine",
"{u} may decrease the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tetracaine"
]
],
[
[
"Fluvoxamine",
"{u} may decrease the metabolism of {v}",
"Sevoflurane"
],
[
"Sevoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tetracaine"
]
],
[
[
"Fluvoxamine",
"{u} may increase the serotonergic activities of {v}",
"Buspirone"
],
[
"Buspirone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tetracaine"
]
]
] |
Fluvoxamine can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Tetracaine
Fluvoxamine may increase the severity of adverse effects when combined with Ethanol and Ethanol may increase the central nervous system depressant activities of Tetracaine
Fluvoxamine may increase the central nervous system depressant activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Tetracaine
Fluvoxamine may increase the severity of adverse effects when combined with Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Tetracaine
Fluvoxamine may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Tetracaine
Fluvoxamine may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Tetracaine
Fluvoxamine may decrease the metabolism of Primidone and Primidone may increase the severity of adverse effects when combined with Tetracaine
Fluvoxamine may decrease the metabolism of Sevoflurane and Sevoflurane may increase the severity of adverse effects when combined with Tetracaine
Fluvoxamine may increase the serotonergic activities of Buspirone and Buspirone may increase the severity of adverse effects when combined with Tetracaine
|
DB01203
|
DB08881
| 1,038 | 495 |
Nadolol
|
Vemurafenib
|
Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects. Nadolol was granted FDA approval on 10 December 1979.
|
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
|
The serum concentration of Vemurafenib can be increased when it is combined with Nadolol.
| 72 |
[
[
[
1038,
95,
495
]
],
[
[
1038,
18,
8154
],
[
8154,
172,
495
]
],
[
[
1038,
21,
28917
],
[
28917,
175,
495
]
],
[
[
1038,
236,
171
],
[
171,
26,
495
]
],
[
[
1038,
155,
689
],
[
689,
196,
495
]
],
[
[
1038,
76,
1030
],
[
1030,
196,
495
]
],
[
[
1038,
230,
1293
],
[
1293,
196,
495
]
],
[
[
1038,
155,
705
],
[
705,
209,
495
]
],
[
[
1038,
236,
42
],
[
42,
209,
495
]
],
[
[
1038,
225,
1027
],
[
1027,
209,
495
]
]
] |
[
[
[
"Nadolol",
"{u} may increase the serum concentration of {v}",
"Vemurafenib"
]
],
[
[
"Nadolol",
"{u} (Compound) downregulates {v} (Gene)",
"CSRP1"
],
[
"CSRP1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Nadolol",
"{u} (Compound) causes {v} (Side Effect)",
"Dry skin"
],
[
"Dry skin",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Nadolol",
"{u} may increase the hypotensive activities of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Vemurafenib"
]
],
[
[
"Nadolol",
"{u} (Compound) resembles {v} (Compound)",
"Treprostinil"
],
[
"Treprostinil",
"{u} may increase the QTc prolonging activities of {v}",
"Vemurafenib"
]
],
[
[
"Nadolol",
"{u} may increase the bradycardic activities of {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may increase the QTc prolonging activities of {v}",
"Vemurafenib"
]
],
[
[
"Nadolol",
"{u} may increase the bradycardic activities of {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may increase the QTc prolonging activities of {v}",
"Vemurafenib"
]
],
[
[
"Nadolol",
"{u} (Compound) resembles {v} (Compound)",
"Salbutamol"
],
[
"Salbutamol",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Vemurafenib"
]
],
[
[
"Nadolol",
"{u} may increase the hypotensive activities of {v}",
"Isocarboxazid"
],
[
"Isocarboxazid",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Vemurafenib"
]
],
[
[
"Nadolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Vemurafenib"
]
]
] |
Nadolol (Compound) downregulates CSRP1 (Gene) and CSRP1 (Gene) is downregulated by Vemurafenib (Compound)
Nadolol (Compound) causes Dry skin (Side Effect) and Dry skin (Side Effect) is caused by Vemurafenib (Compound)
Nadolol may increase the hypotensive activities of Pentobarbital and Pentobarbital can increase the metabolism of Vemurafenib
Nadolol (Compound) resembles Treprostinil (Compound) and Treprostinil may increase the QTc prolonging activities of Vemurafenib
Nadolol may increase the bradycardic activities of Pasireotide and Pasireotide may increase the QTc prolonging activities of Vemurafenib
Nadolol may increase the bradycardic activities of Metoclopramide and Metoclopramide may increase the QTc prolonging activities of Vemurafenib
Nadolol (Compound) resembles Salbutamol (Compound) and Salbutamol may increase the severity of QTc prolonging effects when combined with Vemurafenib
Nadolol may increase the hypotensive activities of Isocarboxazid and Isocarboxazid may increase the severity of QTc prolonging effects when combined with Vemurafenib
Nadolol may increase the severity of adverse effects when combined with Sotalol and Sotalol may increase the severity of QTc prolonging effects when combined with Vemurafenib
|
DB01337
|
DB00340
| 73 | 64 |
Pancuronium
|
Metixene
|
A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than curare but has less effect on the circulatory system and on histamine release.
|
Metixene (or methixene) is a anticholinergic used as an antiparkinsonian agent.
|
The risk or severity of adverse effects can be increased when Pancuronium is combined with Metixene.
| 48 |
[
[
[
73,
71,
64
]
],
[
[
73,
6,
5535
],
[
5535,
160,
64
]
],
[
[
73,
178,
26
],
[
26,
24,
64
]
],
[
[
73,
71,
40
],
[
40,
71,
64
]
],
[
[
73,
71,
942
],
[
942,
225,
64
]
],
[
[
73,
225,
19
],
[
19,
71,
64
]
],
[
[
73,
81,
1531
],
[
1531,
235,
64
]
],
[
[
73,
246,
686
],
[
686,
92,
64
]
],
[
[
73,
249,
1041
],
[
1041,
95,
64
]
],
[
[
73,
107,
1261
],
[
1261,
261,
64
]
]
] |
[
[
[
"Pancuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metixene"
]
],
[
[
"Pancuronium",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compound)",
"Metixene"
]
],
[
[
"Pancuronium",
"{u} may increase the anticholinergic activities of {v}",
"Tiotropium"
],
[
"Tiotropium",
"{u} may increase the anticholinergic activities of {v}",
"Metixene"
]
],
[
[
"Pancuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Vecuronium"
],
[
"Vecuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metixene"
]
],
[
[
"Pancuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diphenoxylate"
],
[
"Diphenoxylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metixene"
]
],
[
[
"Pancuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Anisotropine methylbromide"
],
[
"Anisotropine methylbromide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metixene"
]
],
[
[
"Pancuronium",
"{u} may increase the ulcerogenic activities of {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may increase the ulcerogenic activities of {v}",
"Metixene"
]
],
[
[
"Pancuronium",
"{u} may decrease the therapeutic efficacy of {v}",
"Isoflurophate"
],
[
"Isoflurophate",
"{u} may decrease the therapeutic efficacy of {v}",
"Metixene"
]
],
[
[
"Pancuronium",
"{u} may increase the serum concentration of {v}",
"Chlorthalidone"
],
[
"Chlorthalidone",
"{u} may increase the serum concentration of {v}",
"Metixene"
]
],
[
[
"Pancuronium",
"{u} may increase the tachycardic activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the tachycardic activities of {v}",
"Metixene"
]
]
] |
Pancuronium (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Metixene (Compound)
Pancuronium may increase the anticholinergic activities of Tiotropium and Tiotropium may increase the anticholinergic activities of Metixene
Pancuronium may increase the severity of adverse effects when combined with Vecuronium and Vecuronium may increase the severity of adverse effects when combined with Metixene
Pancuronium may increase the severity of adverse effects when combined with Diphenoxylate and Diphenoxylate may increase the severity of adverse effects when combined with Metixene
Pancuronium may increase the severity of adverse effects when combined with Anisotropine methylbromide and Anisotropine methylbromide may increase the severity of adverse effects when combined with Metixene
Pancuronium may increase the ulcerogenic activities of Potassium chloride and Potassium chloride may increase the ulcerogenic activities of Metixene
Pancuronium may decrease the therapeutic efficacy of Isoflurophate and Isoflurophate may decrease the therapeutic efficacy of Metixene
Pancuronium may increase the serum concentration of Chlorthalidone and Chlorthalidone may increase the serum concentration of Metixene
Pancuronium may increase the tachycardic activities of Dronabinol and Dronabinol may increase the tachycardic activities of Metixene
|
DB01198
|
DB01685
| 542 | 1,417 |
Zopiclone
|
Topiroxostat
|
Zopiclone is a novel hypnotic agent used in the treatment of insomnia. Its mechanism of action is based on modulating benzodiazepine receptors. In addition to zopiclone's benzodiazepine pharmacological properties it also has some barbiturate-like properties.
|
Topiroxostat is a selective xanthine oxidase inhibitor developed for treatment and management of hyperuricemia and gout. Xanthine oxidase, or xanthine oxidoreductase (XOR), regulates purine metabolism, and inhibition of the enzyme results in efficacious reduction of serum urate levels. Xanthine oxidase inhibitors are classified into two groups; purine analogs such as and, and non-purine agents which includes topiroxostat. While is considered a first-line therapy in treating hyperuricemic conditions, it is often associated with side effects and ineffective in reducing uric acid levels under recommended dosing regimens. Renal complications are major comorbidities that limit the therapy as dose reductions are recommended. Topiroxostat and its metabolites are shown to be unaffected by renal complications, thus may be effective in patients with chronic kidney diseases. Approved for therapeutic use in Japan since 2013, topiroxostat is
|
The metabolism of Topiroxostat can be decreased when combined with Zopiclone.
| 46 |
[
[
[
542,
69,
1417
]
],
[
[
542,
69,
451
],
[
451,
69,
1417
]
],
[
[
542,
71,
401
],
[
401,
69,
1417
]
],
[
[
542,
192,
543
],
[
543,
69,
1417
]
],
[
[
542,
95,
615
],
[
615,
69,
1417
]
],
[
[
542,
180,
150
],
[
150,
69,
1417
]
],
[
[
542,
251,
1110
],
[
1110,
69,
1417
]
],
[
[
542,
225,
314
],
[
314,
69,
1417
]
],
[
[
542,
95,
530
],
[
530,
71,
1417
]
],
[
[
542,
38,
1261
],
[
1261,
95,
1417
]
]
] |
[
[
[
"Zopiclone",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
]
],
[
[
"Zopiclone",
"{u} may decrease the metabolism of {v}",
"Omeprazole"
],
[
"Omeprazole",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
]
],
[
[
"Zopiclone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Loratadine"
],
[
"Loratadine",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
]
],
[
[
"Zopiclone",
"{u} may increase the central nervous system depressant activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
]
],
[
[
"Zopiclone",
"{u} may increase the serum concentration of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
]
],
[
[
"Zopiclone",
"{u} can increase the metabolism of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
]
],
[
[
"Zopiclone",
"{u} may decrease the serum concentration of {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
]
],
[
[
"Zopiclone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dapsone"
],
[
"Dapsone",
"{u} may decrease the metabolism of {v}",
"Topiroxostat"
]
],
[
[
"Zopiclone",
"{u} may increase the serum concentration of {v}",
"Dihydroergotamine"
],
[
"Dihydroergotamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Topiroxostat"
]
],
[
[
"Zopiclone",
"{u} may increase the central nervous system depressant activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the serum concentration of {v}",
"Topiroxostat"
]
]
] |
Zopiclone may decrease the metabolism of Omeprazole and Omeprazole may decrease the metabolism of Topiroxostat
Zopiclone may increase the severity of adverse effects when combined with Loratadine and Loratadine may decrease the metabolism of Topiroxostat
Zopiclone may increase the central nervous system depressant activities of Mirtazapine and Mirtazapine may decrease the metabolism of Topiroxostat
Zopiclone may increase the serum concentration of Sildenafil and Sildenafil may decrease the metabolism of Topiroxostat
Zopiclone can increase the metabolism of Fosphenytoin and Fosphenytoin may decrease the metabolism of Topiroxostat
Zopiclone may decrease the serum concentration of Enzalutamide and Enzalutamide may decrease the metabolism of Topiroxostat
Zopiclone may increase the severity of adverse effects when combined with Dapsone and Dapsone may decrease the metabolism of Topiroxostat
Zopiclone may increase the serum concentration of Dihydroergotamine and Dihydroergotamine may increase the severity of adverse effects when combined with Topiroxostat
Zopiclone may increase the central nervous system depressant activities of Dronabinol and Dronabinol may increase the serum concentration of Topiroxostat
|
DB00653
|
DB01377
| 405 | 94 |
Magnesium sulfate
|
Magnesium oxide
|
A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)
|
Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses.
|
The risk or severity of adverse effects can be increased when Magnesium sulfate is combined with Magnesium oxide.
| 48 |
[
[
[
405,
71,
94
]
],
[
[
405,
192,
84
],
[
84,
179,
94
]
],
[
[
405,
192,
652
],
[
652,
38,
94
]
],
[
[
405,
197,
54
],
[
54,
43,
94
]
],
[
[
405,
225,
449
],
[
449,
71,
94
]
],
[
[
405,
192,
434
],
[
434,
71,
94
]
],
[
[
405,
97,
877
],
[
877,
89,
94
]
],
[
[
405,
192,
270
],
[
270,
89,
94
]
],
[
[
405,
243,
1017
],
[
1017,
89,
94
]
],
[
[
405,
251,
1561
],
[
1561,
89,
94
]
]
] |
[
[
[
"Magnesium sulfate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium oxide"
]
],
[
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Fluticasone propionate"
],
[
"Fluticasone propionate",
"{u} can decrease the bioavailability of {v}",
"Magnesium oxide"
]
],
[
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Gabapentin"
],
[
"Gabapentin",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium oxide"
]
],
[
[
"Magnesium sulfate",
"{u} may increase the neuromuscular blocking activities of {v}",
"Tubocurarine"
],
[
"Tubocurarine",
"{u} may increase the neuromuscular blocking activities of {v}",
"Magnesium oxide"
]
],
[
[
"Magnesium sulfate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolfenamic acid"
],
[
"Tolfenamic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium oxide"
]
],
[
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Flunarizine"
],
[
"Flunarizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium oxide"
]
],
[
[
"Magnesium sulfate",
"{u} may decrease the serum concentration of {v}",
"Fleroxacin"
],
[
"Fleroxacin",
"{u} may decrease the absorption and serum concentration of {v}",
"Magnesium oxide"
]
],
[
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may decrease the absorption and serum concentration of {v}",
"Magnesium oxide"
]
],
[
[
"Magnesium sulfate",
"{u} may decrease the absorption and serum concentration of {v}",
"Lipoic acid"
],
[
"Lipoic acid",
"{u} may decrease the absorption and serum concentration of {v}",
"Magnesium oxide"
]
],
[
[
"Magnesium sulfate",
"{u} may decrease the serum concentration of {v}",
"Triethylenetetramine"
],
[
"Triethylenetetramine",
"{u} may decrease the absorption and serum concentration of {v}",
"Magnesium oxide"
]
]
] |
Magnesium sulfate may increase the central nervous system depressant activities of Fluticasone propionate and Fluticasone propionate can decrease the bioavailability of Magnesium oxide
Magnesium sulfate may increase the central nervous system depressant activities of Gabapentin and Gabapentin may increase the central nervous system depressant activities of Magnesium oxide
Magnesium sulfate may increase the neuromuscular blocking activities of Tubocurarine and Tubocurarine may increase the neuromuscular blocking activities of Magnesium oxide
Magnesium sulfate may increase the severity of adverse effects when combined with Tolfenamic acid and Tolfenamic acid may increase the severity of adverse effects when combined with Magnesium oxide
Magnesium sulfate may increase the central nervous system depressant activities of Flunarizine and Flunarizine may increase the severity of adverse effects when combined with Magnesium oxide
Magnesium sulfate may decrease the serum concentration of Fleroxacin and Fleroxacin may decrease the absorption and serum concentration of Magnesium oxide
Magnesium sulfate may increase the central nervous system depressant activities of Prochlorperazine and Prochlorperazine may decrease the absorption and serum concentration of Magnesium oxide
Magnesium sulfate may decrease the absorption and serum concentration of Lipoic acid and Lipoic acid may decrease the absorption and serum concentration of Magnesium oxide
Magnesium sulfate may decrease the serum concentration of Triethylenetetramine and Triethylenetetramine may decrease the absorption and serum concentration of Magnesium oxide
|
DB00483
|
DB01177
| 60 | 207 |
Gallamine triethiodide
|
Idarubicin
|
A synthetic nondepolarizing blocking drug. The actions of gallamine triethiodide are similar to those of tubocurarine, but this agent blocks the cardiac vagus and may cause sinus tachycardia and, occasionally, hypertension and increased cardiac output. It should be used cautiously in patients at risk from increased heart rate but may be preferred for patients with bradycardia. (From AMA Drug Evaluations Annual, 1992, p198)
|
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
|
Gallamine triethiodide may increase the respiratory depressant activities of Idarubicin.
| 39 |
[
[
[
60,
62,
207
]
],
[
[
60,
62,
892
],
[
892,
1,
207
]
],
[
[
60,
21,
28549
],
[
28549,
175,
207
]
],
[
[
60,
71,
45
],
[
45,
43,
207
]
],
[
[
60,
249,
939
],
[
939,
62,
207
]
],
[
[
60,
71,
40
],
[
40,
62,
207
]
],
[
[
60,
71,
237
],
[
237,
223,
207
]
],
[
[
60,
76,
1037
],
[
1037,
223,
207
]
],
[
[
60,
43,
640
],
[
640,
223,
207
]
],
[
[
60,
193,
557
],
[
557,
71,
207
]
]
] |
[
[
[
"Gallamine triethiodide",
"{u} may increase the respiratory depressant activities of {v}",
"Idarubicin"
]
],
[
[
"Gallamine triethiodide",
"{u} may increase the respiratory depressant activities of {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} (Compound) resembles {v} (Compound)",
"Idarubicin"
]
],
[
[
"Gallamine triethiodide",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Gallamine triethiodide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mecamylamine"
],
[
"Mecamylamine",
"{u} may increase the neuromuscular blocking activities of {v}",
"Idarubicin"
]
],
[
[
"Gallamine triethiodide",
"{u} may increase the serum concentration of {v}",
"Succinylcholine"
],
[
"Succinylcholine",
"{u} may increase the respiratory depressant activities of {v}",
"Idarubicin"
]
],
[
[
"Gallamine triethiodide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Vecuronium"
],
[
"Vecuronium",
"{u} may increase the respiratory depressant activities of {v}",
"Idarubicin"
]
],
[
[
"Gallamine triethiodide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may decrease the metabolism of {v}",
"Idarubicin"
]
],
[
[
"Gallamine triethiodide",
"{u} may increase the bradycardic activities of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may decrease the metabolism of {v}",
"Idarubicin"
]
],
[
[
"Gallamine triethiodide",
"{u} may increase the neuromuscular blocking activities of {v}",
"Quinine"
],
[
"Quinine",
"{u} may decrease the metabolism of {v}",
"Idarubicin"
]
],
[
[
"Gallamine triethiodide",
"{u} may decrease the neuromuscular blocking activities of {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Idarubicin"
]
]
] |
Gallamine triethiodide may increase the respiratory depressant activities of Epirubicin and Epirubicin (Compound) resembles Idarubicin (Compound)
Gallamine triethiodide (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Idarubicin (Compound)
Gallamine triethiodide may increase the severity of adverse effects when combined with Mecamylamine and Mecamylamine may increase the neuromuscular blocking activities of Idarubicin
Gallamine triethiodide may increase the serum concentration of Succinylcholine and Succinylcholine may increase the respiratory depressant activities of Idarubicin
Gallamine triethiodide may increase the severity of adverse effects when combined with Vecuronium and Vecuronium may increase the respiratory depressant activities of Idarubicin
Gallamine triethiodide may increase the severity of adverse effects when combined with Mirabegron and Mirabegron may decrease the metabolism of Idarubicin
Gallamine triethiodide may increase the bradycardic activities of Betaxolol and Betaxolol may decrease the metabolism of Idarubicin
Gallamine triethiodide may increase the neuromuscular blocking activities of Quinine and Quinine may decrease the metabolism of Idarubicin
Gallamine triethiodide may decrease the neuromuscular blocking activities of Torasemide and Torasemide may increase the severity of adverse effects when combined with Idarubicin
|
DB00181
|
DB08910
| 991 | 208 |
Baclofen
|
Pomalidomide
|
Baclofen is a gamma-aminobutyric acid (GABA) agonist used as a skeletal muscle relaxant. Although originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.[A245323, A245338] Baclofen is used to manage severe muscle spasms of cerebral or spinal cord origins, including multiple sclerosis and traumatic brain injury. Baclofen was investigated for use in alcohol dependence and withdrawal; however, evidence is limited and there is inconsistent evidence to suggest its clinical efficacy in managing alcohol dependence or withdrawal symptoms.[A173905, A173908, A245338]
|
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
|
The risk or severity of adverse effects can be increased when Baclofen is combined with Pomalidomide.
| 48 |
[
[
[
991,
71,
208
]
],
[
[
991,
21,
28509
],
[
28509,
175,
208
]
],
[
[
991,
225,
171
],
[
171,
26,
208
]
],
[
[
991,
71,
142
],
[
142,
26,
208
]
],
[
[
991,
184,
674
],
[
674,
30,
208
]
],
[
[
991,
192,
1266
],
[
1266,
38,
208
]
],
[
[
991,
38,
1257
],
[
1257,
192,
208
]
],
[
[
991,
54,
1046
],
[
1046,
208,
208
]
],
[
[
991,
225,
611
],
[
611,
223,
208
]
],
[
[
991,
225,
480
],
[
480,
71,
208
]
]
] |
[
[
[
"Baclofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pomalidomide"
]
],
[
[
"Baclofen",
"{u} (Compound) causes {v} (Side Effect)",
"Mediastinal disorder"
],
[
"Mediastinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pomalidomide"
]
],
[
[
"Baclofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Pomalidomide"
]
],
[
[
"Baclofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Pomalidomide"
]
],
[
[
"Baclofen",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Pomalidomide"
]
],
[
[
"Baclofen",
"{u} may increase the central nervous system depressant activities of {v}",
"Paraldehyde"
],
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Pomalidomide"
]
],
[
[
"Baclofen",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Pomalidomide"
]
],
[
[
"Baclofen",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Pomalidomide"
]
],
[
[
"Baclofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may decrease the metabolism of {v}",
"Pomalidomide"
]
],
[
[
"Baclofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etizolam"
],
[
"Etizolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pomalidomide"
]
]
] |
Baclofen (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Pomalidomide (Compound)
Baclofen may increase the severity of adverse effects when combined with Pentobarbital and Pentobarbital can increase the metabolism of Pomalidomide
Baclofen may increase the severity of adverse effects when combined with Phenytoin and Phenytoin can increase the metabolism of Pomalidomide
Baclofen can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Pomalidomide
Baclofen may increase the central nervous system depressant activities of Paraldehyde and Paraldehyde may increase the central nervous system depressant activities of Pomalidomide
Baclofen may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the central nervous system depressant activities of Pomalidomide
Baclofen may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Pomalidomide
Baclofen may increase the severity of adverse effects when combined with Lidocaine and Lidocaine may decrease the metabolism of Pomalidomide
Baclofen may increase the severity of adverse effects when combined with Etizolam and Etizolam may increase the severity of adverse effects when combined with Pomalidomide
|
DB01267
|
DB00455
| 1,007 | 401 |
Paliperidone
|
Loratadine
|
Paliperidone is the primary active metabolite of risperidone. The mechanism of action is unknown but it is likely to act via a similar pathway to risperidone. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. It is available as an extended-release tablet, a once-monthly intramuscular injection, an every-three-month intramuscular injection, and a twice-yearly gluteal injection.[L16168,L37744,L4137,L37749]
|
Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.
|
The risk or severity of adverse effects can be increased when Paliperidone is combined with Loratadine.
| 48 |
[
[
[
1007,
71,
401
]
],
[
[
1007,
6,
10964
],
[
10964,
160,
401
]
],
[
[
1007,
21,
28614
],
[
28614,
175,
401
]
],
[
[
1007,
71,
150
],
[
150,
26,
401
]
],
[
[
1007,
225,
171
],
[
171,
26,
401
]
],
[
[
1007,
38,
1262
],
[
1262,
192,
401
]
],
[
[
1007,
192,
679
],
[
679,
38,
401
]
],
[
[
1007,
59,
543
],
[
543,
38,
401
]
],
[
[
1007,
54,
1365
],
[
1365,
208,
401
]
],
[
[
1007,
209,
640
],
[
640,
223,
401
]
]
] |
[
[
[
"Paliperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Loratadine"
]
],
[
[
"Paliperidone",
"{u} (Compound) binds {v} (Gene)",
"HRH1"
],
[
"HRH1",
"{u} (Gene) is bound by {v} (Compound)",
"Loratadine"
]
],
[
[
"Paliperidone",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Loratadine"
]
],
[
[
"Paliperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Loratadine"
]
],
[
[
"Paliperidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Loratadine"
]
],
[
[
"Paliperidone",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Loratadine"
]
],
[
[
"Paliperidone",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Loratadine"
]
],
[
[
"Paliperidone",
"{u} may decrease the antihypertensive activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Loratadine"
]
],
[
[
"Paliperidone",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Loratadine"
]
],
[
[
"Paliperidone",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Quinine"
],
[
"Quinine",
"{u} may decrease the metabolism of {v}",
"Loratadine"
]
]
] |
Paliperidone (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Loratadine (Compound)
Paliperidone (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Loratadine (Compound)
Paliperidone may increase the severity of adverse effects when combined with Fosphenytoin and Fosphenytoin can increase the metabolism of Loratadine
Paliperidone may increase the severity of adverse effects when combined with Pentobarbital and Pentobarbital can increase the metabolism of Loratadine
Paliperidone may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Loratadine
Paliperidone may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Loratadine
Paliperidone may decrease the antihypertensive activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Loratadine
Paliperidone may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Loratadine
Paliperidone may increase the severity of QTc prolonging effects when combined with Quinine and Quinine may decrease the metabolism of Loratadine
|
DB00476
|
DB00150
| 828 | 1,373 |
Duloxetine
|
Tryptophan
|
Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence. Duloxetine continues to be investigated for the treatment of pain in cancer, surgery, and more.
|
An essential amino acid that is necessary for normal growth in infants and for nitrogen balance in adults. It is a precursor of indole alkaloids in plants. It is a precursor of serotonin (hence its use as an antidepressant and sleep aid). It can be a precursor to niacin, albeit inefficiently, in mammals.
|
Duloxetine may increase the serotonergic activities of Tryptophan.
| 63 |
[
[
[
828,
86,
1373
]
],
[
[
828,
206,
968
],
[
968,
155,
1373
]
],
[
[
828,
95,
495
],
[
495,
55,
1373
]
],
[
[
828,
223,
31
],
[
31,
225,
1373
]
],
[
[
828,
71,
23
],
[
23,
225,
1373
]
],
[
[
828,
240,
221
],
[
221,
86,
1373
]
],
[
[
828,
86,
71
],
[
71,
86,
1373
]
],
[
[
828,
206,
39
],
[
39,
86,
1373
]
],
[
[
828,
71,
1308
],
[
1308,
86,
1373
]
],
[
[
828,
223,
163
],
[
163,
86,
1373
]
]
] |
[
[
[
"Duloxetine",
"{u} may increase the serotonergic activities of {v}",
"Tryptophan"
]
],
[
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} (Compound) resembles {v} (Compound)",
"Tryptophan"
]
],
[
[
"Duloxetine",
"{u} may increase the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Tryptophan"
]
],
[
[
"Duloxetine",
"{u} may decrease the metabolism of {v}",
"Minaprine"
],
[
"Minaprine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tryptophan"
]
],
[
[
"Duloxetine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tryptophan"
]
],
[
[
"Duloxetine",
"{u} may increase the serotonergic activities of {v}",
"Nortriptyline"
],
[
"Nortriptyline",
"{u} may increase the serotonergic activities of {v}",
"Tryptophan"
]
],
[
[
"Duloxetine",
"{u} may increase the serotonergic activities of {v}",
"Toloxatone"
],
[
"Toloxatone",
"{u} may increase the serotonergic activities of {v}",
"Tryptophan"
]
],
[
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Selegiline"
],
[
"Selegiline",
"{u} may increase the serotonergic activities of {v}",
"Tryptophan"
]
],
[
[
"Duloxetine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sumatriptan"
],
[
"Sumatriptan",
"{u} may increase the serotonergic activities of {v}",
"Tryptophan"
]
],
[
[
"Duloxetine",
"{u} may decrease the metabolism of {v}",
"Oxycodone"
],
[
"Oxycodone",
"{u} may increase the serotonergic activities of {v}",
"Tryptophan"
]
]
] |
Duloxetine may increase the orthostatic hypotensive activities of Levodopa and Levodopa (Compound) resembles Tryptophan (Compound)
Duloxetine may increase the serum concentration of Vemurafenib and Vemurafenib may increase the severity of QTc prolonging effects when combined with Tryptophan
Duloxetine may decrease the metabolism of Minaprine and Minaprine may increase the severity of adverse effects when combined with Tryptophan
Duloxetine may increase the severity of adverse effects when combined with Procarbazine and Procarbazine may increase the severity of adverse effects when combined with Tryptophan
Duloxetine may increase the serotonergic activities of Nortriptyline and Nortriptyline may increase the serotonergic activities of Tryptophan
Duloxetine may increase the serotonergic activities of Toloxatone and Toloxatone may increase the serotonergic activities of Tryptophan
Duloxetine may increase the orthostatic hypotensive activities of Selegiline and Selegiline may increase the serotonergic activities of Tryptophan
Duloxetine may increase the severity of adverse effects when combined with Sumatriptan and Sumatriptan may increase the serotonergic activities of Tryptophan
Duloxetine may decrease the metabolism of Oxycodone and Oxycodone may increase the serotonergic activities of Tryptophan
|
DB01124
|
DB01175
| 297 | 324 |
Tolbutamide
|
Escitalopram
|
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to
|
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from
|
Tolbutamide may increase the hypoglycemic activities of Escitalopram.
| 8 |
[
[
[
297,
31,
324
]
],
[
[
297,
69,
556
],
[
556,
1,
324
]
],
[
[
297,
6,
10999
],
[
10999,
160,
324
]
],
[
[
297,
21,
28848
],
[
28848,
175,
324
]
],
[
[
297,
180,
177
],
[
177,
26,
324
]
],
[
[
297,
251,
147
],
[
147,
26,
324
]
],
[
[
297,
223,
173
],
[
173,
26,
324
]
],
[
[
297,
223,
219
],
[
219,
28,
324
]
],
[
[
297,
182,
169
],
[
169,
28,
324
]
],
[
[
297,
31,
951
],
[
951,
31,
324
]
]
] |
[
[
[
"Tolbutamide",
"{u} may increase the hypoglycemic activities of {v}",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} may decrease the metabolism of {v}",
"Citalopram"
],
[
"Citalopram",
"{u} (Compound) resembles {v} (Compound)",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal distension"
],
[
"Abdominal distension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} may decrease the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} may decrease the metabolism of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} may increase the anticoagulant activities of {v}",
"Phenindione"
],
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Escitalopram"
]
],
[
[
"Tolbutamide",
"{u} may increase the hypoglycemic activities of {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may increase the hypoglycemic activities of {v}",
"Escitalopram"
]
]
] |
Tolbutamide may decrease the metabolism of Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Tolbutamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Escitalopram (Compound)
Tolbutamide (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Escitalopram (Compound)
Tolbutamide can increase the metabolism of Rifapentine and Rifapentine can increase the metabolism of Escitalopram
Tolbutamide may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Escitalopram
Tolbutamide may decrease the metabolism of Nevirapine and Nevirapine can increase the metabolism of Escitalopram
Tolbutamide may decrease the metabolism of Warfarin and Warfarin may increase the anticoagulant activities of Escitalopram
Tolbutamide may increase the anticoagulant activities of Phenindione and Phenindione may increase the anticoagulant activities of Escitalopram
Tolbutamide may increase the hypoglycemic activities of Miglitol and Miglitol may increase the hypoglycemic activities of Escitalopram
|
DB01433
|
DB00703
| 984 | 1,367 |
Methadyl acetate
|
Methazolamide
|
A narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence.
|
A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
|
The risk or severity of adverse effects can be increased when Methadyl acetate is combined with Methazolamide.
| 48 |
[
[
[
984,
71,
1367
]
],
[
[
984,
71,
1481
],
[
1481,
225,
1367
]
],
[
[
984,
240,
828
],
[
828,
206,
1367
]
],
[
[
984,
71,
968
],
[
968,
206,
1367
]
],
[
[
984,
192,
1083
],
[
1083,
71,
1367
]
],
[
[
984,
71,
499
],
[
499,
71,
1367
]
],
[
[
984,
225,
921
],
[
921,
71,
1367
]
],
[
[
984,
1,
355
],
[
355,
71,
1367
]
],
[
[
984,
38,
1265
],
[
1265,
71,
1367
]
],
[
[
984,
54,
471
],
[
471,
71,
1367
]
]
] |
[
[
[
"Methadyl acetate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Methadyl acetate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acetazolamide"
],
[
"Acetazolamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Methadyl acetate",
"{u} may increase the serotonergic activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Methazolamide"
]
],
[
[
"Methadyl acetate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Methazolamide"
]
],
[
[
"Methadyl acetate",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Methadyl acetate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Methadyl acetate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Methadyl acetate",
"{u} (Compound) resembles {v} (Compound)",
"Phenoxybenzamine"
],
[
"Phenoxybenzamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Methadyl acetate",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Methadyl acetate",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
]
] |
Methadyl acetate may increase the severity of adverse effects when combined with Acetazolamide and Acetazolamide may increase the severity of adverse effects when combined with Methazolamide
Methadyl acetate may increase the serotonergic activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Methazolamide
Methadyl acetate may increase the severity of adverse effects when combined with Levodopa and Levodopa may increase the orthostatic hypotensive activities of Methazolamide
Methadyl acetate may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the severity of adverse effects when combined with Methazolamide
Methadyl acetate may increase the severity of adverse effects when combined with Clomipramine and Clomipramine may increase the severity of adverse effects when combined with Methazolamide
Methadyl acetate may increase the severity of adverse effects when combined with Nalbuphine and Nalbuphine may increase the severity of adverse effects when combined with Methazolamide
Methadyl acetate (Compound) resembles Phenoxybenzamine (Compound) and Phenoxybenzamine may increase the severity of adverse effects when combined with Methazolamide
Methadyl acetate may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the severity of adverse effects when combined with Methazolamide
Methadyl acetate may increase the sedative activities of Rotigotine and Rotigotine may increase the severity of adverse effects when combined with Methazolamide
|
DB13167
|
DB00547
| 796 | 110 |
Alclofenac
|
Desoximetasone
|
Alclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.
|
A topical anti-inflammatory glucocorticoid used in dermatoses, skin allergies, psoriasis, etc.
|
The risk or severity of adverse effects can be increased when Alclofenac is combined with Desoximetasone.
| 48 |
[
[
[
796,
71,
110
]
],
[
[
796,
71,
135
],
[
135,
155,
110
]
],
[
[
796,
71,
134
],
[
134,
1,
110
]
],
[
[
796,
225,
388
],
[
388,
71,
110
]
],
[
[
796,
49,
776
],
[
776,
225,
110
]
],
[
[
796,
233,
768
],
[
768,
71,
110
]
],
[
[
796,
71,
1351
],
[
1351,
71,
110
]
],
[
[
796,
182,
687
],
[
687,
71,
110
]
],
[
[
796,
71,
124
],
[
124,
249,
110
]
],
[
[
796,
92,
1059
],
[
1059,
259,
110
]
]
] |
[
[
[
"Alclofenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desoximetasone"
]
],
[
[
"Alclofenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clobetasol propionate"
],
[
"Clobetasol propionate",
"{u} (Compound) resembles {v} (Compound)",
"Desoximetasone"
]
],
[
[
"Alclofenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clocortolone"
],
[
"Clocortolone",
"{u} (Compound) resembles {v} (Compound)",
"Desoximetasone"
]
],
[
[
"Alclofenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desoximetasone"
]
],
[
[
"Alclofenac",
"{u} may increase the neuroexcitatory activities of {v}",
"Rosoxacin"
],
[
"Rosoxacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desoximetasone"
]
],
[
[
"Alclofenac",
"{u} may increase the nephrotoxic activities of {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desoximetasone"
]
],
[
[
"Alclofenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acemetacin"
],
[
"Acemetacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desoximetasone"
]
],
[
[
"Alclofenac",
"{u} may increase the anticoagulant activities of {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the severity of adverse effects when combined with {v}",
"Desoximetasone"
]
],
[
[
"Alclofenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Estrone"
],
[
"Estrone",
"{u} may increase the serum concentration of {v}",
"Desoximetasone"
]
],
[
[
"Alclofenac",
"{u} may decrease the therapeutic efficacy of {v}",
"Metolazone"
],
[
"Metolazone",
"{u} may increase the hypokalemic activities of {v}",
"Desoximetasone"
]
]
] |
Alclofenac may increase the severity of adverse effects when combined with Clobetasol propionate and Clobetasol propionate (Compound) resembles Desoximetasone (Compound)
Alclofenac may increase the severity of adverse effects when combined with Clocortolone and Clocortolone (Compound) resembles Desoximetasone (Compound)
Alclofenac may increase the severity of adverse effects when combined with Flurbiprofen and Flurbiprofen may increase the severity of adverse effects when combined with Desoximetasone
Alclofenac may increase the neuroexcitatory activities of Rosoxacin and Rosoxacin may increase the severity of adverse effects when combined with Desoximetasone
Alclofenac may increase the nephrotoxic activities of Olsalazine and Olsalazine may increase the severity of adverse effects when combined with Desoximetasone
Alclofenac may increase the severity of adverse effects when combined with Acemetacin and Acemetacin may increase the severity of adverse effects when combined with Desoximetasone
Alclofenac may increase the anticoagulant activities of Nafamostat and Nafamostat may increase the severity of adverse effects when combined with Desoximetasone
Alclofenac may increase the severity of adverse effects when combined with Estrone and Estrone may increase the serum concentration of Desoximetasone
Alclofenac may decrease the therapeutic efficacy of Metolazone and Metolazone may increase the hypokalemic activities of Desoximetasone
|
DB00312
|
DB00254
| 171 | 755 |
Pentobarbital
|
Doxycycline
|
A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236)
|
Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.
|
The serum concentration of Doxycycline can be decreased when it is combined with Pentobarbital.
| 74 |
[
[
[
171,
97,
755
]
],
[
[
171,
6,
4590
],
[
4590,
160,
755
]
],
[
[
171,
26,
169
],
[
169,
28,
755
]
],
[
[
171,
99,
680
],
[
680,
187,
755
]
],
[
[
171,
82,
45
],
[
45,
43,
755
]
],
[
[
171,
26,
495
],
[
495,
55,
755
]
],
[
[
171,
33,
539
],
[
539,
209,
755
]
],
[
[
171,
26,
613
],
[
613,
69,
755
]
],
[
[
171,
33,
1077
],
[
1077,
69,
755
]
],
[
[
171,
192,
587
],
[
587,
69,
755
]
]
] |
[
[
[
"Pentobarbital",
"{u} may decrease the serum concentration of {v}",
"Doxycycline"
]
],
[
[
"Pentobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Doxycycline"
]
],
[
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Phenindione"
],
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Doxycycline"
]
],
[
[
"Pentobarbital",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Doxycycline"
]
],
[
[
"Pentobarbital",
"{u} may increase the hypotensive activities of {v}",
"Mecamylamine"
],
[
"Mecamylamine",
"{u} may increase the neuromuscular blocking activities of {v}",
"Doxycycline"
]
],
[
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Doxycycline"
]
],
[
[
"Pentobarbital",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Artemether"
],
[
"Artemether",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Doxycycline"
]
],
[
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Pentobarbital",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Isavuconazonium"
],
[
"Isavuconazonium",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Pentobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
]
] |
Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxycycline (Compound)
Pentobarbital can increase the metabolism of Phenindione and Phenindione may increase the anticoagulant activities of Doxycycline
Pentobarbital may increase the serum concentration of the active metabolites of Ifosfamide and Ifosfamide may reduce the serum concentration of the active metabolites of Doxycycline
Pentobarbital may increase the hypotensive activities of Mecamylamine and Mecamylamine may increase the neuromuscular blocking activities of Doxycycline
Pentobarbital can increase the metabolism of Vemurafenib and Vemurafenib may increase the severity of QTc prolonging effects when combined with Doxycycline
Pentobarbital may reduce the serum concentration of the active metabolites of Artemether and Artemether may increase the severity of QTc prolonging effects when combined with Doxycycline
Pentobarbital can increase the metabolism of Ticlopidine and Ticlopidine may decrease the metabolism of Doxycycline
Pentobarbital may reduce the serum concentration of the active metabolites of Isavuconazonium and Isavuconazonium may decrease the metabolism of Doxycycline
Pentobarbital may increase the central nervous system depressant activities of Ethanol and Ethanol may decrease the metabolism of Doxycycline
|
DB00396
|
DB00207
| 458 | 645 |
Progesterone
|
Azithromycin
|
Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in various contraceptive preparations to prevent ovulation and fertilization, as well as in other formulations to promote and support pregnancy. Please see [Medroxyprogesterone acetate], [Megestrol acetate], [Dydrogesterone] and [Hydroxyprogesterone] entries for information on various other forms of progesterone. Pharmaceutical progesterone is made from a plant source as a starting material and is chemically identical to progesterone of human ovarian origin [FDA label]. Progesterone is available in gelatinized capsule form, vaginal gel form, tablet form, vaginal insert form, and injection form, all used for various purposes [Label,F389
|
Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides. In March 2020, a small
|
The metabolism of Azithromycin can be decreased when combined with Progesterone.
| 46 |
[
[
[
458,
69,
645
]
],
[
[
458,
69,
143
],
[
143,
196,
645
]
],
[
[
458,
6,
8339
],
[
8339,
160,
645
]
],
[
[
458,
21,
28633
],
[
28633,
175,
645
]
],
[
[
458,
180,
147
],
[
147,
26,
645
]
],
[
[
458,
189,
1076
],
[
1076,
196,
645
]
],
[
[
458,
69,
392
],
[
392,
42,
645
]
],
[
[
458,
95,
1098
],
[
1098,
42,
645
]
],
[
[
458,
97,
932
],
[
932,
196,
645
]
],
[
[
458,
69,
266
],
[
266,
223,
645
]
]
] |
[
[
[
"Progesterone",
"{u} may decrease the metabolism of {v}",
"Azithromycin"
]
],
[
[
"Progesterone",
"{u} may decrease the metabolism of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Azithromycin"
]
],
[
[
"Progesterone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Azithromycin"
]
],
[
[
"Progesterone",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Azithromycin"
]
],
[
[
"Progesterone",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Azithromycin"
]
],
[
[
"Progesterone",
"{u} may decrease the absorption of {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may increase the QTc prolonging activities of {v}",
"Azithromycin"
]
],
[
[
"Progesterone",
"{u} may decrease the metabolism of {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may increase the QTc prolonging activities of {v}",
"Azithromycin"
]
],
[
[
"Progesterone",
"{u} may increase the serum concentration of {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may increase the QTc prolonging activities of {v}",
"Azithromycin"
]
],
[
[
"Progesterone",
"{u} may decrease the serum concentration of {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may increase the QTc prolonging activities of {v}",
"Azithromycin"
]
],
[
[
"Progesterone",
"{u} may decrease the metabolism of {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may decrease the metabolism of {v}",
"Azithromycin"
]
]
] |
Progesterone may decrease the metabolism of Erythromycin and Erythromycin may increase the QTc prolonging activities of Azithromycin
Progesterone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Azithromycin (Compound)
Progesterone (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Azithromycin (Compound)
Progesterone can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Azithromycin
Progesterone may decrease the absorption of Fluconazole and Fluconazole may increase the QTc prolonging activities of Azithromycin
Progesterone may decrease the metabolism of Chlorpromazine and Chlorpromazine may increase the QTc prolonging activities of Azithromycin
Progesterone may increase the serum concentration of Panobinostat and Panobinostat may increase the QTc prolonging activities of Azithromycin
Progesterone may decrease the serum concentration of Aripiprazole and Aripiprazole may increase the QTc prolonging activities of Azithromycin
Progesterone may decrease the metabolism of Indinavir and Indinavir may decrease the metabolism of Azithromycin
|
DB02187
|
DB04573
| 115 | 1,127 |
Equilin
|
Estriol
|
An estrogenic steroid produced by horses. It has a total of four double bonds in the A- and B-ring. High concentration of equilin is found in the urine of pregnant mares.
|
A hydroxylated metabolite of estradiol or estrone that has a hydroxyl group at C3-beta, 16-alpha, and 17-beta position. Estriol is a major urinary estrogen. During pregnancy, large amount of estriol is produced by the placenta. Isomers with inversion of the hydroxyl group or groups are called epiestriol. Though estriol is used as part of the primarily North American phenomenon of bioidentical hormone replacement therapy, it is not approved for use by the FDA or Health Canada. It is however available in the United States by prescription filled only by compounding pharmacies. It has also been approved and marketed throughout Europe and Asia for approximately 40 years for the treatment of post-menopausal hot flashes.
|
The serum concentration of Estriol can be increased when it is combined with Equilin.
| 72 |
[
[
[
115,
119,
1127
]
],
[
[
115,
155,
299
],
[
299,
1,
1127
]
],
[
[
115,
95,
622
],
[
622,
1,
1127
]
],
[
[
115,
6,
2309
],
[
2309,
160,
1127
]
],
[
[
115,
7,
13586
],
[
13586,
161,
1127
]
],
[
[
115,
18,
7482
],
[
7482,
172,
1127
]
],
[
[
115,
225,
687
],
[
687,
34,
1127
]
],
[
[
115,
225,
364
],
[
364,
257,
1127
]
],
[
[
115,
1,
79
],
[
79,
119,
1127
]
],
[
[
115,
95,
124
],
[
124,
119,
1127
]
]
] |
[
[
[
"Equilin",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the serum concentration of {v}",
"Estriol"
]
],
[
[
"Equilin",
"{u} (Compound) resembles {v} (Compound)",
"Ethinylestradiol"
],
[
"Ethinylestradiol",
"{u} (Compound) resembles {v} (Compound)",
"Estriol"
]
],
[
[
"Equilin",
"{u} may increase the serum concentration of {v}",
"Mestranol"
],
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Estriol"
]
],
[
[
"Equilin",
"{u} (Compound) binds {v} (Gene)",
"SHBG"
],
[
"SHBG",
"{u} (Gene) is bound by {v} (Compound)",
"Estriol"
]
],
[
[
"Equilin",
"{u} (Compound) upregulates {v} (Gene)",
"CNPY3"
],
[
"CNPY3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Estriol"
]
],
[
[
"Equilin",
"{u} (Compound) downregulates {v} (Gene)",
"GNAS"
],
[
"GNAS",
"{u} (Gene) is downregulated by {v} (Compound)",
"Estriol"
]
],
[
[
"Equilin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may decrease the anticoagulant activities of {v}",
"Estriol"
]
],
[
[
"Equilin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etoricoxib"
],
[
"Etoricoxib",
"{u} may increase the thrombogenic activities of {v}",
"Estriol"
]
],
[
[
"Equilin",
"{u} (Compound) resembles {v} (Compound)",
"Estrone sulfate"
],
[
"Estrone sulfate",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the serum concentration of {v}",
"Estriol"
]
],
[
[
"Equilin",
"{u} may increase the serum concentration of {v}",
"Estrone"
],
[
"Estrone",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the serum concentration of {v}",
"Estriol"
]
]
] |
Equilin (Compound) resembles Estriol (Compound) and
Equilin (Compound) resembles Ethinylestradiol (Compound) and Ethinylestradiol (Compound) resembles Estriol (Compound)
Equilin may increase the serum concentration of Mestranol and Mestranol (Compound) resembles Estriol (Compound)
Equilin (Compound) binds SHBG (Gene) and SHBG (Gene) is bound by Estriol (Compound)
Equilin (Compound) upregulates CNPY3 (Gene) and CNPY3 (Gene) is upregulated by Estriol (Compound)
Equilin (Compound) downregulates GNAS (Gene) and GNAS (Gene) is downregulated by Estriol (Compound)
Equilin may increase the severity of adverse effects when combined with Nafamostat and Nafamostat may decrease the anticoagulant activities of Estriol
Equilin may increase the severity of adverse effects when combined with Etoricoxib and Etoricoxib may increase the thrombogenic activities of Estriol
Equilin (Compound) resembles Estrone sulfate (Compound) and Estrone sulfate (Compound) resembles Estriol (Compound) and Estrone sulfate may increase the serum concentration of Estriol
Equilin may increase the serum concentration of Estrone and Estrone (Compound) resembles Estriol (Compound) and Estrone may increase the serum concentration of Estriol
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.